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SUMMARY
The development of recombinant DNA technology has enabled the 
molecular genetic basis of a number of inherited diseases to be 
established. This thesis describes the application of this 
technology to the study of hereditary Cl-inhibitor deficiency or 
hereditary angio-oedema (HAE). In addition, the findings of a 
clinical survey of HAE in Scotland are presented.
Hereditary angio-oedema is an autosomal dominant disease in 
which there is either a quantitative (Type I HAE) or functional 
(Type II HAE) deficiency of Cl-inhibitor, this protein being an 
important inhibitor of complement system activation and an inhibitor 
of other serine protease dependent plasma mediator systems. In 
Type I HAE, which constitutes approximately 85% of cases, 
functionally normal Cl-inhibitor is present in the serum but at low 
levels. This contrasts with Type II HAE in which there are normal or 
sometimes elevated levels of serum Cl-inhibitor as measured by 
immunoassay, though most of this is in the form of a functionally 
inactive molecule. Clinically Type I and Type II disease cannot be 
distinguished since both present with recurrent attacks of 
subcutaneous or submucous oedema.
In this study restriction fragment length polymorphism (RFLP) 
analysis of the Cl-inhibitor gene was carried out on genomic DNA 
isolated from 25 normal, unrelated individuals and on genomic DNA 
samples from 12 Type I HAE kindred and two Type II HAE kindred. A 
total of 38 restriction endonucleases were used to digest each DNA 
sample followed by agarose gel electrophoresis and Southern blotting 
of each sample onto nylon hybridisation membranes. Each digested DNA 
sample was then probed with a radiolabelled exon 2-8 Cl-inhibitor
- 10 -
cDNA which represents the full protein coding sequence of the 
Cl-inhibitor gene.
Four of the 12 Type I HAE kindred were shown to have unique 
disease-specific RFLPs affecting one allele of the Cl-inhibitor 
gene. Localisation studies clearly demonstrated that the gene 
mutations responsible for each RFLP affected exon 4, the 3f exon/ 
intron boundary of exon 6, exon 7 and exon 8 of the Cl-inhibitor 
gene. Family studies showed that each mutation co-segregated with 
the disease. Mutations affecting exon 6 and exon 8 had not been 
reported previously in Type I HAE. Both these mutations were small, 
possibly point mutations and it is highly likely that the mutation 
at the extreme 3' boundary of exon 6 results in loss of the donor 
splice site for excision of the sixth intron during RNA processing. 
The effect of the small exon 8 mutation is less certain. Nucleotide 
sequence analysis of both these mutated areas is currently being 
undertaken. This should help to establish their likely effects. The 
remaining two mutations, which were shown to be a complete exon 4 
deletion and a complete exon 7 deletion, had recently been 
documented in Type I HAE by other investigators. No RFLPs were 
identified in the two Type II HAE kindred.
Detection of a disease-specific RFLP in 33% of the Type I HAE 
kindred tested represents a significantly higher detection rate than 
other published studies in which 16% was the previous maximum. This 
increase appears to reflect the greater number of restriction 
enzymes employed since no other methodological differences were 
apparent. These results suggest that Type I HAE is likely to be due 
to a multiplicity of gene mutations as is seen in other genetic
- 11 -
diseases including p-thalassaemia, haemophilia A and haemophilia B.
Cl-inhibitor gene RFLPs were generated by the restriction 
enzymes Kpn I and Hgi AI in the normal population. The Kpn I RFLP 
had not been reported previously and was shown to be due to a 
mutation that lay approximately lOkb downstream of the Cl-inhibitor 
gene. The Hgi AI RFLP had already been observed in normal 
individuals from North America and arose due to a point mutation 
within the Cl-inhibitor gene itself. Both RFLPs fulfill criteria 
which are likely to make them useful as indirect genetic markers of 
the mutant Cl-inhibitor allele in those HAE families who lack a 
disease-specific RFLP.
The clinical survey of HAE in Scotland identified a total of 
46 patients which represents a disease incidence of approximately 
one patient per 110,000 of the population. This is the first 
documented attempt to calculate disease incidence in Scotland. It 
became evident from the survey that despite the development of more 
effective treatment regimes in recent years, significant disease- 
associated morbidity and mortality still existed within the 
relatively young patient population. This observation provided ample 
justification for studying the molecular genetics of HAE since an 
understanding of this aspect of the disease is central to future 
disease prevention in the form of prenatal diagnosis.
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1.1 Cl-inhibitor deficiency
Hereditary Cl-inhibitor deficiency or hereditary angio-oedema 
(HAE) is an autosomal dominant disease caused by either a 
quantitative (Type I HAE) or functional (Type II HAE) deficiency of 
Cl-inhibitor, an important inhibitor of activation of the complement 
system of proteins and of other serine protease dependent plasma 
mediator systems. Although not a common disease its clinical 
presentation is often characteristic and before the advent of modem 
drug therapy it was responsible for the deaths of many patients in 
their early adult years. In addition to the hereditary forms of the 
disease, acquired Cl-inhibitor deficiency is now a well recognised 
entity. The autoimmune aetiology of this acquired deficiency state 
will be described.
It is appropriate to commence this introduction with a concise 
review of the complement system in order to ensure that the 
Cl-inhibitor protein is placed in context. Thereafter a detailed 
description of Cl-inhibitor structure and function will be 
undertaken, an understanding of which is central to an appreciation 
of the pathogenesis of Cl-inhibitor deficiency states.
1.2 The complement system
The complement system comprises a group of at least 20 
distinct plasma proteins which have a key role to play in host 
defence against infection and in helping to mediate 
inflammation (1). These proteins can be divided into four main 
groups, namely the classical pathway components, the alternative
- 14 -
pathway components, the terminal components and the control proteins 
(Table 1). Today the interactions that occur between the different 
components during complement system activation are fairly well 
defined although the fine details of some of these molecular 
interactions still remain unresolved.
Complement activation occurs in a cascade fashion similar to 
that seen in the coagulation and kinin mediator systems. At several 
points in the activation sequence an inactive precursor molecule or 
zymogen is activated with the aquisition of proteolytic activity 
which is specific for its substrate. This substrate is in turn 
activated ready to carry out its role in the cascade. One of the 
main consequences of such a cascade system is that stepwise 
amplification occurs at each activation step since the newly 
generated proteolytic enzyme is able to activate a number of 
substrate molecules. For this reason tight control of the cascade is 
maintained by a number of mechanisms, one of which is the presence 
of plasma and cell membrane regulatory proteins. Cl-inhibitor is one 
of the plasma proteins which regulates complement activation. The 
complement system can be activated by either the classical or 
alternative pathways. Classical pathway activation usually follows 
binding of antigen to antibody, whereas alternative pathway 
activation may occur independently of antibody. The alternative 
pathway is continuously undergoing low-grade turnover only becoming 
fully activated in the presence of a suitable activating substance. 
Fhylogenetically the alternative pathway probably represents a more 
ancient activation pathway which is independent of the specific 
immune response, namely antibody. For this reason it is able to
- 15 -
TABLE 1 THE CGMPLQ4ENT SYSTEM OF PROTEINS
COMPONENT SERUM CONC. POLYPEPTIDE CHAIN
Qig/ml) STRUCTURE
CLASSICAL PATHWAY
Clq 75 18(6x3)
Clr 100 1
Cls 80 1
C4 430 3
C2 20 1
ALTERNATIVE PATHWAY
B 150 1
D 2 1
P 30 4
C3 1300 2
TERMINAL SEQUENCE
C3 1300 2
C5 75 2
C6 60 1
C7 60 1
C8 80 3
C9 50 1
CONTROL PROTEINS
Cl-INHIBITOR 180 1
C4 BINDING PROTEIN (C4bp) 250 6-8
I (C3b/C4b INACTIVATOR) 50 2
H (plH GLOBULIN) 300 1
S PROTEIN (vitronectin) 150 1
CARBOXYPEPTIDASE N ? ?
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respond very quickly to invasion by micro-organisms.
Activation of either pathway results in target-cell bound 
enzymes that cleave and activate C3 and C5 (C3 convertase and 
C5 convertase respectively). Subsequent activation of the 
multimolecular membrane attack complex (MAC) from the terminal 
complement components C5-9 can then occur. The MAC can act to lyse 
the target cell or bacteria. In addition, a number of biologically 
active peptides, not necessary for perpetuating the cascade, are 
released during the activation sequence. A number of these peptides 
are active as inflammatory mediators, the relevance of which will 
become apparent later during the discussion of the pathogenesis of 
the clinical manifestations of Cl-inhibitor deficiency.
1.2.1 Classical pathway
The classical pathway consists of six components Cl, C4, C2, 
Cl-inhibitor, C4 binding protein (C4bp) and Factor I (I) which are 
necessary for the formation and regulation of the classical pathway 
C3 convertase, C4b2a, and the C5 convertase, C4b2a3b (Figure 1). The 
initial activation step in vivo is the interaction of Cl with 
antigen-antibody complexes which contain IgM or IgG antibody (2). Cl 
itself is a calcium dependent macromolecule comprising three 
glycoproteins Clq, Clr and Cls as two reversibly interacting 
subunits Clq and the tetramer Cls-Clr-Clr-Cls (Cl^Cls^) (3). It is 
the Clq moiety which interacts with the immunoglobulin Fc region. 
Multi valent attachment is required for Clq activation meaning that 
one cell surface bound molecule of IgM is sufficient for activation 
whereas two adjacent molecules of IgG are needed (4). Immune complex
- 17 -
1
CLASSICAL PATHWAY 
Cl
Activator e.g. 
immune complex'
C3
Cl
C2
CA
> -> CAb2a
CAa and C2b
C3a <r
C3b-
ALTERNATIVE PATHWAY
Low-grade spontaneous 
hydrolysis
C3(H20)
D
C3(H20),Bb<--- C3(H20),B
DP— C3b,Bb,P< C3b,B <-----
AMPLIFICATION
L .
r
L J
------- i
CA23b or C3b,Bb,C3b,P 1
C6-9
C5b <r
C5a
_L_ C5
C5b-9I
TARGET LYSIS
TERMINAL SEQUENCE I
FIGURE 1
Activation cascade of the complement system of proteins. For clarity 
the control proteins have not been included.
- 18 -
interaction with Clq is not the only mechanism of classical pathway 
activation. A number of other substances such as the lipid A moiety 
of endotoxin, mitochondrial membranes, certain gram negative 
bacteria and complexes of C-reactive protein with pneumococcal 
polysaccharide can also produce Cl activation (5). The relative 
importance of such activation in vivo is unclear. In addition, Cl 
activation may occur in the absence of an activator. This process of 
spontaneous autoactivation is rather inefficient and appears to be 
prevented by Cl-inhibitor in normal individuals (6).
The Clq subcomponent of Cl binds to an activator and so leads 
to a conformational change in Clq which in turn allows conversion of 
the Clr and Cls subcomponents to their active forms as serine 
proteases (7). This conversion involves autocatalytic cleavage of 
native Clr to active Clr which acts to produce a single proteolytic 
cleavage in native Cls to generate activated Cls (8,9). Activated 
Cls, as part of the Cl macromolecule, can then carry out proteolytic 
cleavage and activation of C4 and C2. C4 is cleaved into C4b and C4a 
with the small peptide C4a being released as one of the 
anaphylatoxins (10). Newly generated C4b has two important 
biological activities. Firstly, it is able to bind covalently to 
immune complexes or other acceptor molecules on activating surfaces 
through the formation of an ester or amide bond between C4b and the 
acceptor molecule. This bond forming ability is extremely labile and 
is dependent upon the presence in native C4 of an internal 
thiolester group which becomes accessible on activation (11). Only 
around 10% of C4 which is converted to C4b will bind in this manner 
to an activating surface. The remaining 90% will react with the
- 19 -
hydroxyl group of water to form C4bi which is unable to participate 
in further complement activation. Secondly, newly generated C4b 
possesses a stable magnesium ion dependent binding site for C2 or, 
more specifically, the C2b fragment of C2 (12). C2 can therefore 
become bound to C4b to form the proconvertase C4bC2 which is acted 
upon by activated Cls cleaving C2 into C2a and C2b (13). Thereafter 
C2a becomes bound to C4b and it is this C2a fragment which possesses 
the enzymatic site of the classical pathway C3 convertase, C4b2a 
(14,15). This C3 convertase is inherently unstable with C2a rapidly 
decaying off the complex although it can be reconstituted with fresh 
cleavage of C2 by activated Cl (12). This instability helps prevent 
the generation of excessive classical pathway C3 convertase 
activity.
Rigid control of classical pathway activation is maintained by 
Cl-inhibitor, C4bp and I. A more detailed discussion of the role of 
Cl-inhibitor will be presented later, however, in simple terms it 
inhibits activated Clr and Cls. C4bp and I control the availability 
of C4b and so control assembly of the classical pathway C3 
convertase, C4b2a. I achieves this by degrading C4b to C4c and C4d 
in the presence of its co-factor C4bp which, as its name suggests, 
binds to C4b (16). Spontaneous decay/dissociation of C4b2a appears 
to be enhanced by C4bp (17).
1.2.2 Alternative pathway
Six components, namely C3, factor B (B), factor D (D), 
factor P (P), factor H (H) and factor I (I) are involved in the 
initiation, generation and maintenance of the alternative pathway C3
- 20 -
and C5 convertases, C3bBbP and C3bBbC3b respectively. The activation 
mechanisms are complex and are summarised in Figure 1.
Initiation occurs through low-grade hydrolysis of fluid-phase 
C3 to give C3(HZ0) (18). In the presence of magnesium ions C3(HZ0) 
can bind B which is then cleaved by D which is normally present in 
plasma in its activated form. Ba is released leaving C3(H^0)Bb as 
the initial C3 convertase (19). This low efficiency fluid-phase 
convertase cleaves C3 into C3a, an anaphylatoxin, and metastable 
C3b, the latter being deposited on and covalently binding to the 
surfaces of surrounding particles (20). The C3b-dependent positive 
feedback or amplification loop can now operate (Figure 1) since each 
newly generated C3b molecule has the potential to form the more 
efficient C3 convertase, C3bBb, in the presence of B, D and 
magnesium ions. This can occur both in the fluid-phase and on the 
surface of nearby particles. Factor P has a stabilising effect on 
C3bBb since it retards the decay of Bb from C3bBb and hence prolongs 
the half-life of the alternative pathway C3 convertase (21). Control 
of alternative pathway amplification is carried out by H and I both 
in the fluid-phase and on non-activating surfaces. I, in the 
presence of H as a co-factor, degrades C3b to iC3b which can no 
longer bind B to generate the C3 convertase (16). In addition, H 
alone acts to both restrict the formation of, and to accelerate the 
rate of decay of C3bBb and C3bBbP (22). It should be mentioned at 
this point that certain widely distributed cell-associated proteins 
serve a regulatory role in the complement system. Decay acceleration 
factor (DAF), membrane co-factor protein (MCP) and complement 
receptor type 1 (CRl) are thought to be important (23). DAF prevents
- 21 -
alternative pathway C3 convertase assembly and mediates convertase 
dissociation, an effect which is also observed for the classical 
pathway C3 convertase. MCP has co-factor activity for I mediated 
degradation of C3b to iC3b. CRl has both DAF and MCP activity.
Overall it is thought that prevention of C3b deposition on 
host cells by the actions of these regulatory proteins stops damage 
occurring to host tissues during episodes of complement 
activation (23). This tight regulation of alternative pathway 
activation is valid for fluid-phase and non-activating surfaces. 
However, substances which activate the alternative pathway do so 
through the fact that their surfaces provide a sanctuary for the C3b 
generated by C3(H^0)Bb. This surface-bound C3b is protected from the 
control proteins H and I but it is still able to bind B and P to 
form C3bBbP (24,25). Alternative pathway activators therefore allow 
a shift from low-grade fluid-phase activation to efficient 
solid-phase turnover. Such activators often have surfaces which are 
low in sialic acid (26,27), the net effect of which is to reduce the 
number of regulatory protein binding sites on C3b without affecting 
factor B binding sites (28). In the future it is likely that 
substances other than sialic acid will be found to be important in 
distinguishing activating surfaces from non-activators.
1.2.3 Terminal sequence
The terminal sequence is the final common pathway that leads 
to completion of the complement activation cascade irrespective of 
whether initial activation occurred via the classical or alternative 
pathways (Figure 1). One molecule of C5, C6, C7 and C8, plus up to
- 22 -
18 C9 molecules constitute the terminal sequence proteins whose 
highly ordered interaction results in the formation of the membrane 
attack complex (MAC), C5b-9. When assembled, this macromolecular 
complex has a hydrophobic outer layer which allows insertion into 
biological membranes. A hydrophilic core creates a transmembrane 
channel through which water and ions can pass. Insertion of 
sufficient numbers of MACs into a target-cell membrane can lead to 
the membrane becoming "leaky" with resulting osmotic lysis and cell 
death. The terminal sequence therefore represents a mechanism by 
which the complement system can mediate cell injury or can lyse 
susceptible bacteria.
Activation of the terminal sequence follows formation of C5 
convertase activity. This is dependent upon covalent binding of C3b 
adjacent to cell surface or activating surface bound classical 
and alternative pathway C3 convertases, C4b2a and C3bBb 
respectively (29). C3b covalently binds to the C4b component of 
C4b2a whereas it binds to the C3b moiety of C3bBb. Each of the C5 
convertases is therefore designated C4b2a3b and C3bBbC3b. This newly 
bound C3b acts as a binding site for native C5 and renders it 
susceptible to cleavage into C5a and C5b by the C2a or Bb moiety of 
each convertase. In the classical pathway C5 convertase, C4b2a3b, 
C4b is also involved in the C5 binding site. Each C3 convertase 
therefore generates the C3b necessary to convert its specificity to 
a C5 convertase.
Assembly of the membrane attack complex follows C5 cleavage 
into C5a and C5b. C5a, the third anaphylatoxin, is released leaving 
C5b which has a metastable binding site for C6. Bimolecular C5b6
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remains loosely bound to C3b on the target-cell surface until 
interaction with C7 occurs. At this time the C5b67 complex undergoes 
a hydrophilic-amphiphilic transition and inserts itself into lipid 
membranes in its immediate vicinity (30). The lipid membranes may 
belong to nucleated cells, erythrocytes, bacteria or viruses and the 
insertion event commits MAC assembly to a specific site. The 
inserted C5b67 now acts as a membrane-bound C8 "receptor" by binding 
C8 and the C5b-8 complex penetrates deeper into the hydrophobic
O
bilayer creating a 30A diameter transmembrane channel (31).
Subsequent binding of C9 occurs and as increasing numbers of C9
molecules are incorporated (C9 polymerisation) the channel structure
©
increases its size up to a 100A diameter pore in the membrane (32). 
Significant water and ion fluxes can then occur with possible lysis 
of the target (33). Interestingly calcium ion flux induced by MAC 
formation in nucleated cells can produce cell activation rather than 
cytolysis.
Not surprisingly inhibitors of MAC channel formation exist as 
a defence measure against bystander host cell lysis at sites of 
complement activation. Plasma S protein and very low density 
lipoprotein (VLDL) inhibit the binding of C5b-7 complexes 
to membranes (34). In addition, S protein prevents C9 
polymerisation (35). A number of widely distributed membrane 
associated proteins including C8 binding protein, 20 kilodalton 
homologous restriction factor or CD59 also exist and act to inhibit 
MAC mediated pore formation (36,37,38). Their importance is 
demonstrated by the fact that deficiency states can lead to 
inappropriate host cell lysis as occurs in paroxysmal nocturnal
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haemoglobinuria (39).
From the foregoing description it is apparent that tight 
control of the complement activation cascade is maintained at many 
points, such is the potential biological potency of the system once 
activated. It is not surprising that defective functioning of one of 
these control measures, such as occurs in Cl-inhibitor deficiency, 
has important and potentially detrimental consequences for the host 
as will be described later. First it is appropriate to briefly 
outline the biological activities of the complement system to allow 
a better appreciation of its areas of involvement.
1.2.4 Biological activities of the complement system
A number of biological activities important to host defence 
are mediated, at least in part, through the complement system. It is 
now known to be involved in mediating cytolysis (33), increasing 
vascular permeability (40), promoting vasodilatation (41), inducing 
oedema formation (42,43), increasing neutrophil adhesiveness
(44,45), stimulating inflammatory cell chemotaxis (46,47), mediating 
opsonisation and enhancing phagocytosis (48,49,50,51), inducing 
release of toxic oxygen species and lysosomal enzymes from 
phagocytic cells (52,53,54,55), controlling the handling of immune 
complexes (56), stimulating leukocytosis (57) and modulating 
lymphocyte functions (58). The complement components and peptides 
thought to mediate each process are shown in Table 2.
Vasodilatation, increased vascular permeability and oedema formation 
are of particular relevance in Cl-inhibitor deficiency states. Their 
possible mediation by complement system cleavage products will be
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TABLE 2 BIOLOGICAL ACTIVITIES OF THE COMPLQiHfr SYSTEM
BIOLOGICAL ACTIVITY COMPONENT(S) INVOLVED
Cytolysis MAC (C5b-9)
Increased vascular permeability, 
vasodilatation and oedema 
formation.
Increased neutrophil 
adhesiveness
Chemotaxis
Opsonisation and phagocytosis
Release of toxic oxygen species 
and lysosomal enzymes
Handling of immune complexes
Leukocytosis
Modulation of lymphocyte 
functions
C4a, C3a, C5a, C2 peptides
C5a, C5a des arg
C5a, C5a des arg,
C3a (weak), C4a (very weak)
C3b, iC3b, C4b
C5a, C5a des arg, C3b, C3e
C3b
C3e, C3d-k
C4a, C3a, C3d-k, C5a,
C5a des arg
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described later. The vital role played by the complement system in 
ensuring the biological integrity and indeed survival of an organism 
is amply demonstrated by complement deficiency states other than 
hereditary Cl-inhibitor deficiency. Examples of these deficiency 
states and their major associated diseases (59) are listed in 
Table 3. Development of these diseases is not surprising when the 
list of biological activities is considered.
1.3 Cl-inhibitor
1.3.1 Discovery and physico-chemical characterisation
During the 1950s human serum was found to contain a heat- 
sensitive substance that inhibited the enzymatic activity of 
activated Cl (60). This substance was called Cl-esterase-inhibitor 
and was first isolated by Pensky et al in 1961 (61). Independently, 
but around the same time, Schultze et al described a protein they 
named alpha-2-neuramino-glycoprotein whose function initially was 
unknown (62). Subsequent work demonstrated its identity with Cl- 
esterase-inhibitor and thereafter the two names were used 
interchangeably (63). Today the name Cl-inhibitor is preferred.
Characterisation of Cl-inhibitor has shown it to be one of the 
most heavily glycosylated proteins in human plasma with carbohydrate 
accounting for approximately 35% of its 104-105,000 dalton molecular 
weight (64). Electrophoretically it is an alpha-2-globulin and 
structurally it consists of a single polypeptide chain (65). 
Electron microscopy suggests a two domain structure comprising a
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TABLE 3 HOMOZYGOUS COMPLEMENT DEFICIENCY STATES AND MAJOR 
ASSOCIATED DISEASES
DEFICIENT COMPONENT DISEASE
Clq Immune complex disease including 
systemic lupus erythematosus (SLE)
Clr Immune complex disease including SLE 
and glomerulonephritis
Cls
C2
Immune complex disease including SLE
Immune complex disease including SLE or 
an SLE-like illness
C4 Immune complex disease including an 
SLE-like illness
C3 Recurrent bacterial infections 
especially by encapsulated organisms; 
immune complex disease including SLE
Factor P Fulminant bacterial infections, 
particularly Neisserial infections
Factor D Recurrent bacterial respiratory tract 
infections
Factor I Recurrent bacterial infections 
including respiratory tract infections 
and meningitis
Membrane attack 
components C5, C6, C7, 
C8 or C9
Recurrent systemic meningococcal or 
gonococcal bacteraemia
Factor H Recurrent meningococcal infections
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33nm long, 2nm diameter rod-like domain and a terminal 4nm diameter 
globular head domain. This structure is entirely compatible with the 
known low sedimentation co-efficient of 3.67S (66).
The carbohydrate composition and pattern of attachment to the 
polypeptide chain are interesting. There appear to be 20 
oligosaccharide units attached to the amino-acid backbone, 17 of 
these units being attached to the N-terminal region of the 
polypeptide chain (67). Both 0-linked and N-linked glycosylation is 
present, the former initially being suggested by a relatively high 
content of N-acetylgalactosamine amongst the carbohydrate moieties 
and by the relatively high serine/threonine content of the protein. 
The function of the glycosylation is unclear. Neither the N-linked 
nor the 0-linked oligosaccharide units appear to be necessary for 
the functional activity of Cl-inhibitor against activated Cls 
(68,69). This finding is probably not surprising when it is realised 
that the reactive site of Cl-inhibitor is located at its C-terminal 
end, well away from the highly glycosylated N-terminus. The 
possibility that heavy glycosylation was necessary for efficient 
secretion of the protein after synthesis has been considered, 
however, experimental evidence derived from the study of 
Hep G2 cells did not support this idea (70). Since mononuclear 
phagocytes, fibroblasts and umbilical vein endothelial cells also 
synthesise Cl-inhibitor (71,72,73) a role for glycosylation in these 
cell types should also be sought. The activity of deglycosylated 
Cl-inhibitor against other target proteases has not been 
investigated.
The entire 478 amino-acid sequence of Cl-inhibitor is now
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known along with the sequence of its 12 amino-acid N-terminal signal 
peptide (67). The reactive site or active centre of the Cl-inhibitor 
molecule lies close to the carboxy-terminal end as described by- 
Sal vesen et al (74). They localised the site by carrying out 
amino-acid sequence analysis of the four kilodalton carboxy-terminal 
peptide released from Cl-inhibitor during complex formation with 
activated Cls. This analysis indicated that the reactive site was 
centred round the arginine residue at position 444. This was termed 
the PI residue of the reactive site. The residue adjacent to this 
arginine on the carboxy-terminal side was threonine 445 and this was 
called the Pi* residue. Based on these initial observations 
subsequent work has now established the overall mechanism of 
interaction of Cl-inhibitor with target proteases. The reactive site 
contains a substrate sequence or bait sequence which is recognised 
by the substrate binding site of the target protease (75). Guided by 
the bait sequence the target protease complexes with Cl-inhibitor, 
recognises the PI arginine residue then cleaves the acyl bond 
between it and the PI' residue so creating the four kilodalton 
peptide sequenced by Salvesen. Creation of this peptide also 
explains the appearance of the new N-terminal threonine residue 
described by Nilsson (76). Cl-inhibitor is now covalently bound 
through its reactive site PI residue to the target protease and 
since Cl-inhibitor has only one reactive site it forms equimolar 
complexes with its target proteases. Furthermore, the covalent 
nature of the bond formed between the inhibitor and the protease 
explains the resistance of the enzyme-inhibitor complex to powerful 
denaturants (77,78). Protease inhibition is achieved because access
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of substrate to the protease is prevented by Cl-inhibitor which is 
covalently bound to the protease.
It is now universally accepted that Cl-inhibitor can be 
assigned to the serpin (serine £rotease inhibitor) group of proteins 
by virtue both of the properties just described and because of 
sequence homology with other members of the serpin family. Included 
in the serpin family are alpha-1-antitrypsin, alpha-1- 
antichymotrypsin, antithrombin III, mouse contrapsin, heparin 
cofactor II and endothelial cell plasminogen activator 
inhibitor (79,80). All of these are plasma protease inhibitors 
except the last one, which is a cell-associated inhibitor. On the 
basis of sequence homology angiotensinogen, chicken ovalbumin and 
barley protein Z are also included in the serpin family despite 
having no known serine protease inhibitory activity (79,81). The 
degree of sequence homology which exists between Cl-inhibitor and 
other serpins is approximately 20-27%, a percentage homology similar 
to that seen between many other serpin family members (67). The 
areas of homology between Cl-inhibitor and the other serpins are 
scattered over 80% of the length of the polypeptide chain although 
most lie between amino-acid residue 120 and the carboxy-terminus. 
Discrete stretches of strong homology are interspersed with less 
homologous stretches. Based on these data it is felt that the genes 
coding for the serpins, including the Cl-inhibitor gene, are likely 
to have arisen from a common ancestral gene.
The exact tertiary structure of Cl-inhibitor has not been 
fully characterised. However, comparison with fellow serpin 
alpha-1-antitrypsin, whose structure is known, shows similarities
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particularly in certain key areas (82). A good example is the
p-sheet that forms a large planar surface of serpin molecules 
including Cl-inhibitor. One strand of this p-sheet is thought to 
bend back on itself to form a highly stressed loop over the planar 
surface so connecting the active centre to the carboxy-terminal 
segment of the molecule. The hinge region at the base of this loop 
is highly conserved amongst the serpins, including Cl-inhibitor, 
because maintenance of this stressed loop appears to be critical for 
serpin function (67). By comparison, those sequences which are least 
conserved often appear to map to areas on the surface of the
molecule away from the stressed loop. It is argued that it is these 
surface differences that help to define overall protease 
specificity, absolute specificity being decided by the active centre 
bait sequence and PI residue. Recent work relating conformational 
stability of the serpins to alterations in structure during complex 
formation with their target proteases has shed light on a few 
previously unexplained observations in serpin biochemistry. As just 
described, alpha-1-anti trypsin, alpha-1-antichymotrypsin, Cl- 
inhibitor and antithrombin III have been shown to have a stressed 
loop structure containing the PI residue. On complexing with the
target protease the acyl bond between the Pi and Plf residues is
cleaved thereby inducing a large conformational change in the serpin 
which results in "wide" separation of the newly created amino- 
terminus and carboxy-terminus. The overall effect is to relax the 
stressed loop so increasing the conformational stability of the 
molecule (83). This seems to explain why resynthesis of the cleaved 
Pl-Pl' peptide bond does not occur in vivo with recovery of a
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"reactivated" inhibitor. Furthermore, this transition from a 
strained intact state to a relaxed modified conformation may explain 
why new antigenic determinants (neoantigens) are exposed on the 
surface of Cl-inhibitor and alpha-1-antitrypsin following their 
interaction with a target protease (84,85). It is suggested that 
exposure of these neoantigens may be important in the recognition of 
serpin/protease complexes by cell surface receptors involved in 
their clearance from the circulation (86). This process, which does 
not seem to be specific for a particular serpin/protease complex, 
may be dependent upon exposure of a shared serpin sequence which in 
the native molecule is hidden in the interior but which is 
externalised ready for use after the inhibitor complexes with its 
target protease.
In summary, Cl-inhibitor is a protein whose functional 
activity can be disrupted by small, critically placed alterations in 
its structure. This fact will be evident when the Cl-inhibitor gene 
mutations responsible for the dysfunctional Cl-inhibitor molecules 
that characterise Type II HAE are described.
1.3.2 Biological roles of Cl-inhibitor
Cl-inhibitor is capable of inactivating a number of plasma 
serine pro teases including activated Clr and Cls, plasmin, 
kallikrein and coagulation factors XIa and Xlla plus the 
enzymatically active fragments derived from Xlla, Xllf. It is 
therefore potentially involved in regulating a number of the 
proteolytic processes which are central to complement activation, 
coagulation, fibrinolysis and inflammation. The involvement of
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Cl-inhibitor in each of these major biological effector systems will 
be described.
Cl-inhibitor inactivates enzymatically active Clr and Cls, the 
initial enzymes of the classical pathway of complement activation 
(87,88,89,90,91). The interaction is through the reactive site of 
each molecule and it is a typical serpin interaction. Cl-inhibitor 
is the most important circulating inhibitor of activated Clr and Cls 
and, until recently, was thought to be the only serpin with 
significant inhibitory activity against activated Clr and Cls (92). 
Interestingly, however, a pro tease inhibitor produced by fibroblasts 
called protease Nexin I has been shown to have activity against 
activated Cls (93). Nexin I, now shown to be a serpin family member, 
has marked structural similarity to Cl-inhibitor over the area of 
its reactive site, so helping to explain its activity against 
activated Cls. It has been suggested that because Nexin I is 
produced by fibroblasts and is at a very low concentration in the 
plasma, its role is more likely to be one of mediating protease 
control extravascularly. By comparison, Cl-inhibitor is abundant in 
the plasma as are its main target proteases and so it is better 
suited to an intravascular inhibitory role. Nexin I also resembles 
Cl-inhibitor in that it has demonstrable inhibitory activity against 
coagulation factor Xlla and kallikrein.
The rate of interaction of Cl-inhibitor with activated Clr and 
Cls is not identical in that activated Clr reacts more slowly with 
Cl-inhibitor compared with activated Cls (94). In addition, the rate 
of interaction with activated Cls is less affected by alterations in 
temperature, ionic strength or calcium concentration (94,95). The
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exact physiological significance of these observations is not 
certain.
The foregoing description was based on observations made on 
the interactions between Cl-inhibitor, activated Clr and Cls as 
isolated components. In vivo, however, Clr and Cls are found as part 
of the calcium dependent macromolecular Cl complex along with Clq. 
It is therefore essential to examine the effects of Cl-inhibitor on 
macromolecular Cl to ensure that all its biologically relevant 
actions are appreciated. At this point a more detailed description 
of the subunit structure of macromolecular Cl is required. This will 
facilitate an understanding of the proposed interactions between 
Cl-inhibitor and Cl that are now thought to be central to 
controlling the two main types of Cl activation, namely immune 
complex induced activation and spontaneous autoactivation.
Macromolecular Cl comprises a complex of Clq with the tetramer 
Cls-Clr-Clr-Cls (Clr^Cls,.). Clr and Cls are now known to have at 
least two main domains, an interactive and a catalytic domain, each 
of which is divided into subdomains (96). The interactive subdomains 
are thought to be responsible for at least three interactive 
functions - 1) calcium binding; 2) mediating Clr-Cls interaction as 
part of tetramer formation (Cls-Clr-Clr-Cls); 3) mediating
interaction between the Cls-Clr-Clr-Cls tetramer and Clq. The 
catalytic subdomains or <y-B domains also appear to have at least 
three functions - 1) mediating the serine protease activity of Clr 
and Cls; 2) substrate recognition; 3) in the case of Clr mediating 
monomer-monomer interaction as part of tetramer formation 
(Cls-Clr-Clr-Cls). It is this Clr monomer-monomer interaction to
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form a Clr dimer (-Clr-Clr-) that is now thought to be central to Cl 
autoactivation (97). Since this interaction is mediated by a tf-B 
region interaction, binding of Cl-inhibitor to this same region, as 
will be described presently, could be important for the control of 
autoactivation.
In summary, there appear to be distinct subdomains in Clr and 
Cls which mediate tetramer formation, Clq binding, serine protease 
activity and Cl autoactivation. Cl activation and Cl-inhibitor 
interaction with the serine protease and autoactivation related 
domains will now be described.
Two forms of macromolecular Cl activation appear to exist. 
Firstly, there is the process of rapid, highly efficient activation 
in the presence of a known activator such as an immune complex. 
Secondly, there is spontaneous Cl autoactivation which is a slower, 
less efficient process. The role that Cl-inhibitor plays in 
modulating the first form of Cl activation is well established. In 
this situation it covalently interacts with the already activated 
serine protease domains of Clr and Cls within macromolecular 
Cl (89). It does not act to prevent Cl activation (98). This 
covalent interaction is accompanied by dissociation of the activated 
macromolecular Cl into Clq, which remains bound to the immune 
complex, and Cl-inhibitor-Clr-Cls complexes (99). For this release 
reaction to occur the Cl-inhibitor interaction with Clr appears more 
important than the Cls interaction (90). Measurement of these 
Cl-inhibitor-Clr-Cls complexes in plasma and other biological fluids 
has been used by some investigators to quantify classical complement 
pathway activation (100,101).
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Controversy arises when the mechanisms responsible for Cl 
autoactivation and its control by Cl-inhibitor are considered. The 
concept of autoactivation is generally accepted but the fine details 
of the molecular mechanisms involved are unclear. Two main schools 
of thought exist. On one side there is evidence to support the idea 
that spontaneous autoactivation of Cl is a rather slow process 
brought about by thermal motion acting on macromolecular Cl to 
generate activated Clr (102). The role of Cl-inhibitor is to rapidly 
and covalently complex with the small amounts of activated Clr 
generated and so inhibit its enzymatic activity. Spontaneous 
autoactivation of Cl in this model is therefore kept under tight 
control in normal individuals by a classical serpin interaction. The 
alternative theory suggests that the key to spontaneous 
autoactivation of Cl is the self activating ability of Clr. When 
present as Clr ^ in macromolecular Cl (ClqClraClsa.), Clr a. is said to 
be able to self activate so leading to the generation of activated 
Cls (97,103). It is suggested that in addition to covalent binding 
of Cl-inhibitor to already activated Clr, as described in the 
previous paragraph, there is a second form of interaction which 
specifically prevents Clr^ . self activation and so prevents Cl 
autoactivation. This interaction is dependent upon non-covalent 
binding of Cl-inhibitor to the tf-B region of Clr at a point that 
appears not to involve the Clr serine protease subdomain (104). The 
net result is prevention of spontaneous autoactivation of Cl, 
although in this role Cl-inhibitor is not acting as a serpin. It is 
possible that the heavily glycosylated amino-terminus, an area which 
is not necessary for its serpin activity, is required for this
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interaction. Weak specific binding of Cl-inhibitor to native Cl had 
been observed previously (105) and had been reported as being 
mediated by a domain on Cl-inhibitor which was distinct from its 
active centre. This may represent a similar interaction to the one 
which is responsible for inhibition of Cl autoactivation. Further 
work is required to define these interactions fully.
Recently Okada and Utsumi have described another possible &-B 
region interaction. When an immune complex binds to the Clq 
subcomponent of native Cl the CH3 domain of the IgG in the immune
complex appears to compete with Cl-inhibitor for access to the tf-B
domains of the Clr dimer present in the same macromolecular Cl 
unit (106). Prevention of Cl-inhibitor binding to the #-B region 
allows the Clr dimer to be activated following the immune
complex/Clq interaction.
The relevance of the foregoing discussion becomes apparent 
when clinical Cl-inhibitor deficiency is considered. A
characteristic finding is excessive activation of the classical 
pathway of complement in the absence of known Cl activators. In this 
situation the importance of uncontrolled spontaneous Cl 
autoactivation as a result of the Cl-inhibitor deficiency state 
becomes obvious. It is also relevant that certain small immune 
complexes which are normally incapable of inducing classical pathway 
activation can do so in experimental systems in which Cl-inhibitor 
levels are low (107). Lowering of the threshold for complement 
activation by these complexes seems to have occurred. Should in vivo 
correlates for this exist, this could help to explain the apparent 
lack of detectable, accepted classical pathway activators in
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Cl-inhibitor deficiency states. Clearly much still has to be learned 
about Cl activation and its control both in normal and pathological 
situations.
1.3.3 Cl-inhibitor involvement in the coagulation, fibrinolytic and 
kallikrein systems
Cl-inhibitor inactivates a range of serine proteases other 
than activated Clr and Cls. The proteases involved are coagulation 
factors XIa, Xlla and Xllf, plasmin and kallikrein (108,109,
110,111). In vivo the inhibition of factors Xlla, Xllf and
kallikrein appears to be of biological significance. Cl-inhibitor 
seems to inactivate about 90% of Xlla and Xllf generated in vivo 
with this percentage falling to 40%-50% for kallikrein (112,113, 
114,115). Alpha-2-macroglobulin inhibits most of the remaining 
50%-60% of kallikrein. By comparison, Cl-inhibitor appears to make a 
very small contribution to the in vivo inactivation of factor XIa 
and plasmin. Most of the former is inactivated by alpha-1-
antitrypsin whereas alpha-2-antiplasmin and alpha-2-macroglobulin 
inhibit the vast majority of plasmin generated in vivo (116,117). 
Cl-inhibitor inactivates all these proteases in a manner similar to 
that for activated Clr and Cls. It is possible that some of these 
proteases could produce classical pathway activation in Cl-inhibitor 
deficiency states. Plasmin is, however, the only protease for which 
there is definite experimental evidence of an ability to activate 
Cl (118).
In summary, since evidence exists for activation of both the 
coagulation and kinin systems in Cl-inhibitor deficiency states, it
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is possible that such activation may contribute to the clinical and 
biochemical manifestations of the disease.
Overall the foregoing description has been an attempt to 
highlight those areas of Cl-inhibitor structure and function which 
are felt to be relevant to a discussion of disease induced by 
Cl-inhibitor deficiency. The remainder of this introduction will now 
focus on Cl-inhibitor deficiency with particular emphasis being 
placed on the hereditary forms of the disease. Included will be a 
description of clinical aspects of hereditary Cl-inhibitor 
deficiency followed by the molecular pathology and molecular 
genetics of the disease.
1.4 Hereditary Cl-inhibitor deficiency
1.4.1 Historical aspects
The first description of this disorder was written by Quincke 
in 1882 but it was Osier in 1888 who first produced a detailed 
account of the disease (119,120). A later description of the 
disorder as it affected five generations of one family placed it 
in a hereditary disease category (121). The name hereditary 
angioneurotic oedema was widely used for the disease as a result of 
the observation that emotional stress could precipitate symptomatic 
attacks (122). Today hereditary Cl-inhibitor deficiency or 
hereditary angio-oedema (HAE) is preferred. Donaldson and 
Evans (123) are credited with first identifying that a deficiency of
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plasma Cl-inhibitor was the cause of HAE although in the year prior 
to their description Landerman et al (124) noted a decrease in the 
serum levels of an inhibitor of kallikrein in patients with HAE. 
Hindsight shows that Landerman was describing a deficiency of 
Cl-inhibitor.
1.4.2 Clinical features of HAE
Such was the thoroughness of his report that nearly all the 
major clinical characteristics of HAE were described by Osier in 
1888 (120). The disease is characterised by recurrent attacks of 
acute, circumscribed, non-inflammatory subcutaneous and submucosal 
oedema (125). Anatomically the face, limb extremities, genitalia, 
upper respiratory tract and gastro-intestinal tract are affected 
most commonly by the oedema which is classically non-pitting, non­
pruritic and is not accompanied by marked erythema or increased 
temperature in the affected area. The symptoms experienced by a 
patient during an attack are dependent on the main sites affected. 
The subcutaneous oedema, which can be readily observed, usually 
starts from a single site and spreads outwards to a variable degree 
until, in severe cases, it may affect a whole limb or the entire 
face. A feeling of tightness or tingling may precede the appearance 
of the oedema by a few hours but subsequently the usual time course 
followed is an increase in the degree and extent of oedema for up to 
48 hours then gradual reduction over the next 48 or 72 hours. A 
similar time course is followed by oedema at other anatomical sites. 
Children in particular can develop erythematous mottling or, less 
commonly, an appearance similar to erythema marginatum or erythema
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multiforme either with or without typical attacks of subcutaneous 
oedema. It seems that the skin manifestations of HAE are more common 
in patients before puberty, involvement of other sites, with the 
possible exception of the gastro-intestinal system, being seen more 
frequently thereafter.
Involvement of the upper respiratory tract, particularly 
laryngeal oedema, represents the most life-threatening and often the 
most acutely distressing clinical manifestation of HAE. Death by 
asphyxiation due to laryngeal oedema is the only recorded fatal 
complication of the disease (126).
Gastro-intestinal involvement can occur anywhere between mouth 
and anal canal producing a wide range of symptoms. Abdominal pain 
represents by far the most common symptom, the pain typically being 
an acute cramping or colicky pain superimposed on a persistent dull 
ache (127). In addition, anorexia, nausea, vomiting, abdominal 
distension and watery diarrhoea are all well recognised symptoms. 
Abdominal symptoms may occur without any sign of skin involvement 
and may even precede the onset of cutaneous signs by a number of 
years. Abdominal pain may lead to unnecessary surgery with the true 
diagnosis only becoming apparent later. Compared with involvement of 
the preceding systems, oedema of the geni t o-ur inary system, 
pulmonary oedema and even localised cerebral oedema are extremely 
rare events.
Symptomatic attacks of angio-oedema leading to diagnosis often 
commence during childhood, usually before the onset of 
puberty (128). Exceptions do exist in that symptoms and signs have 
been recorded as commencing during infancy and even as late as the
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sixth decade of life in a few individuals. However, for most 
patients with a long history of the disease, the fifth and sixth 
decades herald a welcome reduction in both the severity of symptoms 
and the frequency of attacks. A number of years often elapse between 
the appearance of symptoms and definitive diagnosis due to a 
combination of factors including mild symptomatology, mild or no 
initial cutaneous involvement and a high medical threshold for 
diagnosis. Even a sudden asphyxial death may be recorded in a family 
without the diagnosis being made.
An important consideration in HAE is the nature of the trigger 
which precipitates each acute attack. An identifiable trigger is 
noted by approximately 50% of patients with the commonest trigger 
being tissue trauma to either a limb or to the oropharynx 
(126,128,129). Tooth extraction and tonsillectomy are particularly 
notorious for inducing laryngeal swelling. Included in a long list 
of other precipitating factors are infection, emotional stress, 
prolonged pressure or vibration, over-exposure to sunlight, 
menstruation, early pregnancy and the oestrogen containing oral 
contraceptive pill (130). Interestingly the second and third 
trimesters of pregnancy often induce a reversal of the increased 
frequency of attacks seen in early pregnancy. The basis for this 
appears to be the absolute increase in the amount of circulating 
Cl-inhibitor that occurs later in pregnancy due to increased blood 
volume, although the serum Cl-inhibitor concentration is decreased.
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1.4.3 Abnormalities in the complement, coagulation and fibrinolytic 
systems in HAE
An abnormal complement profile is seen in HAE. Cl-inhibitor 
deficiency allows excessive Cl activation and subsequent consumption 
of its substrates C4 and C2 with resulting diminished serum 
concentrations of both proteins (130). C4 levels are commonly low 
even during periods of disease remission. During periods of active 
disease C4 frequently falls to very low levels and activated Cl can 
be detected in the serum. Since C4 and C2 consumption is in the 
fluid-phase little C3 convertase activity is generated and C3 levels 
remain within the normal range although an increased rate of C3 
turnover has been observed (131). As already described one of the 
central problems in the pathogenesis of HAE is the nature of the 
mechanisms responsible for Cl activation. It is likely that in most 
circumstances immune complex induced activation is not important. 
Uncontrolled autoactivation of Cl requires serious consideration in 
HAE. At 37 ° C HAE plasma shows spontaneous activation of the 
complement system at a rate which is inversely proportional to the 
Cl-inhibitor level (132). In addition, normal plasma partially 
depleted of Cl-inhibitor shows significant spontaneous Cl 
autoactivation when the Cl-inhibitor concentration is around 25% of 
normal, a concentration which is close to that found in the plasma 
of many HAE patients. It seems that increased autoactivation of Cl 
in situations of Cl-inhibitor deficiency is a very significant 
finding.
A further source of activated Cl in HAE may be as a result of 
interactions between components of the coagulation and fibrinolytic
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cascades and Cl. Cl-inhibitor is thought to be physiologically
important for the inactivation of activated factor XII (Xlla and
Xllf) and kallikrein. Since it is known that activated factor XII 
and kallikrein are able to generate plasmin from plasminogen and 
that plasmin can activate Cl, the amount of activated Cl generated 
from such a source is likely to increase in a Cl-inhibitor 
deficiency state (118,133,134,135,136). The demonstration of 
kallikrein and activated factor XII in HAE plasma lends support to 
this theory (137,138). Furthermore, tissue trauma, which commonly 
induces attacks of angio-oedema in HAE patients, is known to result
in factor XII activation (139). Overall, therefore, evidence exists
to support the involvement of the coagulation, fibrinolytic and 
kallikrein systems in generating activated Cl. Also of relevance is 
the recent description of a C2-like plasma protein which can be 
cleaved by kallikrein to generate small peptides which may be 
involved in the mediation of the physical signs and symptoms of HAE. 
This protein is described in Section 1.4.4.
1.4.4 Mediation of symptoms in HAE
Characterisation of the mediator or mediators which induce the 
tissue oedema in HAE has raised much controversy and recently has 
come full circle. The histopathological changes seen in affected 
tissues from patients with HAE consist of marked interstitial oedema 
and venular dilatation. No significant inflammatory cell infiltrate 
is present. The main conclusion drawn from these observations was 
that conventional inflammatory mediators were unlikely to be 
responsible for the tissue changes. Initial lines of investigation
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identified and partially purified a small, heat-stable kinin-like 
peptide from the plasma of HAE patients (140). This peptide had the 
ability to increase vascular permeability when injected into guinea 
pig skin as well as being able to induce smooth muscle contraction 
and was therefore suspected of being bradykinin. Further 
investigation however showed that compared with bradykinin it 
differed in size, electrophoretic mobility, isoelectric point and 
trypsin susceptibility (141). Furthermore, the biological effects of 
bradykinin following subcutaneous injection include pain and 
erythematous swelling, features not seen in patients with HAE (125). 
Attention now focussed on the complement system itself as the source 
of the peptide for the following reasons. Firstly, C4 and C2 
appeared necessary for peptide generation in that its appearance in 
HAE serum could be inhibited by antibodies against C4 and C2 (142). 
Secondly, intradermal injection of activated Cls into normal 
individuals induced local, pain-free, non-pruritic swelling whose 
macroscopic and microscopic appearance closely resembled the angio- 
oedema seen in HAE patients (143). Thirdly, the active enzymatic 
site of Cls was required for generating the peptide. Fourthly, C2 
deficient individuals failed to respond to intradermal injection of 
activated Cls whereas a C3 deficient patient responded normally 
(144,145,146). These results were confirmed using an animal model in 
which C2 deficient guinea pigs did not respond to intradermal 
injection of activated Cls but responsiveness developed after 
partial restoration of their C2 levels with purified C2 (147). These 
data suggest that C2 is necessary for peptide generation but it may 
not be the source of the peptide. Evidence which suggested that the
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kinin-like peptide was derived from C2 came from a study in which 
activated Cls, C2 and plasmin were incubated together (148). This 
resulted in a small peptide which increased vascular permeability 
and produced smooth muscle contraction being released from the 
carboxy-terminus of C2b. The observations of Curd et al (149), 
Fields et al (150) and Smith and Kerr (151), however, did not 
support the generation of kinin activity from C2. For example, Smith 
and Kerr (151) incubated large amounts of C2 with trypsin, activated 
Cls, plasmin and kallikrein but failed to show any kinin generation. 
Overall, these groups of workers were more in favour of bradykinin 
being the mediator of tissue oedema in HAE. It was argued that 
Cl-inhibitor deficiency allowed kallikrein to act unhindered on high 
molecular weight kininogen to produce bradykinin and so tissue 
swelling. Recently, however, Rosen et al have demonstrated 
generation of a small set of peptides from the carboxy-terminus of 
C2b using activated Cls and plasmin in combination (152). They used 
these peptides along with a 25 amino-acid long synthetic peptide 
corresponding to the carboxy-terminus of C2b to cause rat smooth 
muscle contraction and to increase human vascular permeability with 
oedema formation following their intradermal injection. Finally, the 
most recent potential source of a mediator of tissue changes in HAE 
is the newly described C2-like plasma sialoglycoprotein sgp 120 
(153). It has been shown that kallikrein can cleave this protein to 
generate a small peptide which causes capillary leakage and tissue 
oedema in guinea pigs (154). Cl-inhibitor has no direct inhibitory 
effect on this active peptide, however, it does inhibit kallikrein 
which is necessary for generation of the peptide from sgp 120. This
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possibly represents an important pathogenetic interaction between 
the complement system and the kinin generating/contact activation 
system in HAE. Further work is required to establish the importance 
of sgp 120 in HAE.
In summary, although the pathogenesis of HAE is still not 
understood current evidence indicates that the complement, 
coagulation, fibrinolytic and kinin systems may all be contributing 
either directly or indirectly to producing the tissue changes seen 
during acute attacks of the disease. This complexity of interactions 
reflects the diverse actions of Cl-inhibitor. Spg 120 may be shown 
to be of great importance.
1.4.5 Acquired Cl-inhibitor deficiency
This form of Cl-inhibitor deficiency is less common than HAE 
(155,156). It is important to be aware of the diagnosis since the 
clinical presentation is usually identical to HAE. The complement 
profile is also very similar in that serum Cl-inhibitor, C2 and C4 
levels are low with C3 levels being normal. Unlike HAE, however, 
serum Cl levels are often very low due to Cl consumption. The 
aetiology of acquired Cl-inhibitor deficiency is interesting. There 
appear to be two mechanisms which can give rise to the disease, both 
of which are auto-antibody mediated. Firstly, in those cases where 
the disease is associated with a malignant B cell lympho- 
proliferative disorder an auto-anti-idiotype antibody is 
produced (155). This antibody is directed against the monoclonal 
immunoglobulin expressed on the surface of the malignant B cells and 
leads to idio type/ant i-idio type immune complex formation, Cl
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activation and Cl-inhibitor consumption. Secondly, there is a group 
of patients where no B cell malignancy is present but auto­
antibodies are found (156). These antibodies are directed against 
Cl-inhibitor itself and act to inhibit its function by binding to 
the inhibitor and possibly affecting its structure. Furthermore, 
binding of the auto-antibody to Cl-inhibitor renders the inhibitor 
more susceptible to proteolytic cleavage and so inactivation by its 
normal substrates including activated Clr, activated Cls and 
plasmin. The net effect of both mechanisms is to produce 
Cl-inhibitor deficiency.
1.4.6 Treatment of HAE
It was only after the biochemical basis of HAE was established 
that treatment regimes became less empirical and more targeted. 
Today treatment can be categorised under two main headings:
1) prophylaxis and 2) treatment of an acute attack (130).
1) Prophylaxis. This can be divided into long term and short term 
prophylaxis both of which are achieved by the same therapeutic 
agents. Short term prophylaxis is reserved for patients who normally 
experience minimal disease activity and so do not require long term 
prophylaxis. Nevertheless these patients may develop acute attacks 
of laryngeal oedema when they undergo a surgical procedure, 
particularly dental extraction or operations requiring general 
anaesthesia with endotracheal intubation.
The two main groups of agents used in prophylaxis are 
attenuated androgenic steroids and anti-fibrinolytic drugs. It was 
Spaulding in 1960 who first demonstrated the efficacy of oral
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methyltestosterone in preventing attacks of HAE (157). This drug was 
used initially due to the misconception that it might be effective 
because of its anti-histaminic properties. Anti-histamines 
are however ineffective in HAE despite the presence of 
histaminuria (158). Methyltestosterone was effective because it 
increased the circulating levels of Cl-inhibitor and relieved the 
deficiency state (159). The major problem with methyltestosterone 
and some of its derivatives was their marked masculinising side- 
effects (130). It was Gelfand et al who demonstrated the beneficial 
effect of danazol in HAE in 1976 (160). Danazol is a derivative of 
ethinyltestosterone with weak androgenic properties but is effective 
at preventing attacks of angio-oedema by increasing circulating 
levels of Cl “inhibitor. The benefits of methyltestosterone were seen 
but there was a marked reduction in the incidence of the undesirable 
side-effects. 17-alpha-alkylation of the steroid is necessary for 
activity in HAE since non 17-alpha-alkylated steroids have no 
therapeutic effect (161). Today a second attenuated androgen, 
stanazolol, is also available for the treatment of HAE (162). After 
starting treatment with danazol or stanazolol, Cl-inhibitor levels 
start to rise within a few days, a maximal effect being seen after 
7-14 days although Cl-inhibitor levels rarely enter the normal 
range (163). Interestingly clinical improvement is not dependent 
upon achieving maximal Cl-inhibitor levels (164). Indeed, a 
beneficial effect is often apparent before any measurable increase 
in serum Cl-inhibitor levels is seen.
Anti-fibrinolytic agents comprise the second group of drugs 
used prophylactically in HAE. In general they are used less
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frequently today than the attenuated androgenic steroids with some 
individuals showing a relatively poor response to them. Fortunately 
such individuals often respond well to steroids. The two agents that 
can be used are epsilon-aminocaproic acid (EACA) and its analogue 
tranexamic acid which is more potent than EACA in treating HAE 
(165,166,167). Their mechanism of action is thought to be twofold. 
Firstly, Cl activation appears to be reduced due to drug-induced 
inhibition of plasmin which can then no longer activate Cl. 
Secondly, at higher concentrations EACA seems to be directly 
inhibitory to Cl activation (130). Today EACA is not used in HAE 
because the high dosages required put patients at risk of developing 
drug-induced myopathy.
2) Treatment of acute attacks. The mainstay of treatment in this 
situation is Cl-inhibitor replacement therapy either as Cl-inhibitor 
concentrate or as fresh frozen plasma (168). When available, 
Cl-inhibitor concentrate is to be preferred, however it is 
expensive, it can be difficult to obtain and there is the danger of 
it containing the human immunodeficiency virus or hepatitis B virus. 
Securing the airway if threatened by laryngeal oedema and 
symptomatic relief such as analgesia are other important aspects of 
treating acute attacks (130).
In summary, current treatment regimes are more effective at 
controlling HAE in many patients. It is now less common for an 
asphyxial death to be encountered in HAE compared with a generation 
before when approximately one third of all patients died of the 
disease in their early adult years. It should be remembered, 
however, that modern treatment is not without its problems and no
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cure is achieved. The only hope of cure lies in an analysis of the 
molecular pathology and molecular genetics of the disease.
1.4.7 Molecular pathology of HAE
HAE is an autosomal dominant disease which can be divided into 
two types (169). Type I HAE, which comprises approximately 85% of 
cases, is characterised by reduced levels of circulating 
Cl-inhibitor, the levels during remission ranging from 5% to 30% of 
normal in most cases. The Cl-inhibitor protein that is present is 
functionally normal. This contrasts with Type II HAE in which there 
is normal or elevated antigenic levels of circulating Cl-inhibitor. 
However, the majority of this Cl-inhibitor is dysfunctional with 
only small amounts of normal Cl-inhibitor being present. Clinically 
the two disease types are indistinguishable. A consequence of the 
normal serum levels of Cl-inhibitor in Type II HAE is that antigenic 
screening for Cl-inhibitor deficiency will often fail to detect 
Type II disease. Assessment of Cl-inhibitor functional activity is 
required to make this diagnosis (170).
A level of functionally normal Cl-inhibitor of 30% or below in 
Type I and Type II HAE is an interesting finding considering that 
both forms of the disease have an autosomal dominant mode of 
inheritance. With this mode of inheritance HAE patients must be 
heterozygous for the gene defect and so a normal gene must be 
present. In this situation the expectation would be that under the 
influence of the normal gene circulating Cl-inhibitor levels should 
be close to 50% of normal. In Type I HAE it was initially proposed 
that a defect in Cl-inhibitor gene regulation rather than an
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intrinsic structural gene abnormality would explain these findings. 
By comparison, in Type II HAE, since both a normal and a mutant 
Cl-inhibitor protein were present, it was more likely that a 
structural gene defect was responsible for this form of the disease. 
It is now accepted that the reason for the reduction below 50% in 
circulating normal Cl-inhibitor levels in both forms of the disease 
is consumption of normal Cl-inhibitor through its interaction with 
susceptible proteases (171,172). The single normal Cl-inhibitor 
allele is not able to sustain a production rate sufficient to 
maintain circulating Cl-inhibitor levels at 50%. Analysis of the 
catabolic rate of Cl-inhibitor in HAE patients is consistent with 
this concept (173). Further supportive evidence was derived from in 
vitro studies of Cl-inhibitor synthesis that had been carried out 
using mononuclear phagocytes and fibroblasts isolated from patients 
with Type I HAE (72,174). Cl-inhibitor synthesis rates as assessed 
by intracellular and extracellular Cl-inhibitor concentrations and 
Cl-inhibitor mKNA abundancies in these studies were found to be 40% 
to 50% of normal.
In type II HAE many dysfunctional Cl-inhibitor proteins have 
been studied. In the investigations carried out by Donaldson and her 
colleagues the dysfunctional protein from eight different kindred 
appeared to show heterogeneity in both structure and function of the 
mutant proteins when their electrophoretic properties and their 
inhibitory capabilities were analysed (175). When the eight 
different dysfunctional proteins were used in functional assays 
against the substrates activated Cls, plasma kallikrein, activated 
forms of factor XII and plasmin, each Cl-inhibitor mutant showed a
unique spectrum of activity (169,176). Each protein blocked the 
activities of the enzymes tested to a different degree, most showing 
lesser degrees of inhibition compared with normal Cl-inhibitor. 
Limited structural analysis which has been carried out on a number 
of mutant Cl-inhibitor proteins also suggests a degree of structural 
heterogeneity (177,178,179). This degree of heterogeneity at a 
structural and functional level has been interpreted by Donaldson as 
indicating likely heterogeneity of Cl-inhibitor gene mutations 
causing Type II HAE. This has not been confirmed by molecular 
genetic studies.
1.4.8 Molecular genetics of HAE
The logical investigative progression in HAE based on the 
foregoing data was to identify and define the Cl-inhibitor gene 
mutations responsible for the two hereditary forms of the disease. 
This was not possible until the relatively recent isolation of a 
number of complementary DNA (cDNA) clones for human Cl-inhibitor 
including an exon 2-8 Cl-inhibitor cDNA which represents the full 
protein coding sequence (67,180,181,182,183). In addition, the 
normal Cl-inhibitor gene was cloned and was shown to comprise eight 
exons and seven introns (Figure 2) covering a total of approximately 
17 kilobases of DNA on chromosome 11 (67,180,183). As described in 
the previous section, evidence existed to suggest that there may be 
more than one structural gene mutation responsible for Type II HAE. 
In type I HAE, although a similar state of affairs was suspected, 
there was less certainty about the outcome of structural gene 
analysis. Currently the identification and characterisation of the
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FIGURE 2
Structure of the normal Cl-inhibitor gene. There are eight exons 
shown as rectangles and seven introns shown as a line connecting the 
exons and marked TVS (for intervening sequence). The gene is 
approximately 17kb in length although the 5' boundary of the gene 
and of the first exon has not yet been fully characterised. The 
position of the sequence coding for the reactive site is marked in 
exon 8.
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molecular genetic lesions responsible for both Type I and Type II 
HAE are being undertaken in a number of laboratories worldwide. 
Already certain facts have been established.
In Type II HAE Cl-inhibitor gene mutations affecting the 
reactive site of the molecule have been characterised. Most of these 
mutations change the PI residue of the reactive site, commonly 
producing an arginine (CGC) to cysteine (TGC) or arginine to
histidine (CAC) substitution (184,185). From a total of 14 Type II 
patients examined, nine (approximately 70%) have been shown to have 
one of these PI mutations (185). Curiously the four other amino- 
acids which could be expected from point mutations in this area have 
not been seen. The hypermutability of this area is most probably 
explained by the presence of a CpG dinucleotide in the normal codon 
for the PI arginine residue (186). Confirmation of these amino-acid 
changes derived from nucleotide sequence data was obtained by
limited proteolysis of dysfunctional Cl-inhibitor proteins and 
amino-acid sequencing. Aulak et al (185) noted that these Pi
mutations would render the peptide bond between the PI residue and 
the PI' threonine residue insensitive to trypsin cleavage. However, 
the peptide bond sensitive to an elastase derived from Pseudomonas 
aeruginosa lying three residues upstream from the Pi residue would 
be unaffected by the mutation. If a PI mutated protein was digested 
with this elastase and the released C-terminal peptide subjected to 
N-terminal amino-acid sequencing, the nature of the mutated Pi
residue could be determined.
Mutation of the PI reactive site residue is not a surprising 
finding in Type II HAE. It was already known that some dysfunctional
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Cl-inhibitor proteins had either negligible anti-protease activity 
or else had activity that was significantly different from normal 
Cl-inhibitor. A mutated reactive site in these proteins helps to 
explain these observations. However, an as yet unresolved problem 
exists. This is exemplified by two of the mutant dysfunctional 
proteins which had been reported as having markedly differing enzyme 
inhibitory profiles but have been shown recently to have identical 
PI mutations. Either this mutation is not the sole cause of the 
enzyme inhibitory profile and a second gene mutation exists or, 
alternatively, the inhibitory profile differences are purely in 
vitro phenomena. This latter possibility could have been produced by 
contaminating proteases or by contaminating normal Cl-inhibitor 
protein in the dysfunctional protein preparations (169). Based on 
current evidence this latter possibility seems more likely.
In six of the 14 dysfunctional Cl-inhibitor genes and proteins 
examined no PI residue mutation was identified. It therefore seems 
that mutations elsewhere in the gene can be responsible for Type II 
HAE. To date one other mutated site has been identified in Type II 
HAE. This is a G to A substitution within the eighth exon that 
alters amino-acid 436 from alanine to threonine (187). This altered 
amino-acid lies eight amino-acids N-terminal to the Pi residue in 
the P9 position. It is thought that this position contributes to the 
maintenance of the stressed conformation of the active centre which 
is required for normal functioning of the Cl-inhibitor protein. 
Overall it is likely that in Type II HAE a limited number of 
critically placed mutations will be found to be responsible for the 
disease.
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The molecular genetic basis of Type I HAE, as it is currently 
understood, comprises two main categories of Cl-inhibitor 
gene mutation. Firstly, Stoppa-Lyonnet et al demonstrated 
deletion/insertion events in the 5' half of the gene in 
approximately 16% of their Type I HAE patients (188,189). The 
mutations described were mainly exon 4 deletions but deletion of the 
third exon and exon 4 duplication have also been observed. The 
second type of mutation reported by Ariga et al affected the 3' end 
of the Cl-inhibitor gene and took the form of an exon 7 deletion 
(190). The observation of a shortened Cl-inhibitor mRNA species was 
the initial clue which led to characterisation of this gene 
mutation. Both forms of mutation were shown to co-segregate 
absolutely with Type I HAE in affected families. It is now thought 
that these two forms of gene abnormality are generated by a very 
similar molecular mechanism. Sequence analysis of the normal 
Cl-inhibitor gene has revealed the presence of tandemly arranged 
clusters of ALU repeat sequences in the third and fourth introns 
which flank the fourth exon and in the sixth and seventh introns 
which flank the seventh exon (191). It is proposed that these ALU 
sequences allow non-homologous crossing over at meiosis and so lead 
to deletion/insertion events centred round the fourth and seventh 
exons. Precedents for such an event are recognised in familial 
hypercholesterolaemia where duplication of the 5 ’ end of the low 
density lipoprotein receptor gene occurred following unequal 
crossing over between intronic ALU repeat sequences (192). In Tay- 
Sachs disease a partial deletion of the p-hexosaminidase gene due to 
ALU repeat sequences has also been described (193). Interestingly
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Stoppa-Lyonnet has not observed an exon 7 deletion and Ariga has 
never detected a 5’ deletion/insertion event in their patient 
populations. The explanation for this is unclear but ethnic 
differences in the two populations studied have been considered 
significant in this regard. No methodological differences could 
account for it. Characterisation of the gene lesions responsible for 
HAE heralds the possibility of prenatal diagnosis for the disease.
In summary, the molecular genetic abnormalities responsible 
for Type I and Type II HAE are gradually being characterised. 
Further work is needed in order to establish the full spectrum of 
Cl-inhibitor gene mutations that cause HAE.
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1.5 Alms of the study
1) Identify Cl-inhibitor gene restriction fragment length 
polymorphisms (RFLPs) in the normal population.
2) Identify Cl-inhibitor gene RFLPs in families with Type I HAE and 
Type II HAE.
3) Localise and characterise the genomic mutations responsible for 
the RFLPs.
4) Establish whether these mutations co-segregate with HAE and 
therefore whether they could be used as disease markers.
5) Establish the technique of genomic library construction using a 
bacteriophage vector in preparation for isolating and nucleotide 
sequencing mutated Cl-inhibitor genes.
6) Carry out a clinical survey of HAE in Scotland in order to 
establish disease incidence, symptom profiles, treatment 
regimes, disease-related morbidity and mortality and finally to 
establish the level of interest in prenatal diagnosis within HAE 
families.
At the outset of this investigation there were no published 
data on the nucleotide sequence of the normal Cl-inhibitor gene nor 
was there any information on the nature of Cl-inhibitor gene 
mutations in HAE. The availability of a number of Cl-inhibitor 
cDNAs, including the exon 2-8 cDNA, made RFLP analysis a logical 
initial investigative step for the following reasons - 1) It was 
relatively simple to carry out. 2) It would allow rapid analysis of 
the normal gene and its flanking sequences. 3) It had the potential
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to identify and permit localisation of disease-specific gene 
mutations in a number of HAE families.
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2.1 Materials
2.1.1 Chemicals 
Agarose (ultra pure) 
Alpha-32P-dCTP (PB10205) 
Ammonium acetate 
Ammonium chloride 
Ampicillin
Adenosine 5'-triphosphate (ATP)
Bacteriophage DNA (lambda 
wild type)
Bactoagar
Bactotryptone
Bactoyeast extract
Biogel A-1.5 (100-200 mesh)
Boric acid
Bowtowel 40 (white)
Bovine serum albumin
Bromophenol blue
Butan-2-ol
Caesium chloride (ultra pure)
Calcium chloride
Chloroform
Collodion bags
Dextran blue
Dextran sulphate
Diethyl ether
Disodium hydrogen 
orthophosphate
GIBC0-BRL Ltd.
Amersham International PLC. 
BDH Chemicals Ltd.
BDH Chemicals Ltd.
Sigma Chemical Company 
Sigma Chemical Company
Northumbria Biologicals Ltd. 
Difco Laboratories 
Difco Laboratories 
Difco Laboratories 
Bio-rad Laboratories 
BDH Chemicals Ltd.
Bowater Scott Ltd.
Sigma Chemical Company 
BDH Chemicals Ltd.
BDH Chemicals Ltd.
GIBC0-BRL Ltd.
BDH Chemicals Ltd.
BDH Chemicals Ltd.
Sartorius Ltd.
Pharmacia Chemicals 
Sigma Chemical Company 
BDH Chemicals Ltd.
BDH Chemicals Ltd.
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Dithiothreitol
Ecosint A
EMBL 3 cloning kit
Ethanol (95%)
Ethidium bromide
Ethylenediamine 
tetra-acetic acid (EDTA)
Ficoll 400
Filter paper (3MM)
Formamide
Gelatin powder
Gigapack Gold Bacteriophage 
Packaging Kit
Glucose
Glycerol
Heparin sodium
Hybond-N hybridisation 
membranes
Hydrochloric acid 
(concentrated)
Hydroxyquinoline
Kodak X-Omat AR X-ray film
Magnesium chloride
Magnesium sulphate
Maltose
Millex-GS filter units 
Phenol crystals 
Phenol red
Phosphate buffered saline 
tablets
Sigma Chemical Company 
National Diagnostics 
Stratagene 
BDH Chemicals Ltd.
Sigma Chemical Company
BDH Chemicals Ltd.
Sigma Chemical Company 
Whatman
Fluka Gar ant ie Ltd.
BDH Chemicals Ltd.
Stratagene
BDH Chemicals Ltd.
BDH Chemicals Ltd.
Leo Laboratories Ltd.
Amersham International PLC.
BDH Chemicals Ltd.
Sigma Chemical Company 
Kodak (U.K.) Ltd.
BDH Chemicals Ltd.
BDH Chemicals Ltd.
Sigma Chemical Company
Millipore
Koch Light Ltd.
Sigma Chemical Company
Qxoid Ltd.
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Pipette tips (yellow and blue)
Polaroid type 57 high speed 
film
Polyadenylic acid
Polycytidylic acid
Polyvinylpyrolidone 360
Potassium acetate
Potassium chloride
Potassium hydrogen carbonate
Random Priming Kit
Salmon sperm DNA.
Screw cap polypropylene 
microtubes (1.5 ml)
Seaplaque agarose
Sodium acetate
Sodium chloride
Sodium citrate
Sodium dihydrogen 
orthophosphate
Sodium dodecyl sulphate (SDS)
Sodium hydroxide pellets
Sodium lauroyl sarcosine 
(sarcosine)
Spermidine
Sucrose (ultra pure)
TRIS-base
TRIS-HC1
Costar
Polaroid Ltd.
Sigma Chemical Company 
Sigma Chemical Company 
Sigma Chemical Company 
BDH Chemicals Ltd.
BDH Chemicals Ltd.
BDH Chemicals Ltd. 
Boehringer Mannheim Corp. 
Sigma Chemical Company
Sarstedt Ltd.
EMC Bioproducts 
BDH Chemicals Ltd.
BDH Chemicals Ltd.
BDH Chemicals Ltd.
BDH Chemicals Ltd.
BDH Chemicals Ltd.
BDH Chemicals Ltd.
Sigma Chemical Company 
Sigma Chemical Company 
Schwartz/Mann Biotech. 
Boehringer Mannheim Corp. 
Sigma Chemical Company
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2.1.2 Enzymes
Calf intestinal alkaline 
phosphatase
Klenow fragment of E. coli 
DNA. polymerase 1
Lysozyme
Proteinase K
Restriction endonucleases
RNase A 
RNase Tl 
T4 DNA ligase
Boehringer Mannheim Corp.
Boehringer Mannheim Corp.
Sigma Chemical Company
Boehringer Mannheim Corp.
GIBCO-BRL Ltd.
New England Biologicals 
Northumbria Biologicals Ltd.
Sigma Chemical Company
Sigma Chemical Company
Boehringer Mannheim Corp.
2.1.3 Recombinant
Exon 2-8 Cl-inhibitor cDNA (pCli)
This cDNA cloned into the Bam HI site of pUC 13 was a generous 
gift from Dr. S.C. Bock, Rockefeller University, New York. The cDNA 
is 1.8 kilobases (kb) in length and represents the full protein 
coding sequence of the Cl-inhibitor gene (67). Characterisation of 
this recombinant molecule is described in Section 3.1.
2.1.4 Control and patient blood samples
Blood samples from 25 unrelated control individuals were 
obtained during the course of blood donation to the Scottish Blood 
Transfusion Service. During the normal processing of a donated unit
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of whole blood a leukocyte rich "buffy coat" was prepared and was 
usually discarded. This ’’buffy coat" was used as a source of high 
molecular weight DNA from these individuals. All the controls were 
healthy Caucasians between the ages of 18 and 60 years. The DNA. from 
each of these 25 samples was used to establish whether Cl-inhibitor 
gene RFLPs were present in the normal population for the restriction 
endonucleases employed.
Blood samples from 12 families with Type I HAE and from two 
families with Type II HAE were collected. The purpose of the study 
was explained to each individual and consent obtained before 
venesection was carried out. A total of 45 individuals from the 12 
Type I HAE families were venesected. Serum Cl-inhibitor and C4 
levels were measured for each individual by Mrs. J. Veitch, 
Department of Pathology, Western Infirmary, Glasgow. This showed 
that of the 45 individuals venesected 26 were Type I HAE patients. A 
more detailed description of each RFLP positive Type I HAE family 
will be given in Section 3.5. A total of four blood samples were 
obtained from two Type II HAE families. Measurement by Mrs. J. 
Veitch of serum Cl-inhibitor and C4 levels in addition to 
Cl-inhibitor functional activity in these samples showed that in one 
family the samples were from two affected and one normal family 
member and that the single sample from the second family was from a 
Type II HAE patient, no sample being available from a normal family 
member. Initially DNA samples from one affected family member from 
each Type I and l^pe II HAE kindred were screened for Cl-inhibitor 
gene RFLPs. When an abnormality was found DNA samples from all 
available normal and affected family members were then examined in
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order to establish whether the RFLP co-segregated with the disease 
in that family.
2.2 Methods
2.2.1 Collection of blood samples and preparation of peripheral 
blood leukocytes
Those blood samples collected from HAE family members were 
placed in sterile tubes and anticoagulated with sodium heparin at a 
concentration of approximately 50 international units of heparin per 
millilitre of blood. The "buffy coats" were received in a sterile 
bag from the Blood Transfusion Service having been anticoagulated 
with sodium citrate.
Harvesting the peripheral blood leukocytes from each sample 
involved lysing the erythrocytes in red cell lysis buffer 
(0.83% (w/v) ammonium chloride, 0.1% (w/v) potassium hydrogen
carbonate and O.lmM EDTA). Lysis was achieved by adding three 
volumes of sterile lysis buffer to one volume of blood or buffy 
coat, mixing, then incubating for 20 minutes at room temperature. 
Centrifugation of the mixture at 1000 x gmax for 10 minutes in an 
MSE 4L centrifuge at room temperature pelleted the leukocytes and 
any unlysed erythrocytes. The supernatant was removed and the cell 
pellet resuspended in 20 mis of fresh lysis buffer. Repetition of 
the whole process twice gave a virtually pure white cell pellet. 
Following the third centrifugation step the leukocytes were 
resuspended in 20 mis of sterile phosphate buffered saline (one
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phosphate buffered saline tablet dissolved in deionised water to a 
final volume of 100 mis), pelleted by centrifugation and washed once 
more to remove the last traces of the lysis buffer. The leukocytes 
could then be used directly for genomic DNA preparation or frozen as 
a pellet in liquid nitrogen for use at a later date.
2.2.2 Preparation of high molecular weight genomic DNA from 
peripheral blood leukocytes
The method employed was an adaptation of the one described by 
Gross-Bellard et al (194). Peripheral blood leukocytes derived from 
20 mis of whole blood were resuspended in 10 mis of sterile lQmM 
TRIS-HC1 (pH 8.0), lQmM NaCl, lQmM EDTA in a sterile polypropylene 
tube. An even cell suspension with no clumps was best. Sodium 
lauroyl sarcosine was then added to 4% (w/v) and proteinase K to 
100 pg/ml. Following gentle tumbling of this mixture on a rotating 
mixer for 16 hours at 37 °C, an equal volume of phenol/chloroform 
(1/1 v/v) saturated with TE buffer (lOmM TRIS-HC1 (pH 7.6), ImM 
EDTA) was added. Gentle tumbling on a rotating mixer at room 
temperature followed until the aqueous and phenol phases were 
completely mixed (20-30 minutes). Centrifugation at 250 x gmax for 
10 minutes in an MSE 4L centrifuge at room temperature separated the 
two phases allowing the upper, viscous, aqueous phase to be removed 
with a wide bore pipette and transferred to a sterile glass flask. 
Care was taken to ensure that the creamy looking aqueous/phenol 
interface was not transferred. Sterile 3M sodium acetate (pH 5.2) 
was added to the aqueous fraction to a concentration of 0.3M 
followed by 2.5 volumes of ice-cold 95% ethanol. The ethanol was
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stirred slowly into the aqueous phase using a sterile glass rod and 
the strands of DNA precipitating at the ethanol/aqueous interface 
were wound onto the glass rod. Fluid was expelled from the DNA by 
pressing it against the side of the flask. Further dehydration of 
the DNA was achieved by washing it in 70% (v/v) ethanol followed by 
95% ethanol and finally a wash each in chloroform then diethyl 
ether. Each wash lasted 2 minutes. Air drying of the DNA for 10 
minutes followed and once dry it was resuspended overnight in 
sterile 0.1 x SSC (15mM NaCl, 1.5mM sodium citrate). Treatment with 
boiled RNase A added to a final concentration of 50 pg/ml and with 
RNase Tl added to 2 ^ g/ml was then carried out for 3 hours at 37 °C. 
The reaction was stopped by the addition of 0.5M EDTA pH 7.0 to a 
concentration of lOmM, sarcosine to 4% (w/v) and proteinase K to 
50 pg/ml. Gentle tumbling for a further 3 hours at 37 °C was carried 
out followed by a repetition of the phenol/chloroform extraction 
step twice and extraction with chloroform alone twice. DNA 
precipitation, dehydration and drying were carried out as described 
before. Finally, the DNA was resuspended in sterile TE buffer (lQmM 
TRIS-HCL (pH 7.6), ImM EDTA) the volume of which was adjusted to 
give a concentration of DNA of 200-400 pg/ml. The DNA was stored at 
4°C until needed.
2.2.3 Restriction endonuclease digestion of genomic DNA
Usually 6 p.g of leukocyte genomic DNA was digested to 
completion with each of the 38 restriction endonucleases at a 
concentration of 10 units of enzyme/pg DNA in a total digest volume 
of 160 p i under the conditions recommended by the manufacturer for
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each enzyme. A total digest time of 6 hours was employed with half 
of the total amount of endonuclease being added for the first 
3 hours and an equal amount of enzyme added for the second 3 hour 
period. Following digestion, each DNA. sample was precipitated by 
adding 16 jil of sterile 7.5M ammonium acetate followed by 4 4 0 ^  of 
95% ethanol. After mixing, each sample was stored overnight at -20°C 
and the DNA then pelleted by centrifugation at 6000 x gmax for 
20 minutes at 4°C in an Eppendorf 5412 microfuge. The supernatant 
was discarded, the DNA pellet washed in 1 ml of ice-cold 70% ethanol 
and repelleted by a further 5 minutes of centrifugation. Again the 
supernatant was discarded and the DNA pellet vacuum dried for 30 
seconds before being resuspended in 13 p i of sterile TE buffer (lQmM 
TRIS-HCL (pH 7.6), ImM EDTA) ready for gel electrophoresis.
When a DNA sample required to be digested by two endonucleases 
each digest was carried out separately, the DNA being ethanol 
precipitated and resuspended in sterile TE buffer between digests as 
well as after the second digest. This protocol for double digests 
prevented the occurrence of partial digests by the second 
endonuclease used. The addition of sterile spermidine to a 
concentration of lQmM in the second digest reaction also helped 
ensure complete digestion of the DNA.
2.2.4 Gel electrophoresis
Agarose gel electrophoresis was the standard technique 
employed. Routinely a 200 mm x 135 mm x 9 mm gel containing 150 mis 
of 0.8% (w/v) ultra pure agarose in TBE buffer (89mM TRIS-base 
(pH 8.2), 9QmM boric acid, 2.5mM EDTA) was used. To prepare an
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agarose solution the agarose was added to the TBE buffer and the 
mixture autoclaved in a domestic style pressure cooker at full 
pressure for 10 minutes. The mixture was then allowed to cool to 
approximately 40 °C before pouring into a perspex mould sealed by 
biohazard tape at either end. A 20 tooth comb was positioned such 
that it sat 3mm clear of the base of the mould and was 20mm from 
the top edge of the gel. After the gel had set, usually around 
30 minutes, the comb was removed and the gel placed in the 
electrophoresis tank along with 1.6 litres of TBE buffer, the buffer 
covering the surface of the gel to a depth of 10mm. Electrophoresis 
of genomic DNA samples was carried out using a Kingshill stabilised 
power supply (model 15A01C) for a period of 16 hours at 40 volts 
with the current control at its maximum setting giving a current of 
2 milliamps. If separation of DNA fragments of similar molecular 
size was required the electrophoresis run times were lengthened up 
to a maximum of 64 hours at 25 volts.
2.2.5 Southern blotting of genomic DNA
Gel electrophoresis was carried out as detailed above with 
6 pg of DNA per lane. Before loading each DNA sample into the gel 
0.1 volume of sterile dye mix containing lQmM TRIS-HC1 (pH 8.0), 
lQmM EDTA, 0.1% (w/v) bromophenol blue and 30% (w/v) sucrose was 
added to each sample. Standard molecular weight markers were 
routinely run in the two outside lanes of each gel. These markers 
were lambda bacteriophage DNA restricted with Hind III or a 
combination of Eco RI and Hind III giving sets of molecular weight 
marker bands as follows - lambda Hind III 23.1kb, 9.4kb, 6.4kb,
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4.4kb, 2.3kb, 2.0kb and 0.5kb; lambda Eco RI/Hind III 21.2kb, 5.1kb, 
4.2kb, 3.5kb, 2.0kb, 1.9kb, 1.5kb, 1.3kb, 0.9kb, 0.8kb, 0.5kb and 
O.lkb. At the end of the electrophoresis run the gels were 
photographed and the DNA transferred to a hybridisation membrane 
according to the method of Southern (195).
Before photography the DNA in the gel was stained by immersing 
the gel in 500 mis of TBE running buffer containing ethidium bromide 
at a concentration of 0.5 ;ig/ml for 15 minutes. Excess ethidium 
bromide was removed by soaking the gel in 500 mis of TBE for 
10 minutes and the gel was then photographed lying alongside a 300mm 
ruler while being illuminated by a 320nm UV light box. Polaroid type 
57 high speed film was used for photography. Prior to DNA transfer 
the gel containing the electrophoresed DNA was treated as follows - 
1) The gel was immersed in 500 mis of 0.25M HC1 for 20 minutes to 
depurinate the DNA. 2) The DNA. was then denatured by immersing the 
gel in 500 mis of 1.5M NaCl, 0.5N NaOH for two periods of 20 minutes 
each. 3) The gel was neutralised by immersion in 500 mis of 0.5M 
TRIS-HC1 (pH 7.5), 3M NaCl for three periods of 30 minutes each. 
Following this series of treatments capillary transfer of the DNA 
was undertaken by placing the gel on a glass plate which was raised 
on rubber bungs over the centre of a pyrex pie dish containing 
approximately one litre of 20 x SSC (3M NaCl, 0.3M sodium citrate). 
Three wicks of Whatman 3MM filter paper ran under the gel and dipped 
into the 20 x SSC. Care was taken to ensure no air bubbles were 
trapped between the filter paper wicks and the gel. Four pieces of 
old X-ray film were placed along the edges of the gel to fill and 
seal the gap between the gel edges and the edges of the dish. Their
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presence ensured that no 20 x SSC could pass round the edges of the 
gel. A sheet of precut and presoaked (20 x SSC for 5 minutes) 
Hybond-N hybridisation membrane was now laid over the surface of the 
gel and was overlapped onto the X-ray film round its edges. Again it 
was essential to ensure no air bubbles became trapped between the 
membrane and the gel. Two layers of thin Whatman filter paper soaked 
in 20 x SSC were then placed on top of the hybridisation membrane 
and a 6 inch high stack of white Bowtowels placed on top ensuring 
the whole surface of the filter paper was covered. Finally, a glass 
plate was placed on top of the Bowtowels and a full 500 ml bottle 
placed on the plate. This construction was left for at least 16 
hours to allow DNA transfer, soaked Bowtowels being replaced when 
necessary. Following DNA transfer the hybridisation membrane was 
removed after marking on it the position of the wells of the 
underlying gel and after removing the top left hand comer of the 
membrane which corresponded to the top left comer of the gel. After 
air drying, the membrane was exposed to a weak 320nm UV light source 
in order to cross-link the DNA to the membrane. The membrane was now 
ready for prehybridisation and hybridisation.
2.2.6 Prehybridisation and hybridisation
Central to the detection of a DNA or RNA sequence of interest 
is the process of hybridising a suitably labelled specific DNA or 
RNA probe to the test nucleic acid sample. In this study the genomic 
DNA under investigation was immobilised on Hybond-N membranes as 
described in Section 2.2.5.
Initially all the membranes were prehybridised in order to
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block any non spscifi c  nuclsic acid, bxnding sitss • This process 
involved incubating the membranes for 16 hours at 42°C in a sealed 
polythene bag with a suitable volume of prehybridisation fluid 
containing 50% (v/v) formamide, 0.75M NaCl, 75mM sodium citrate, 
0.1% (w/v) ficoll, 0.1% (w/v) polyvinylpyrolidone, 0.02% ( v / v )  
bovine serum albumin, 50mM sodium dihydrogen phosphate (pH 6.8), 
0.1% (w/v) SDS, 100 pg/ml sheared salmon sperm DNA, 10 pg/ml
polyadenylic acid and 10 pg/ml polycytidylic acid. The volume of 
prehybridisation fluid used was tailored to the size of membrane 
being prehybridised. Thereafter hybridisation could be carried out 
under the same incubation conditions and in the same volume of 
hybridisation fluid. This fluid comprised 50% (v/v) formamide, 0.75M 
NaCl, 75mM sodium citrate, 0.02% (w/v) ficoll, 0.02% (w/v)
polyvinylpyrolidone, 0.004% (w/v) bovine serum albumin, 2QmM sodium 
dihydrogen phosphate (pH 6.8), 0.1% (w/v) SDS, 10% (w/v) dextran 
sulphate, 100 pg/ml sheared salmon sperm DNA, 10 pg/ml polyadenylic 
acid and 10 pg/ml polycytidylic acid. Radiolabelled probe was added 
to the hybridisation fluid such that 1 million cpm/ml was attained. 
Before addition to the hybridisation fluid the probe was boiled for 
10 minutes then rapidly cooled on ice to ensure denaturation of the 
probe nucleic acid secondary structure.
On completion of the hybridisation period the Hybond-N 
membranes were placed in 200 mis of 0.3M NaCl, 30mM sodium citrate, 
0.1% (w/v) SDS for 1 hour at 65°C in a gently shaking water bath. 
Repetition of this process under progressively more stringent 
conditions, namely 75mM NaCl, 7.5mM sodium citrate, 0.1% (w/v) SDS 
then 15mM NaCl, 1.5mM sodium citrate, 0.1% (w/v) SDS followed.
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Washing to this stringency was possible because of the absolute 
homology of the human Cl-inhibitor cDNA probe with the Cl-inhibitor 
gene sequences of interest in the human DNA. samples being studied.
2.2.7 Autoradiography
The washed Hybond-N membranes were sealed in a thin polythene 
bag while still damp and placed along with a sheet of Kodak X-Qmat 
AR X-ray film in an X-ray cassette containing two Dupont Lightening 
Plus intensifying screens. After storage at -70 °C for up to 
seven days the X-ray film was developed in a Kodak 90 second X-ray 
processor.
2.2.8 Radiolabelling of DNA fragments by random priming
In this study random priming was the sole method used to 
produce radiolabelled probes. The process was routinely carried out 
using the Boehringer Mannheim Random Priming Kit which supplied lOx 
concentrated reaction buffer containing the hexanucleotide primers, 
the deoxynucleotides and the Klenow fragment of DNA polymerase 1. A 
standard reaction mixture comprised 2.5 pi (25 ng) of DNA to be 
labelled, 2 pi of the lOx concentrated reaction buffer, 1 pi of 2 ' -  
deoxyadenosine 5'-triphosphate (0.5mM), 1 pi of 2’-deoxyguanosine 
5'-triphosphate (0.5mM), 1 pi of 2,-deoxythymidine 5’-triphosphate 
(0.5mM), 1 pi of Klenow, 5 pi (50pCi) of alpha-32P-2'-deoxycytidine 
5f-triphosphate and 6.5 pi of sterile distilled water. Before 
addition to the reaction mixture the DNA was boiled for 10 minutes 
then cooled rapidly an ice to ensure denaturation of secondary 
structure. The whole reaction was incubated at 37 C for 30 minutes
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then stopped by placing on ice. Radiolabelled DNA could now be 
separated from unincorporated isotope by passing the reaction 
mixture over a small column containing Biogel A-1.5 (100-200 mesh). 
This was achieved by first adding 0.1 volume of sterile dye mix 
containing 50mM TRIS-HC1 (pH 7.6), 5QmM EDTA, 0.02% (w/v) dextran 
blue, 0.02% (w/v) phenol red, 30% (w/v) sucrose and 250 pg/ml 
sheared salmon sperm DNA to the random primed reaction mixture. The 
whole mixture was then added to the Biogel column which was held in 
a Pasteur pipette and washed through with 15mM NaCl, 1.5mM sodium 
citrate, 0.1% (w/v) SDS. Fractions of 0.5 ml were collected and 5 pi 
aliquots of each fraction were added to 5 mis of Ecosint A ready for 
counting on an LKB 1217 liquid scintillation counter. The first 
eluted peak of radioactivity represented the radiolabelled DNA, the 
second peak being unincorporated counts. Routinely the isotope 
incorporation was sufficient to achieve 100-1000 million cpm/pg of 
input DNA. This radiolabelled DNA could then be used for 
hybridisation studies as described in Section 2.2.6.
2.2.9 Preparation of agar plates
Sterile agar plates were required for preparing single 
colonies of host bacterial strains to be used for plasmid 
transformation and bacteriophage growth. The agar requirements for 
each of these situations differed. For simple bacterial streaking of 
host strains before and after plasmid transformation a 1.5% (w/v) 
agar plate was used whereas for bacteriophage growth a 1.2% (w/v) 
agar base overlaid by a 0.6% (w/v) agar top layer was employed.
Agar plates were prepared by dissolving the appropriate amount
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(w/v) of agar in L-broth (pH 7.5) which contained 1% (w/v)
bactotryptone, 0.5% (w/v) bactoyeast extract and 1% (w/v) NaCl. 
Dissolution and sterilisation of the agar/L-broth mix necessitated 
autoclaving it at a pressure of 15 pounds per square inch for 
15 minutes. The autoclaved solution was allowed to cool to 
approximately 40-50°C before adding sterile 1M magnesium sulphate to 
a concentration of lQmM and sterile 20% (w/v) maltose to a 
concentration of 0.2% (w/v). This mixture was then poured into 90mm 
diameter Sterilin plastic petri dishes to a thickness of 5mm. When 
necessary ampicillin was added to the autoclaved, 40-50°C agar 
solution to a concentration of 100 ;ig/ml. The plates were left to 
cool sitting on a perfectly flat surface to ensure an even 5 mm 
thickness of agar. Before use, particularly for bacterial streaking 
to obtain single bacterial colonies, it was important to ensure that 
any condensation that had formed inside the lid of the newly poured 
plate was allowed to evaporate off to give ,ldry, plates. Prepared 
agar plates were stored inverted at 4°C until use or for four weeks 
whichever was the shorter period.
2.2.10 Preparation of competent cells
The host strain of Escherichia coli (E. coli) chosen for 
transformation with the recombinant plasmid pCli described earlier 
was JM83. A single bacterial colony which had been prepared by 
streaking out on a 1.5% (w/v) agar plate without ampicillin was 
inoculated into a 10 ml volume of L-broth and grown overnight in an 
orbital 37°C incubator (New Brunswick Scientific Orbital Incubator). 
Thereafter 1 ml of this culture was added to 100 mis of L-broth
which had been preheated to 37 °C. This mixture was grown at 37°C 
until the 0D600nm reading of the bacterial suspension was 0.4 - 0.6, 
this usually taking approximately 2 hours. Following transfer to 
sterile 50 ml centrifuge tubes the bacterial suspension was cooled 
on ice and the bacteria pelleted by centrifugation at 1000 x gmax 
for 5 minutes at 4°C in an MSE 4L centrifuge. The supernatant was 
then decanted and the bacteria gently resuspended in 25 mis of 
sterile, ice-cold lQmM magnesium sulphate and left on ice for 
30 minutes. The bacteria were repelleted by centrifugation and 
gently resuspended in 12.5 mis of sterile, ice-cold 50mM calcium 
chloride. After storage on ice for a further 15 minutes the bacteria 
were pelleted again by centrifugation before gentle resuspension in 
2 mis of sterile, ice-cold 50mM calcium chloride. These bacteria 
could be used immediately for transformation giving an efficiency of 
approximately 500,000 colony forming units/pg of recombinant plasmid 
DNA. However, if stored at 4°C overnight a 5-fold increase in 
transformation efficiency was seen.
2.2.11 Transformation of competent JM83 with pCli
Using an overnight sample of competent JM83, 50 ng of pCli in 
10 pi of TE buffer (lOmM TRIS-HC1 (pH 7.6),lmM EDTA) were added to 
90 pi of the JM83 in 50mM calcium chloride. Controls which included 
TE buffer alone added to JM83, non-recombinant pUCl3 DNA added to 
JM83 and JM83 alone were also prepared. Each mixture was kept on ice 
for 25 minutes, heat shocked at 42 C for 2 minutes then kept at room
C
temperature for 10 minutes. Thereafter 1 ml of L-broth at 37 C was 
added to each transformation reaction and the mixture incubated with
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shaking for 90 minutes at 37 °C. A 100 pi aliquot of each reaction 
was now spread thinly over the surface of 1.5% (w/v) agar plates 
containing 100 pg/ml ampicillin before being inverted and incubated 
overnight at 37 °C. Only the ampicillin-resistant plasmid carrying 
bacteria grew as colonies on the plates and were selected for 
plasmid DNA isolation and characterisation.
2.2.12 Small scale isolation of plasmid DNA
Plasmid DNA can be isolated from a transformed bacterial 
culture by the method of Bimboim and Doly (196). The protocol 
described below allowed the purification of 0.5-1 pg of plasmid DNA 
which could then be characterised to ensure its identity before bulk 
preparation. The method is dependent upon the fact that alkali 
treatment of a mixture of E. Coli DNA and plasmid DNA produces 
irreversible denaturation of most of the bacterial DNA, however, the 
plasmid DNA can be renatured by neutralisation following the alkali 
treatment.
A single transformed bacterial colony containing the presumed 
plasmid DNA of interest was inoculated into 2 mis of L-broth 
containing the appropriate antibiotic, in this case ampicillin at a 
concentration of 100 pg/ml. After an overnight incubation in a 
shaking incubator at 37°C, 1.5 mis of the bacterial suspension was 
placed in a sterile microfuge tube and centrifuged for 15 seconds at 
6000 x gmax in an Eppendorf 5412 microfuge to pellet the bacteria. 
All the supernatant was carefully removed and the bacteria 
resuspended in 100 pi of sterile lysis solution (25mM TRIS-HC1 
(pH8.0), 50mM glucose, lQmM EDTA) before the addition of lysozyme as
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a powder to a concentration of 2 mg/ml. Once the lysozyme was 
dissolved the samples were left at room temperature for 5 minutes 
then 200 pi of freshly prepared, sterile alkaline/SDS (0.2N NaOH, 1% 
(w/v) SDS) added to each tube. The tubes were inverted sharply 
several times and incubated on ice for 5 minutes before the addition 
of 150 pi of neutralising, ice-cold, sterile 5M potassium acetate 
(pH 4.8). Mixing by tube inversion was carried out before the 
samples were incubated on ice for 10 minutes. The precipitated 
E. coli DNA. and protein could now be pelleted by centrifugation at 
6000 x gmax for 5 minutes. The supernatant was transferred to a 
fresh, sterile microfuge tube and an equal volume of 
phenol/chloroform (1/1 v/v) saturated with TE buffer (lQmM TRIS-HC1 
(pH 7.6), ImM EDTA) added. The tube contents were mixed by tube 
inversion for 1 minute after which the tube was centrifuged at 
6000 x gmax for 1 minute. The upper aqueous phase was removed and 
transferred to a fresh, sterile microfuge tube and boiled RNase A 
was added to a concentration of 100 pg/ml. The mixture was incubated 
at 37°G for 30 minutes to ensure that any RNA present was degraded. 
Addition of 0.1 volume of sterile 7.5M ammonium acetate followed by 
the addition of two volumes of ice-cold 95% ethanol precipitated the 
plasmid DNA. After 15 minutes at room temperature the plasmid DNA 
was pelleted by centrifugation at 6000 x gmax for 10 minutes. The 
pellet was washed once in 70% (v/v) ethanol, recentrifuged for 
5 minutes, the supernatant removed and the DNA pellet vacuum dried 
for 30 seconds before resuspension in 20 pi of sterile TE buffer 
(pH 7.6). The plasmid DNA was characterised by restriction 
endonuclease digestion.
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2.2.13 Large scale isolation of plasmid DNA
The initial steps were almost identical to those used above 
for small scale preparations, however, to ensure greater purity of 
plasmid DNA product equilibrium centrifugation on a caesium chloride 
cushion containing ethidium bromide was carried out following the 
alkali denaturation protocol. The efficacy of the equilibrium 
centrifugation is based on the fact that supercoiled plasmid DNA 
binds less of the ethidium bromide compared with open circular DNA 
or linear DNA. The supercoiled plasmid DNA therefore forms a 
discrete band further down the caesium chloride gradient (197). 
Using this protocol 500-1000 pg of plasmid DNA could be isolated 
from 1 litre of bacterial culture assuming the plasmid was present 
in reasonably high copy number within the bacterial host strain.
A single bacterial colony containing the required plasmid was 
inoculated into 10 mis of L-broth containing the appropriate 
antibiotic which for pCli was ampicillin at a concentration of 
100 pg/ml. The culture was incubated overnight at 37°C in an orbital 
incubator after which the whole bacterial suspension was inoculated 
into 500 mis of L-broth containing ampicillin (100 pg/ml) and the 
incubation continued for 20 hours. The 500 ml culture was placed in 
a sterile 500 ml centrifuge bottle and the bacteria pelleted by 
centrifugation at 4°C for 10 minutes in a Sorval RC 5B centrifuge at 
4000 x gmax. The supernatant was discarded in its entirety and the 
bacterial pellet fully resuspended in 20 mis of sterile lysis 
solution (25mM TRIS-HC1 (pH8.0), 5QmM glucose, lQmM EDTA) before the 
addition of lysozyme as a powder to a concentration of 5 mg/ml. 
Incubation at room temperature for 5 minutes ensured extensive
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bacterial lysis and was followed by the addition of 40 mis of 
freshly prepared, sterile alkaline/SDS (0.2N NaOH, 1% (w/v) SDS) to 
irreversibly denature the bacterial DNA. This mixture was incubated 
for 10 minutes on ice before 30 mis of ice-cold, sterile 5M 
potassium acetate (pH 4.8) were added. After mixing, the sample was 
left on ice for a further 10 minutes. Precipitated bacterial DNA and 
protein were pelleted by centrifugation at 16000 x gmax for 
10 minutes at 4°C in a Sorval RC 5B centrifuge. The supernatant was 
carefully removed to a fresh tube so ensuring that it was not 
contaminated by the precipitate. Isopropanol (0.6 volumes) was added 
to the supernatant and after mixing an incubation at room 
temperature for 15 minutes allowed the plasmid DNA to precipitate. 
Centrifugation at 16000 x gmax for 10 minutes at room temperature in 
a Sorval RC 5B centrifuge pelleted the DNA which was then washed in 
5 mis of 70% (v/v) ethanol before vacuum drying for approximately 
2 minutes. The DNA was now resuspended in 5 mis of sterile TE buffer 
(lOmM TRIS-HC1 (pH 8.0), ImM EDTA) and for every 1 ml of suspension, 
1 gram of solid caesium chloride added. Dissolution of the caesium 
chloride was followed by the addition of ethidium bromide to a 
concentration of 600 pg/ml and the refractive index of the whole 
solution was adjusted to 1.393. This mixture was then centrifuged at 
45000 revolutions per minute for 36 hours at 20 C in a 10 x 10 fixed 
angle rotor of a Centricon ultracentrifuge. The lower band of 
plasmid DNA was harvested and the ethidium bromide removed from the 
DNA solution by repeated extraction (4-6 times) with an equal volume 
of isopropanol saturated with caesium chloride. Removal of the 
caesium chloride could then be carried out by dialysis of the
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plasmid DNA. solution in a collodion bag against several changes of
500 mis of TE buffer (pH 7.6) over 24 hours. The DNA was
precipitated by the addition of 0.1 volume of 3M sodium acetate (pH 
5.2) and 2.5 volumes of ice-cold 95% ethanol. Mixing was followed by 
incubation at -20°C for at least 1 hour and centrifugation at 
16000 x gmax for 15 minutes at 4°C in a Sorval RC 5B centrifuge. The 
pelleted DNA. was washed twice in 5 mis of ice-cold 70% (v/v) 
ethanol, vacuum dried for approximately 2 minutes and resuspended in 
1 ml of sterile TE buffer (pH 7.6). Care was taken to optimise DNA 
recovery by washing the sides of the centrifuge tube with the TE
buffer. The plasmid DNA was divided into aliquots and stored at
-20°C until needed.
2.2.14 Purification of DNA from low melting point agarose gel
This method was employed to isolate specific fragments of the 
recombinant plasmid pCli (Section 3.2) for use as probes when 
localising Cl-inhibitor gene mutations already detected by RFLP 
analysis using the complete exon 2-8 pCli as probe.
Restriction enzyme digestion of pCli was followed by 
electrophoresis through a 0.8% (w/v) Seaplaque agarose gel as
previously described. The gel was examined following ethidium 
bromide staining by illumination under 320nm UV light. The 
appropriate DNA band was excised and the gel slice placed in a 
centrifuge tube containing 2 mis of sterile distilled water. The 
tube was heated to 70°C until the gel slice had melted and dispersed 
through the water. An equal volume of phenol saturated with TE 
buffer (lOmM TRIS-HC1 (pH 7.6), ImM EDTA) was added and vigorously
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mixed with the aqueous phase until an emulsion formed. Thereafter 
the aqueous and phenol phases were separated by centrifugation at 
4000 x gmax for 5 minutes at room temperature in an MSE 4L
centrifuge. The clear aqueous phase was collected and placed in a 
fresh, sterile centrifuge tube. To minimise DNA loss in the thick 
creamy interface that had formed between the aqueous and phenol 
phases after the first phenol extraction, a "back extraction"
procedure was performed. Sterile distilled water (0.5 ml) was added 
and after mixing and recentrifugation the aqueous phase was removed 
and added to the first aqueous phase. This pooled aqueous DNA
solution was re-extracted with phenol a further 4-6 times until the 
interface between the aqueous and phenol phases after centrifugation 
was clear. At this stage two chloroform extractions were performed. 
An equal volume of chloroform was used each time. Before DNA
precipitation the volume of the DNA solution was reduced to 200 pi 
by repeated butan-2-ol extractions at room temperature as follows. 
The DNA solution was inverted several times with an equal volume of 
butan-2-ol, the phases allowed to separate and the butan-2-ol 
removed. A fresh equal volume of butan-2-ol was added and the whole 
process repeated until the aqueous phase was reduced to the required 
200 pi. The DNA was then precipitated by adding 0.1 volume of 
sterile 7.5M ammonium acetate, 2.5 volumes of 95% ethanol, the
solution mixed and stored overnight at -20°C. Pelleting the DNA 
could now be carried out by centrifugation at 6000 x gmax for
15 minutes at 4°C in an Eppendorf 5412 microfuge. The pellet was
washed twice in ice-cold 70% (v/v) ethanol, vacuum dried for
30 seconds and resuspended in sterile TE buffer (pH 7.6).
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Reprecipitation and resuspension of the DNA in sterile TE buffer (pH 
7.6) was then carried out before use in a random priming reaction. 
Long term storage of the DNA fragments in TE buffer (pH 7.6) 
purified in this way was frozen at -20°C in small aliquots.
2.2.15 Construction of human genomic libraries in bacteriophage 
vector EMBL 3
(a) The critical starting point for human genomic library 
construction is the isolation of very high molecular weight human 
genomic DNA (198). The method used for this differed from that 
described in Section 2.2.2. After isolation of the peripheral blood 
leukocytes, as described in Section 2.2.1, the leukocytes were lysed 
in 5 mis of sterile lysis buffer containing lOOmM TRIS-HC1 (pH 7.5), 
lOOmM NaCl, lOmM EDTA and 1% (w/v) sarcosine. Lysis was achieved by 
very careful mixing of the cells with the lysis buffer for 2- 
3 minutes before the addition of proteinase K to a concentration of 
100 pg/ml. This mixture was then incubated for 2 hours at 55°C with 
periodic gentle inversion. Thereafter an equal volume of phenol 
saturated with TE buffer (lOmM TRIS-HC1 (pH 7.6), ImM EDTA) was 
added and gently mixed with the DNA solution for 15 minutes to 
ensure formation of an even emulsion. Centrifugation at 250 x gmax 
for 10 minutes at room temperature in an MSE 4L centrifuge separated 
the aqueous and phenol phases. The aqueous phase was now removed 
into a fresh, sterile centrifuge tube using a wide bore pipette 
ensuring minimal contamination by the creamy looking aqueous/phenol 
interface. Extraction with an equal volume of phenol/chloroform 
(1/1 v/v) saturated with TE buffer (pH 7.6) and then with an equal
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volume of chloroform followed. The final aqueous DNA containing 
phase was dialysed against four changes of 2 litres of sterile TE 
buffer (pH 7.6) containing lOOmM NaCl over a period of 24 hours 
followed by an identical period of dialysis against four changes of 
2 litres of sterile TE buffer (pH 7.6). All dialysis steps were 
carried out at 4°C. Estimation of DNA concentration was achieved by 
running a small aliquot of the DNA against known concentrations of 
lambda bacteriophage DNA in an ethidium bromide stained 0.5% (w/v) 
agarose gel. This was necessary because reading the UV adsorption of 
the DNA solution at 260 nm would have given a markedly inaccurate 
measurement of the DNA concentration due to the content of RNA 
within the DNA preparation.
(b) Partial endonuclease digestion of the high molecular 
weight genomic DNA was performed using the restriction enzyme 
Sau 3AI in order to generate 15-20kb fragments with cohesive ends 
suitable for ligation into the EMBL 3 bacteriophage vector. Sau 3AI 
cuts widely throughout the human genome to generate a set of 
restriction fragments which are representative of the vast majority 
of the sequences present in the human genome. Test digests of the 
genomic DNA were set up initially in which the DNA concentration, 
digest time, digest volume and temperature were kept constant and 
the amount of Sau 3AI varied. Electrophoresis of the resulting 
mixtures of DNA restriction fragments through a 0.5% (w/v) agarose 
gel allowed estimation of the concentration of enzyme which 
generated the maximum number of 15-20kb fragments. This 
concentration +/- 50% was then used to digest larger amounts of 
genomic DNA ready for bulk isolation of the 15-20kb fragments by
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sucrose gradient ultracentrifugation.
(c) Before ultracentrifugation the Sau 3AI digested genomic 
DNA was extracted once with an equal volume of phenol saturated with 
TE buffer (pH 7.6), followed by extraction with an equal volume of 
chloroform. The DNA was then ethanol precipitated by the addition of 
0.1 volume of sterile 7.5M ammonium acetate and 2.5 volumes of 95% 
ethanol. Storage of this mixture for at least one hour at -20°C was 
followed by centrifugation at 6000 x gmax for 10 minutes in an 
Eppendorf 5412 microfuge at 4°C in order to pellet the DNA. The DNA 
pellet was washed in 1 ml of ice-cold 70% (v/v) ethanol, vacuum 
dried for 30 seconds and resuspended in sterile TE buffer (pH 7.6) 
at a concentration of 300 pg/ml. The DNA was now ready for loading 
onto a sucrose gradient.
Sucrose gradients, 10% to 40% sucrose (w/v) in 20mM TRIS-HC1 
(pH 7.1), 1M NaCl, 20mM EDTA were used. Each gradient was made by 
successively underlayering equal volumes of 10%, 15%, 20%, 25%, 30%, 
35% and 40% sterile sucrose solutions into a 14 ml ultracentrifuge 
tube and leaving this to stand for 16 hours at room temperature to 
allow diffusion. A maximum of 100 pg of the digested DNA was layered 
on top of each gradient and the gradients centrifuged for 24 hours 
at 26000 revolutions per minute at 10 °C in a Centricon ultra­
centrifuge using a 6x14 swing out rotor. Each gradient was harvested 
by piercing the bottom of the centrifuge tube with a sterile 
21 gauge needle and collecting six drop fractions. A 10 pi aliquot 
of each of these fractions was electrophoresed through a 0.5% (w/v) 
agarose gel along with standard molecular weight size markers in 
order to identify which fractions contained the 15-20kb DNA
- 88 -
restriction fragments. It was important to adjust the sucrose and 
salt concentration of the molecular weight size markers to that of 
the gradient samples by the addition of a suitable volume of the 
sucrose gradient buffer to the marker samples since the high salt 
concentration markedly affected DNA fragment mobility through the 
gel. The gel was photographed and the fractions containing the 
15-20kb DNA fragments were identified. The DNA was precipitated 
separately from each of these fractions by the addition of two 
volumes of 95% ethanol. Mixing with the ethanol was followed by 
storage of the samples at -20°C for 48 hours before pelleting the 
DNA by centrifugation at 6000 x gmax for 30 minutes in an Eppendorf 
5412 microfuge at 4°C. The DNA pellet was then carefully washed 
twice with 1 ml of ice-cold 70% (v/v) ethanol, vacuum dried for 
30 seconds and resuspended in sterile TE buffer (pH 7.6) to give an 
approximate concentration of 0.5 pg/pl. A small aliquot (0.5-1.0 pi) 
of each DNA sample was electrophoresed through a 0.5% (w/v) agarose 
gel along with suitable molecular weight size markers and the gel 
photographed. Only those fractions which contained DNA fragments 
within the 15-20kb size range were reselected and pooled for further 
use in library construction.
(d) In order to prevent the insert DNA ligating to itself 
before being ligated into the EMBL 3 vector arms the 15-20kb insert 
fragments were phosphatased in order to remove their 5 ’ phosphate 
groups. The phosphatasing protocol was as follows. The DNA fragments 
were ethanol precipitated by the addition of 0.1 volume of sterile 
7.5M ammonium acetate and 2.5 volumes of ice-cold 95% ethanol. 
Incubation at -20 °C for 1 hour was followed by centrifugation at
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6000 x gmax for 10 minutes at 4°C in an Eppendorf 5412 microfuge to 
pellet the DNA which was now washed once in 1 ml of ice-cold 70% 
(v/v) ethanol. The DNA was repelleted by centrifugation at 6000 x 
gmax for 5 minutes, vacuum dried and resuspended in sterile lOmM 
TRIS-HCl (pH 7.5), lOmM EDTA at a concentration of approximately 
200 pg/ml. Calf intestinal alkaline phosphatase was added to a 
concentration of 0.5 unit/pg of DNA and the mixture incubated at 
37°C for 20 minutes. Thereafter sterile 1M NaCl was added to a final 
concentration of 200mM and the mixture extracted twice with an equal 
volume of phenol saturated with TE buffer (pH 7.6) and twice with an 
equal volume of chloroform. The DNA was ethanol precipitated, as 
just described, washed once in 1 ml of ice-cold 70% (v/v) ethanol, 
vacuum dried for 30 seconds and finally resuspended in sterile TE 
buffer (pH 7.6) at a concentration of 0.5 pg/pl.
(e) The next stage in library construction was the ligation of 
the purified, phosphatased 15-20kb insert fragments into the EMBL 3 
bacteriophage vector arms. For this stage commercially available 
EMBL 3 arms were used. An initial check was made to ensure firstly 
that the T4 DNA ligase to be used was active and secondly to ensure 
that the insert DNA had been properly phosphatased. A 1 pi aliquot 
containing 0.5 pg of either the unphosphatased or the phosphatased 
insert DNA was added to a 9 pi ligation reaction containing 1 unit 
of T4 DNA ligase, ImM ATP (pH 7.5), 5QmM TRIS-HCl (pH 8.0), 7mM 
magnesium chloride and ImM dithiothreitol. This mixture was 
incubated for 16 hours at 22°C then electrophoresed through a 0.5% 
(w/v) agarose gel and visualised by ethidium bromide staining of the 
gel. Generation of a high molecular weight band in the
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unphosphatased lane and maintenance of a 15-20kb smear in the 
phosphatased sample proved the activity of the ligase and the 
effectiveness of the phosphatasing respectively. The same batch of 
ligase was used for construction of the library as was used for 
these control ligations.
Library ligations were set up as follows. A ligation reaction 
volume of 5 pi was standardly used for all reactions and contained 
the same relative concentrations of T4 DNA ligase, ATP, TRIS-HCl, 
magnesium chloride and dithiothreitol as just described. The optimal 
ratio for predigested EMBL 3 vector arms to insert DNA in this 
system was found to be 1 pg of EMBL 3 arms to 0.4 pg of insert DNA 
in each ligation reaction. Ligations were incubated at 22°C for 
1 hour then at 4°C for 16 hours.
(f) The number of packageable and therefore viable recombinant 
EMBL 3 bacteriophage DNA molecules generated by the vector/insert 
ligation reaction now had to be assessed. Packaging of the 
recombinant bacteriophage DNA molecules was carried out by using the 
commercially available high efficiency bacteriophage packaging kit, 
Gigapack Gold. Each packaging kit contained "freeze-thaw" and 
"sonic" bacterial extracts which provided all the bacteriophage 
structural proteins necessary for packaging "naked" bacteriophage 
DNA. Following ligation, 4 pi of the ligation reaction were added to 
10 pi of the "freeze-thaw" extract which had just been thawed and 
this mixture was placed immediately on ice. The "sonic" extract 
which had been kept frozen at -70 C until this stage was now quickly 
thawed and 15 pi of it added to the "freeze-thaw"/DNA mixture on 
ice. Stir mixing was immediately carried out and the whole mixture
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then incubated at 22 C for 2 hours. At the end of this period 0.5 ml 
of sterile bacteriophage dilution buffer (50mM TRIS-HCl (pH 7.5), 
lOOmM NaCl, lOmM magnesium sulphate and 0.01% (w/v) gelatin) was 
added to the reaction followed by 20 pi of chloroform. The 
chloroform was mixed gently through the solution by repeated 
inversion and the precipitate which formed during this process 
pelleted by a 10 second centrifugation step in an Eppendorf 5412 
microfuge. The content of viable, packaged bacteriophage particles 
in the supernatant now had to be calculated by titrating the 
bacteriophage on a suitable bacterial host strain. A number of 
essential controls were included in the ligation and packaging steps 
in order to be able to accurately assess the number of viable 
recombinant bacteriophage particles created. These controls 
included - 1) a ligation reaction containing predigested EMBL 3 
bacteriophage arms alone without insert DNA, 2) insert DNA alone 
without arms and 3) arms plus a test insert. These reactions were 
subsequently packaged in order to assess both the background of the 
system and also to test the efficiency of the ligation and packaging 
reactions. The number of packageable, viable, non-recombinant 
bacteriophage that were generated by ligation of the EMBL 3 arms 
alone was particularly important when calculating the efficiency of 
generation of genuine recombinant bacteriophage. In addition, it was 
essential to know how many viable bacteriophage the packaging 
reagents themselves created without any DNA input. For the 
commercial kits used in this study this background was uniformly 
zero.
(g) Titrating the viable bacteriophage generated by the
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ligation/packaging reactions was now undertaken using the 
restrictive bacterial host E. coli NM539 which allowed the growth of 
only recombinant bacteriophage. A single colony of NM539 was picked 
from a 1.5% (w/v) agar plate on which the bacterial species had been 
streaked out. This colony was inoculated into 20 mis of L-Broth
supplemented with magnesium sulphate to lOmM and maltose to 0.2% 
(w/v) and incubated with shaking at 37 °C until the 0D600 reading of 
the bacterial suspension reached 0.5. The bacteria were then 
pelleted by centrifugation at 1000 x gmax for 5 minutes at 4°C in an 
MSE 4L centrifuge, the supernatant poured off and the bacteria 
resuspended in the same volume of ice-cold, sterile lOmM magnesium 
sulphate. Aliquots (100 pi) of this bacterial suspension were added 
to 100 pi of the bacteriophage suspension to be titrated. This
latter suspension comprised 1 pi of the packaging reaction 
supernatant diluted to 100 pi in sterile bacteriophage dilution 
buffer (5QmM TRIS-HCl (pH 7.5), lOOmM NaCl, lOmM magnesium sulphate, 
0.01% (w/v) gelatin). Gentle mixing of the bacterial suspension with 
the bacteriophage dilution was followed by a 15 minute incubation at 
37 °C to allow the bacteriophage to adsorb onto the surface of the 
bacteria. Thereafter 2.5 mis of sterile 0.6% LAM agar (0.6% w/v 
bactoagar in L-Broth (pH 7.5) supplemented with lOmM magnesium
sulphate and 0.2% (w/v) maltose) at 48 °C was added to each
adsorption reaction, mixed by inversion then poured onto the surface 
of a 1.2% (w/v) agar plate prewarmed to 37 C. This top agar layer 
was spread evenly over the surface of the 1.2% bottom agar and 
allowed to set on a perfectly flat surface for 15 minutes at room 
temperature. The plates were now inverted and incubated for 16 hours
- 93 -
at 37 °C. Counting the number of lytic bacteriophage plaques on the 
lawn of bacteria allowed calculation of the number of bacteriophage 
present in the packaging reaction supernatants and so the efficiency 
of recombinant bacteriophage production per pg of input EMBL 3 arms. 
It was then possible to work out the number of subsequent ligation 
and packaging reactions that would have to be carried out to 
complete the library based on the following guidelines. For a human 
genomic library using a 15-20kb insert, approximately 1 million 
recombinants were deemed sufficient to give a 99% chance of the 
library containing the required sequence (199). Once created the 
recombinant bacteriophage were stored at 4°C until needed.
2.2.16 Clinical survey of HAE in Scotland
All Scottish hospital consultants in medicine and its major 
subspecialities, dermatology, paediatrics, haematology, clinical 
immunology, biochemistry and blood transfusion were circulated with 
a letter enquiring whether they had patients with Type I or Type II 
HAE under their care along with an explanation of the reasons for 
the survey. If they were currently managing HAE patients each 
consultant was contacted again and requested to provide the 
following details - number of patients, names, sex, age and clinical 
history. Included in the clinical history was the following 
information - age at diagnosis; symptoms at diagnosis; duration of 
symptoms before diagnosis; treatment; effect of treatment on 
symptoms; factors which precipitate acute disease attacks; remission 
in pregnancy if appropriate; family history of the disease; disease 
related deaths; interest in prenatal diagnosis. This allowed an
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estimation of overall disease incidence and allowed the construction 
of a disease profile for each affected patient and family. It was 
then possible to examine the main problems facing each kindred. When 
no reply was received from a consultant regarding the presence or 
absence of HAE patients under their care, the consultant was 
contacted personally by telephone to obtain the necessary 
information.
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3.1 Characterisation of the Cl-inhibitor cDNA (pCli)
An essential prerequisite for using a recombinant DNA molecule 
as a probe is to confirm its identity. One of the most convenient 
ways of doing this is to carry out a number of restriction enzyme 
digests on the intact molecule in order to demonstrate generation of 
a fragment pattern that can be predicted from its known restriction 
map. For the exon 2-8 Cl-inhibitor cDNA cloned into the Bam HI site
of pUC13 (pCli), as described in Section 2.1.3, three sets of
digests were chosen as follows - (a) pCli digested with Hind III, 
(b) pCli digested with Eco RI and (c) pCli digested with 
Hind III/Eco RI. The restriction maps for the exon 2-8 Cl-inhibitor 
cDNA (67) and for pUC13 (200) predict approximate fragment sizes of 
4.4kb for digest (a), 3.9kb and 0.5kb for digest (b) and 2.6kb,
1.3kb and 0.5kb for double digest (c). Confirmation of these
fragment patterns and sizes is shown in Figure 3. Digest (c) excises 
the entire Cl-inhibitor cDNA from pUCl3 in the form of the 1.3kb and 
0.5kb fragments as described by Bock et al (67).
- 97 -
1 2 3 4 5
kb
21.2 —
5 . 1 —  
3.5—  
2.0—  
0.9 —  
0.5 —
FIGURE 3
Characterisation of pCli. Lanes 1 and 5 represent the molecular 
weight markers generated when lambda bacteriophage DNA is restricted 
with Eco RI/Hind III. Lane 2 represents pCli restricted with 
Hind III which linearises the recombinant and generates a 4.4kb 
fragment. Lane 3 represents pCli restricted with Eco RI which 
generates two fragments of 3.9kb and 0.5kb. Lane 4 represents pCli 
restricted with Hind III/Eco RI which generates three fragments of 
2.6kb, 1.3kb and 0.5kb. The 1.3kb and 0.5kb fragments in lane 4 
comprise the whole of the exon 2-8 Cl-inhibitor cDNA insert. These 
restriction fragment patterns and sizes are those predicted from the 
published restriction map of pCli (67) and pUCl3 (200).
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3.2 Isolation of specific pCli restriction fragments
It was necessary to isolate certain pCli restriction fragments 
which could then be used as probes specific for the 5', middle and 
3’ ends of the Cl-inhibitor gene. As shown in Figure 4, the 5' 
fragment corresponds to the 5' end of the Cl-inhibitor cDNA up to
the Bgl II recognition site in exon 4. The middle fragment extends
from this Bgl II site to the Eco RI site at the very beginning of 
exon 8 and the 3' fragment is the whole of exon 8. For ease of 
purification the 3' fragment was isolated first following Eco RI 
digestion of pCli and electrophoresis of the whole digest reaction 
through a low melting point Seaplaque agarose gel (Figure 5). The 
two DNA fragments generated by Eco RI were then isolated from the
gel as described in Section 2.2.14. The 527 base pair (bp) fragment
was retained for use as the 3' exon 8 specific probe while the 
larger 3.9kb fragment was digested using the endonuclease Bgl II. 
This generated a 584bp fragment representing the middle (exon 4-7) 
probe and a 3.3kb fragment representing the 51 exon 2-4 probe with 
attached pUC13 DNA (Figure 4). The entire 3.3kb fragment was used as 
the 5' probe without removal of the pUC13 DNA.
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FIGURE 4
Restriction map of pCli. The Bgl II and Eco RI restriction sites 
show where the c D M  was cleaved to generate the 51 (exon 2-4), 
middle (exon 4-7) and 3' (exon 8) probes that were used to localise 
the Cl-inhibitor gene mutations.
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FIGURE 5
Isolation of specific pCli restriction fragments. Lanes 1 and 9 
represent the molecular weight size markers generated when lambda 
bacteriophage DNA is restricted with Eco Rl/Hind III. Lane 2 
represents pCli restricted with Hind III generating the 4.4kb 
linearised form. Lane 3 represents pCli restricted with Eco RI 
generating 3.9kb and 0.5kb (527bp) fragments. Lanes 4 and 5 show the 
3.9kb fragment and 527bp fragment respectively after purification of 
each separately from a low melting point agarose gel. The 527bp 
fragment represents exon 8 of pCli as shown in Figure 4. Lane 6 
represents the purified 3.9kb fragment shown in lane 4 restricted 
with Bgl II to generate the 3.3kb and 0.5kb (584bp) fragments. Each 
of these two fragments was purified separately from a low melting 
point agarose gel as shown in lanes 7 and 8. The 584bp fragment 
represents the middle (exon 4-7) fragment of pCli and the 3.3kb 
fragment is the 5* (exon 2-4) fragment of pCli with attached pUCl3 
DNA. Each of the fragments shown in Lanes 5, 7 and 8 were used as 
the 3’, 5' and middle probes respectively.
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3.3 Restriction fragment analysis of the normal Cl-inhibitor gene
A total of 38 separate restriction endonucleases were used to 
study the Cl-inhibitor gene in this investigation. These enzymes are 
listed in Table 4. The restriction fragments generated by each of 
these enzymes as detected by using the exon 2-8 Cl-inhibitor cDNA as 
probe are shown in Figures 6 to 18. The restriction fragment sizes 
generated by each enzyme are marked beside the autoradiographs. Five 
of these enzymes generated multiple small fragments due to the high 
frequency of their recognition sites within the Cl-inhibitor gene 
(Table 5). In addition, some of the bands consisted of multiple 
similarly sized restriction fragments from a number of areas of the 
gene. Identification of a mutation affecting just one of these 
constituent fragments could therefore be difficult with the 
electrophoretic conditions routinely used. In contrast, the enzymes 
listed in Table 6 had few recognition sequences within the 
Cl-inhibitor gene and so many generated a single high molecular 
weight fragment which spanned much of the gene. For these large 
fragments it would require a major gene deletion or insertion to 
produce a detectable alteration in fragment size using 0.8% agarose 
gel electrophoresis. Alternatively, it would need a critically 
placed mutation destroying or creating a recognition site for that 
enzyme. Overall, therefore, the restriction enzymes with either very 
frequent recognition sites within the Cl-inhibitor gene or with very 
infrequent recognition sites were less likely to be recognisably 
informative in RFLP analysis of the Cl-inhibitor gene using these 
electrophoretic conditions. A substantial proportion of the enzymes 
(Table 7) generated multiple well-spaced, easily resolved fragments
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which were more likely to generate identifiable RFLPs when used for 
analysis of the Cl-inhibitor gene. Indeed, as will be described in 
the following sections, a significant number of these enzymes did 
generate identifiable RFLPs. By comparison only a small number of 
the enzymes listed in Tables 5 and 6 contributed useful data.
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TABLE 4 RESTRICTION ENDONUCLEASES USED IN RFLP ANALYSIS OF THE 
Cl—INHIBITOR GENE
RESTRICTION RECOGNITION RESTRICTION RECOGNITION
ENDONUCLEASE SEQUENCE ENDONUCLEASE SEQUENCE
Alu I AG'CT
Apa I GGGCC'C
Ava I C1PyCGPuG
Bam HI CGATCC
Bel I T’GATCA
Bgl I GCCNNNN’NGGC
Bgl II A ’GATCT
Bst Eli G’GTNACC
Cla I AT’CGAT
Dde I CTNAG
Dra I TTT’AAA
Eco RI G’AATTC
Hae II PuGCGC’Py
Hae III GG’CC
Hgi AI G(A/T)GC(A/T),C
Hha I GCG’C
Hinc II GTPy’PuAC
Hind III A'AGCTT
Hinf I G’ANTC
Hpa I GTT'AAC
Kpn I GGTAC'C
Msp I CCGG
Pst I CTGCA'G
Pvu I CGAT’CG
Pvu II CAG’CTG
Rsa I GT’AC
Sal I G’TCGAC
Sau 3AI ’GATC
Sea I AGT'ACT
Sma I CCC'GGG
Sst I GAGCT'C
Sst II CCGC’GG
Stu I AGG’CCT
Taq I T’CGA
Sty I C’C(A/T)(A/T)GG
Xba I T'CTAGA
Xho I C’TCGAG
Xmn I GAANN’NNTTC
Recognition sequences are written 51 to 3’ and the point of cleavage 
is indicated by ’. N represents any nucleotide. Py and Pu indicates 
pyrimidine and purine nucleotides respectively. (A/T) is A or T at 
that position.
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FIGURE 6
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Alu I, Apa I and Ava I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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>FIGURE 7
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Bam HI, Bel I and Bgl I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 8
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Bgl II, Bst Eli and Cla I for the Cl-inhibitor gene 
and detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
Ddel Dral
kb
5.5
5.3 r m
3 . 7 -
2.4 —
0 . 5 -  
0.4 _  
0 . 3 -  
0.2 -
Eco RI
2 0 .3 -  -
4 - 1 - .  
3 . 6 -  *  
3.3^
2.2 - #
FIGURE 9
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Dde I, Dra I and Eco RI for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 10
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Hae II, Hae III and Hha I for the Cl-inhibitor gene 
and detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 11
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Hgi AI, Hinc II and Hind III for the Cl-inhibitor gene 
and detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 12
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Hinf I, Hpa I and Kpn I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 13
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Msp I, Pst I and Pvu I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 14
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Pvu II, Rsa I and Sal I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 15
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Sau 3AI, Sea I and Sma I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 16
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Sst I, Sst II and Stu I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA. as probe.
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FIGURE 17
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Sty I, Taq I and Xba I for the Cl-inhibitor gene and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe.
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FIGURE 18
Restriction fragment patterns and sizes generated by the restriction 
endonucleases Xho I and Xmn I for the Cl-inhibitor gene and detected 
by using the exon 2-8 Cl-inhibitor cDNA. as probe.
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TABLE 5 RESTRICTION MDONUCLEASES WHICH GENERATE MULTIPLE LOW
molecular weight ci-inhibitor gene fragments
RESTRICTION ENDONUCLEASE FRAGMENT SIZES (kb)
Alu I o • 00 0.4, 0.2
Dde I 0.5, 0.4, 0.3, 0.2
Hae III 1.1, 0.7, 0.5, 0.3
Hinf I 0.9, o • 00 0.6, 0.2
Sau 3AI 0.9, •N
oo•o 0.5, 0.3
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TABLE 6 RESTRICTION ENDONUCLEASES WHICH GENERATE HIGH MOLECULAR 
WEIGHT Cl—INHIBITOR GENE FRAGMENTS
RESTRICTION ENDONUCLEASE FRAGMENT SIZES (kb)
Ava I 30.0, 21.0
Bel I 30.0
Bgl I 22.0, 5.2
Cla I 35.0
Hae II 30.0
Hha I 30.0, 5.1
Hpa I 22.0
Pvu I 50.0
Sal I 40.0
Sea I 21.0, 12.0
Sma I 30.0, 6.0
Sst II 45.0
Xho I 40.0
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TABLE 7 RESTRICTION ENDONUCLEASES WHICH GENERATE MULTIPLE WELL 
SPACED Cl-INHIBITOR GENE FRAGMENTS
RESTRICTION ENDONUCLEASE FRAGMENT SIZES (kb)
Apa I 12.0, 8.8, 2.6
Bam HI 7.0, 5.0, 2.3, 1.0
Bgl II 10.8, 10.2, 6.5, 1.9
Bst Eli 10.5, 5.0, 1.5
Dra I 5.5, 5.3, 3.7, 2.4
Eco RI 20.3, 4.1, 3.6, 3.3, 2.2
Hgi AI 2.4, 2.2, 1.7, 1.2, 0.85, 0.4, 0.3
Hinc II 7.6, 4.8, 2.8, 2.6, 1.8
Hind III 14.1, 4.2, 0.6
Kpn I 24.0, 13.0, 4.9
Msp I 3.5, 2.3, 1.9, 1.7, 1.3
Pst I 4.1, 3.1, 2.6, 2.4, 0.4
Pvu II 5.0, 3.2, 2.5, 2.3, 0.9
Rsa I 2.0, 1.9, 1.5, 1.2, 0.7, 0.5
Sst I 12.0, 6.0, 3.0, 1.6
Stu I 11.1, 5.5, 5.2
Sty I 4.8, 3.7, 0.9, 0.7, 0.2
Taq I 4.3, 3.7, 2.6, 2.4, 1.4
Xba I 21.0, 10.5, 1.3
X m  I 16.0, 8.2, 2.3, 1.8
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3.4 Cl-inhibitor gene RFLPs in the normal population
The restriction fragment patterns for all 38 restriction 
enzymes were established for genomic DNA samples from 25 normal 
individuals. Two of the restriction enzymes generated identifiable 
Cl-inhibitor gene RFLPs in these normal individuals. The enzymes 
involved were Kpn I and Hgi AI.
The enzyme Kpn I generated an RFLP which had not been reported 
previously. The polymorphism has two alleles which are represented 
by 30kb and 13kb hybridising fragments (Figure 19). The allele 
frequency for each was 0.2 and 0.8 respectively for a total of 50 
chromosomes examined (Table 8). Studies to localise the genomic 
mutation responsible for this polymorphism showed that both the 
middle (exon 4-7) and the 3' (exon 8) probes detected the 
polymorphic fragments as shown in Figure 20 for the 3' probe. The 5' 
probe detected only the 24kb restriction fragment appropriate for 
the 5* end of the gene (Figure 21). These data in conjunction with 
known Cl-inhibitor gene sequence (183) indicated that the RFLP arose 
due to a mutation involving the first Kpn I recognition site that 
lies approximately lOkb downstream of the 3T end of the Cl-inhibitor 
gene as shown in Figure 22. No further investigations were carried 
out to try and characterise the nature of the mutation. Serum 
Cl-inhibitor levels were measured for all 25 normal individuals 
whose DNA samples had been used. No relationship could be 
demonstrated between possession of a particular Kpn I allelic 
combination and the serum Cl-inhibitor concentration. Family studies 
were consistent with co-dominant Mendelian inheritance for this 
polymorphism.
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Detection of the Hgi AI RFLP in the normal population served 
to confirm the observations of Bock et al in the North American 
population (67). The polymorphism has two alleles represented by 
0.7kb and 0.4kb hybridising fragments as shown in Figure 23. The 
allele frequency was 0.38 and 0.62 respectively for the 50 
chromosomes studied (Table 9). This frequency is very similar to the 
0.32 and 0.68 reported by Bock et al (67). Bock and her colleagues 
established that this polymorphism was due to a G to A mutation in 
the triplet codon for amino-acid 458 in the Cl-inhibitor protein. 
This mutation destroyed the Hgi AI recognition sequence and caused a 
valine (GTG) to methionine (ATG) amino-acid substitution in the 
protein. In this study a relationship could not be demonstrated 
between possession of a particular Hgi AI allelic combination and 
serum Cl-inhibitor concentration or Cl-inhibitor functional 
activity. A co-dominant mode of inheritance was observed in family 
studies.
None of the remaining 36 restriction enzymes showed 
identifiable RFLPs with the electrophoretic conditions employed.
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FIGURE 19
Cl-inhibitor gene RFLP generated by Kpn I and detected by using the 
exon 2-8 Cl-inhibitor cDNA as probe. Lanes 1, 2 and 7 represent a 
homozygote for the 13kb allele, a heterozygote and a homozygote for 
the 30kb allele respectively. All the remaining lanes represent 
homozygotes for the 13kb allele except lane 5 which is a 
heterozygote. The faint 4.9kb fragment which is normally present in 
a genomic Kpn I digest (Figure 12) had migrated off the bottom of 
this gel due to the prolonged electrophoresis time employed to 
ensure good separation of the 30kb and 24kb fragments. There is a 
50% reduction in the intensity of the 13kb fragment in the 
heterozygote lanes 2 and 5 with complete absence of this fragment in 
lane 7 which represents a homozygote for the 30kb allele.
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TABLE 8 POPULATION FREQUENCIES OF Kpn I ALLELES
Kpn I NUMBER OBSERVED PHENOTYPE FREQUENCY
ALLELIC FRAGMENTS
30kb + 30kb 
30kb + 13kb 
13kb + 13kb
2
6
17
0.08
0.24
0.68
ALLELE FREQUENCY
30kb 0.2
13kb 0.8
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FIGURE 20
Cl-inhibitor gene RFLP generated by Kpn I and detected by the 3’ 
(exon 8) probe. Lanes 1, 2 and 6 represent a homozygote for the 13kb 
allele, a heterozygote and a homozygote for the 30kb allele 
respectively. Lanes 3, 4 and 5 represent genomic DNA samples from 
each of these individuals digested with Kpn I/Bgl II generating 
6.5kb and 1.9kb fragments. These are the fragment sizes expected 
from Cl-inhibitor gene sequence data for the 3' end of the gene as 
shown in Figure 22 (183). Lane 7 represents Bgl II digested DNA. 
generating the 6.5kb and 1.9kb fragments as expected for the 3' end 
of the gene.
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FIGURE 21
Cl-inhibitor gene restriction fragment generated by Kpn I and 
detected by the 51 (exon 2-4) probe. Lane 1 represents the invariant 
24.0kb Kpn I fragment which is appropriate for the 5' end of the 
gene (183). Lane 2 represents Bgl II digested DNA from the same 
individual. There is a 10.8kb fragment detected in this lane which 
is appropriate for the 5* end of the gene and which confirms the 5’ 
origin of the 24kb Kpn I fragment.
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FIGURE 22
Restriction map of the 3’ end of the Cl-inhibitor gene. The fragment 
sizes generated by Kpn I and Bgl II digests as detected by the 31 
(exon 8) probe are shown. Exons are represented by open rectangles 
containing the exon number and introns by the line connecting the 
exons. The 30kb fragment is derived from the 13kb fragment by loss 
of the first Kpn I recognition site downstream (31) of the 
Cl-inhibitor gene. The positions of the 6.5kb and 1.9kb fragments 
generated by the Bgl II and Kpn I/Bgl II digests are shown.
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FIGURE 23
Cl-inhibitor gene RFLP generated by Hgi AI and detected by using the 
exon 2-8 Cl-inhibitor cDNA as probe. Lane 1 represents a 
heterozygote for the 0.7kb and 0.4kb alleles and lane 2 represents a 
homozygote for the 0.4kb allele. A 50% reduction in intensity of the 
0.4kb fragment is seen in lane 1 compared with lane 2 as expected 
for this two allele system.
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TABLE 9 POPULATION FREQUENCIES OF Hgi AI AT.T.KT.KS
Hgi AI NUMBER OBSERVED PHENOTYPE FREQUENCY
ALLELIC FRAGMENTS
0.7kb + 0.7kb 1 0.04
0.7kb + 0.4kb 17 0.68
0.4kb + 0.4kb 7 0.28
ALLELE FREQUENCY
0.7kb
0.4kb
0.38
0.62
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3.5 Cl-inhibitor gene RFLPs in hereditary angio-oedema
A total of 12 kindred with Type I HAE and two kindred with 
Type II HAE were screened for Cl-inhibitor gene RFLPs using the exon 
2-8 Cl-inhibitor cDNA as probe. Four of the Type I HAE kindred were 
found to have Cl-inhibitor gene RFLPs which co-segregated with the 
disease. Neither of the Type II HAE kindred showed an identifiable 
abnormality. Once identified, the location of the Cl-inhibitor gene 
mutation responsible for each RFLP was established by using the 51, 
middle and 3’ fragments of the exon 2-8 Cl-inhibitor cDNA as probes. 
Each of these Cl-inhibitor gene RFLPs will be described in turn. 
Family A - The Cl-inhibitor gene RFLP in this family was generated 
by the restriction enzyme Sty I and was represented by an additional 
l.lkb fragment accompanied by a 50% reduction in the intensity of 
the 0.9kb fragment as shown in Figure 24. A total of 23 family 
members from three generations of the family were tested with only 
the nine DNA samples from Type I HAE patients showing the 
polymorphism (Figure 25). Localisation studies showed that the RFLP 
was detected by the middle (exon 4-7) probe (Figure 26). When the 5’ 
(exon 2-4) and the 3’ (exon 8) fragments were used as probes only 
the normal Sty I restriction fragments appropriate for the 5T and 3f 
ends of the gene were detected in both normal and patient samples as 
shown in Figure 27 and Figure 28 respectively. This information in 
conjunction with known Cl-inhibitor gene sequence (183) indicated 
that the polymorphism was due to a mutation within one Cl-inhibitor 
allele that produced loss of the Sty I recognition site that lies 
very close to the 3’ end of the sixth exon (Figure 29). A major 
deletion or insertion event did not appear to be responsible for the
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mutation. This conclusion was based on two sets of observations. 
Firstly, no changes in the sizes of restriction fragments spanning 
the mutated area of the gene were apparent at the resolution of 
Southern analysis. Furthermore, the size of the l.lkb fragment was 
derived by simply adding the sizes of its constituent fragments 
together (0.9kb + 0.2kb). Secondly, the positions of the restriction 
enzyme recognition sites for Rsa I and Hinf I (Figure 29), both of 
which lie within 40 base pairs of the mutated Sty I site, were 
unaffected. The likely significance of the position of this mutation 
at an exon/intron boundary will be discussed.
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FIGURE 24
Cl-inhibitor gene RFLP generated by Sty I in Family A and detected 
by using the exon 2-8 Cl-inhibitor cDNA as probe. Lane 1 represents 
the restriction fragment pattern for a family member with Type I 
HAE. Lane 2 represents the pattern for a normal family member. There 
is an additional l.lkb fragment in lane 1 with a 50% reduction in 
the intensity of the 0.9kb fragment.
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FIGURE 25
Detailed family tree for Family A showing the six main subdivisions 
with males indicated by a square and females by a circle. 
Individuals with Type I HAE are indicated by a star underlying their 
symbol, A dot within the symbol indicates those family members with 
Type I HAE who underwent RFLP analysis.
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FIGURE 26
Cl-inhibitor gene RFLP generated by Sty I in Family A and detected 
by the middle (exon 4-7) probe. Lane 1 represents the restriction 
fragment pattern for a normal family member and lane 2 represents 
the pattern for a family member with Type I HAE. There is an 
additional l.lkb fragment in lane 2 with a 50% reduction in the 
intensity of the 0.9kb fragment. Lane 3 represents Sty I/Bgl II 
digested DNA from the same HAE patient as in lane 2. The polymorphic 
fragments are unaffected however the 3.7kb fragment is reduced in 
size to 2.0kb as predicted from sequence data for this region of the 
Cl-inhibitor gene (183).
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FIGURE 27
Cl-inhibitor gene restriction fragments in Family A as detected by 
the 5' (exon 2-4) probe. Lanes 1 and 2 represent Sty I digested DNA 
from a normal family member and a Type I HAE family member 
respectively. A 4.8kb fragment is generated in both lanes as 
expected for the 5' end of the gene (183). Lanes 3 and 4 represent 
Sty I/Bgl II digested DNA from the same Type I HAE patient and 
normal family member respectively. A 4.8kb fragment is generated in 
both lanes as expected for the 5' end of the gene. Lane 5 represents 
DNA from a Type I HAE family member digested with Bgl II. This 
generates a 10.8kb fragment which is appropriate for the 5' end of 
the gene.
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FIGURE 28
Cl-inhibitor gene restriction fragments in Family A as detected by 
the 3! (exon 8) probe. Lanes 1 and 2 represent Sty I digested DNA 
from a normal family member and a Type I HAE family member 
respectively. A 0.7kb fragment is generated in both lanes as 
expected for the 3f end of the gene (183). Lanes 3 and 4 represent 
Sty I/Bgl II digested DNA from the same Type I HAE patient and 
normal family member respectively. A 0.2kb fragment is generated in 
both lanes as expected for the 3' end of the gene. The 0.2kb 
fragment is very faint in lane 4 as a result of a smaller amount of 
DNA being present in this lane compared with lane 3. Lane 5 
represents DNA from a Type I HAE family member digested with Bgl II. 
This generates 6.5kb and 1.9kb fragments which are appropriate for 
the 3' end of the gene.
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FIGURE 29
Restriction map of the 3f half of the Cl-inhibitor gene as detected 
by the middle (exon 4-7) probe for Family A. Loss of the Sty I site 
at the 3’ end of exon 6 generates the l.lkb fragment (0.9kb + 0.2kb) 
present in family members with Type I HAE. The positions of the 
recognition sites for the restriction enzymes Rsa I and Hinf I which 
flank the mutated Sty I site are shown. These sites are unaffected 
by the mutation in the Cl-inhibitor gene in Family A. The 0.2kb 
fragment was not detected by the exon 2-8 or middle (exon 4-7) probe 
since the nucleotide composition of this fragment includes only four 
nucleotides derived from the sixth exon. The faint signal present in
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FIGURE 29 (continued)
Figure 26 of approximately 0.2kb in size represents more than one 
similarly sized fragment (0.1-0.2kb) derived from the 5* half of the 
gene (183). It does not represent the 0.2kb fragment from the 31 end 
of the sixth exon and 51 end of the sixth intron. The 5f (exon 2-4) 
probe does not apparently detect the 0.1-0.2kb fragments derived 
from the 5' end of the gene in Figure 27 due to the fact that the 
exposure time for the autoradiograph was too short for these low 
intensity fragments to be recorded.
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Family B - Analysis of Bgl II digested DNA from the one affected and 
two available normal family members showed a Cl-inhibitor gene RFLP 
in the Type I HAE patient. The RFLP comprised an additional 8.4kb 
fragment with a 50% reduction in the intensity of the 6.5kb and 
1.9kb fragments as shown in Figure 30. Localisation studies for this 
gene mutation showed that the RFLP was detected by the 3’ (exon 8) 
probe (Figure 31). When the middle and 5' cDNA fragments were used 
as probes only the normal restriction fragments appropriate for 
those areas of the gene were detected as shown in Figure 32 for the 
middle probe. This information in conjunction with known 
Cl-inhibitor gene nucleotide sequence (183) indicated that the 
polymorphism was due to a mutation within one Cl-inhibitor allele 
that produced loss of the Bgl II recognition site present in exon 8 
towards its 5T end (Figure 33). A major deletion or insertion event 
did not appear to have given rise to the mutation since no 
alteration in the sizes of restriction fragments spanning the 
mutated area was seen and the size of the 8.4kb fragment was derived 
by simply adding the sizes of its constituent fragments together 
(6.5kb + 1.9kb). In addition, the positions of the adjacent
restriction sites for Taq I and Pst I (Figure 33) were preserved.
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FIGURE 30
Cl-inhibitor gene RFLP generated by Bgl II in Family B and detected 
by using the exon 2-8 Cl-inhibitor cDNA as probe. Lane 1 represents 
the restriction fragment pattern for a normal family member. Lane 2 
represents the pattern for the Type I HAE family member. There is an 
additional 8.4kb fragment in lane 2 with a 50% reduction in the 
intensity of the 6.5kb and 1.9kb fragments. The 1.9kb fragment is so 
faint at this autoradiograph exposure that the reduction in its 
intensity cannot be appreciated.
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FIGURE 31
Cl-inhibitor gene RFLP generated by Bgl II in Family B and detected 
by the 3’ (exon 8) probe. Lanes 1 and 3 represent the restriction 
fragment pattern for two normal family members. Lane 2 represents 
the pattern for the family member with Type I HAE. There is an 
additional 8.4kb fragment in lane 2 with a 50% reduction in the 
intensity of the 6.5kb and 1.9kb fragments. Lane 4 represents the 
fragment pattern for Bgl II digested DNA from an unrelated control. 
Lanes 5, 6 and 7 represent the restriction fragment patterns for 
Bgl II /Hind III digested DNA from the same two normal family members 
and from the Type I HAE patient (lane 6). An additional 4.2kb 
fragment is present in lane 6 with a 50% reduction in the intensity 
of the 3.7kb and 0.5kb fragments. These are the fragment sizes 
expected for a Bgl II/Hind III digest of the 3* end of the mutated 
and normal gene (183).
0.6—
FIGURE 32
Cl-inhibitor gene restriction fragments in Family B as detected by 
the middle (exon 4-7) probe. Lanes 1 and 3 represent DNA from two 
normal family members digested with Bgl II/Hind III. Lane 2 
represents DNA from the Type I HAE patient digested with 
Bgl II/Hind III. The 9.6kb and 0.6kb fragments generated in all 
three lanes are as expected for the middle region of the gene (183).
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FIGURE 33
Restriction map of the 3’ end of the Cl-inhibitor gene for Family B. 
The 3* (exon 8) probe detects the 6.5kb and 1.9kb Bgl II fragments 
in normal family members. Loss of the Bgl II site in exon 8 
generates the 8.4kb fragment (6.5kb + 1.9kb) present in the Type I 
HAE family member. The positions of the recognition sites for the 
restriction enzymes Taq I and Pst I which flank the mutated Bgl II 
site in exon 8 are shown. These sites are unaffected by the mutation 
in the Cl-inhibitor gene from Family B.
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Family C - A total of eight family members, including six Type I HAE 
patients, were examined for Cl-inhibitor gene RFLPs. RFLPs were 
identified in the six Type I HAE patients with nine separate 
restriction enzymes. There was loss of a Bgl II recognition site 
with generation of an additional 20kb fragment and a 50% reduction 
in the intensity of the 10.8kb and 10.2kb fragments as shown in 
Figure 34. The enzymes Bam HI, Bgl I, Bst Eli, Dra I, Hinc II, Sst I 
and Stu I all generated an additional fragment which was 
consistently about lkb smaller than the corresponding normal 
fragment whose intensity was reduced (Figure 34). Finally, the 
restriction fragment pattern for the enzyme Taq I showed a 50% 
reduction in the intensity of the 1.4kb fragment (Figure 35). There 
was no apparent generation of an additional fragment by Taq I. 
Localisation studies for this gene mutation showed that the RFLPs 
were detected by the 5' and middle probes as shown in Figure 36 for 
the 5' probe. The 3f probe detected identical patient and control 
restriction fragments appropriate in size for the 3' end of the 
Cl-inhibitor gene (Figure 37). These findings interpreted along with 
known Cl-inhibitor gene structure (183) indicated that the mutated 
Bgl II site lay in the fourth exon of one Cl-inhibitor allele 
(Figure 38). Furthermore, when combined with the fact that there was 
a lkb reduction in the size of restriction fragments spanning the 
fourth exon and its flanking introns, this indicated that the gene 
lesion most probably represented an example of the exon 4 deletion 
described recently by Stoppa-Lyonnet et al in Type I HAE (188). This 
was confirmed by the 50% reduction in intensity of the 1.4kb Taq I 
fragment since this fragment spans only the fourth exon and portions
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of its adjacent introns as shown in Figure 38. The apparent lack of 
generation of an additional fragment by Taq I is due to the fact 
that although a complete exon 4 deletion does produce an abnormal 
sized Taq I fragment, this fragment is purely intronic in origin and 
so does not hybridise to the cDNA. probe.
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FIGURE 34
Cl-inhibitor gene RFLPs in Family C detected by using the exon 2-8 
Cl-inhibitor cDNA as probe. Lanes 1 and 2 represent Bgl II digested 
DNA from a normal family member and from a Type I HAE family member 
respectively. There is an additional 20kb fragment in lane 2 with a 
50% reduction in the intensity of the 10.8kb and 10.2kb fragments. 
Each of the lane pairs 3 and 4, 5 and 6, 7 and 8, 9 and 10, 11 and 
12, 13 and 14, 15 and 16 represent normal and Type I HAE patient 
DNAs digested with the following enzymes - Bam HI, Sst I, Hinc II, 
Bgl I, Bst Eli, Stu I and Dra I respectively. There is an additional 
fragment in lanes 4, 6, 8, 10, 12, 14 and 16 which correspond to 
each of the patient lanes for each enzyme. Each additional fragment
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FIGURE 34 (continued)
is approximately lkb smaller than the corresponding normal fragment 
which is reduced in intensity by 50% except for the enzymes Bam HI 
and Sst I where the reduction in intensity is less than this due to 
the fact that the normal "fragment" for each enzyme is a closely 
spaced doublet whose constituent fragments have not been resolved. 
In lanes 1 and 2 the normal 1.9kb fragment generated by Bgl II is 
not visible due to the relatively short exposure time for this 
autoradiograph.
-147-
kb
Taq I 
1 2
4.3 —  mm
3.7” ™
2.6 — mm
2.4/" 
1.4- -
FIGURE 35
Cl-inhibitor gene RFLP generated by Taq I in Family C and detected 
by using the exon 2-8 Cl-inhibitor cDNA as probe. Lane 1 represents 
the restriction fragment pattern for a normal family member and 
lane 2 is the pattern for a family member with Type I HAE. There is 
a 50% reducton in the intensity of the 1.4kb fragment in lane 2. No 
additional fragment is detected.
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FIGURE 36
Cl-inhibitor gene RFLPs generated by Bam HI and Bgl II in Family C 
and detected by the 5' (exon 2-4) probe. Lane 1 represents the 
Bam HI restriction fragment pattern for a normal family member. 
Lane 2 represents the Bam HI fragment pattern for a Type I HAE 
family member. An additional 6.0kb fragment is present in lane 2 
with a 50% reduction in the intensity of the normal singlet 7.0kb 
fragment. Lanes 3 and 4 represent the restriction fragment patterns 
for Bam HI/Bgl II digested DNA from the same Type I HAE patient and 
the same normal family member respectively. The normal, expected 
fragment pattern for the 5 1 end of the gene is generated in 
lane 4 (183) and the 6.0kb polymorphic fragment is maintained in 
lane 3 as expected. Lane 5 represents the restriction fragment 
pattern for Bgl II digested DNA from the same Type I HAE patient DNA 
as used in lanes 2 and 3. There is a 20kb fragment in addition to 
the 10.8kb fragment appropriate for the 5’ end of the gene.
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FIGURE 37
Cl-inhibitor gene restriction fragment patterns generated by Bam HI 
and Bgl II in Family C and detected by the 3’ (exon 8) probe. Lanes
1 and 2 represent Bam HI digested DNA from a normal family member
and a Type I HAE patient. The 7.0kb fragment present in both lanes 
is the fragment size expected for the 3’ end of the gene (183). 
Lanes 3 and 4 represent Bam HI/Bgl II digested DNA. from the same 
Type I HAE patient and normal family member respectively. The 6.7kb 
and 0.3kb fragments generated in both lanes are as expected for the
31 end of the gene.
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FIGURE 38
Restriction map of the 5* end of the Cl-inhibitor gene for Family C. 
The 5r (exon 2-4) probe detects the 10.8Kb Bgl II fragment in normal 
family members. Loss of the Bgl II recognition site in exon 4 due to 
a lkb deletion involving exon 4 generates the additional 2Gkb 
fragment (10.8Kb + 10.2Kb - l.Okb) as shown in lane 5 of Figure 36. 
The size of this deletion is indicated by the reduction in size of 
the normal 7.0kb Bam HI fragment to 6.0kb as shown in lane 2 of 
Figure 36. The position of the 1.4Kb Taq I fragment which spans the 
fourth exon is shown.
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Family D - The single Type I HAE patient in this family of three 
showed Cl-inhibitor gene RFLPs with the following restriction
enzymes - Bam HI, Bgl II, Eco RI, Hind III, Kpn I, Pst I, Pvu II,
Sst I, Stu I and Xmn I. The most informative enzymes were Hind III, 
Kpn I, Pst I, Sst I, Stu I and Xmn I. All of this group, except 
Hind III, generated an obvious additional fragment as shown in 
Figures 39, 40, 41 and 42. For Hind III the only apparent
abnormality was a 50% reduction in the intensity of the 0.6kb 
fragment (Figure 39). Depending on which enzyme was being used this 
complex pattern of altered restriction fragments was detectable by 
both the middle probe and the 3’ probe but not by the 5' probe as 
shown in Figures 43, 44 and 45 for the enzymes Sst I and Stu I. 
These RFLP data combined with the known restriction map of the 
Cl-inhibitor gene (183) were consistent with the following 
Cl-inhibitor gene abnormalities as summarised in Figure 46. 1) Loss 
of the Sst I site which is normally present at the 5' end of the
seventh intron. 2) Loss of the two Pst I sites at the 3f end of the
sixth intron and 5' end of the seventh exon. 3) Loss of the Kpn I 
recognition site which lies within the seventh exon towards its 5’ 
end. 4) Deletion of approximately 1.7kb of DNA affecting the same 
area of the gene as shown by the reduction in size of the 
restriction fragments spanning the seventh exon for each of the 
enzymes Stu I and Xmn I. The 50% reduction in intensity of the 0.6kb 
Hind III fragment was very useful in exactly localising the deletion 
to the seventh exon since the affected 0.6kb fragment comprises only 
the seventh exon and 400bp of flanking sixth and seventh introns. 
These changes are all entirely consistent with the Cl-inhibitor gene
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mutation in this Type I HAE family being a complete deletion of the 
seventh exon and portions of its flanking introns as described by 
Ariga et al (190). The subtle restriction fragment abnormalities 
generated by the enzymes Bam HI, Eco RI and Pvu II also helped to 
confirm the exon 7 deletion. There was a 50% reduction in the 
intensity of one of the normal fragments for each enzyme but without 
the generation of an additional fragment (data not shown). In each 
case this normal fragment with a reduced intensity comprised only 
the seventh exon plus variable lengths of the adjacent sixth and 
seventh introns. Deletion of the seventh exon from 50% of the 
fragments prevented these fragments from hybridising to the cDNA 
probe with a resultant 50% reduction in fragment intensity. The 
absence of an additional fragment was due to the fact that all these 
enzymes cleaved again within both the sixth and seventh introns 
outwith the limits of the deletion so the abnormal sized fragments 
generated were purely intronic in origin. These intronic fragments 
would not hybridise to the cDNA probe. Interestingly this was not 
the explanation for the apparent lack of an additional fragment 
generated by Hind III. Gene sequence data for the normal 
Cl-inhibitor gene (183) indicated that an additional fragment should 
have been generated by Hind III, the size of this fragment being 
14.3kb. A 50% reduction in the intensity of the normal I4.1kb 
fragment should also be seen. With the electrophoretic conditions 
employed, however, this I4.3kb fragment would not be resolved from 
the normal 14.1kb fragment (Figure 39).
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FIGURE 39
Cl-inhibitor gene RFLPs in Family D generated by Pst I and Hind III 
and detected by using the exon 2-8 Cl-inhibitor cDNA as probe. Lanes 
1 and 2 for the Pst I digest represent DNA. from a normal family 
member and from the Type I HAE patient respectively. There is an 
additional 1.7kb fragment in lane 2 with a 50% reduction in the 
intensity of the 2.6kb fragment. Lanes 1 and 2 for the Hind III 
digest represent DNA from a normal family member and from the Type I 
HAE patient. There is a 50% reduction in the intensity of the 0.6kb 
fragment in lane 2. No additional fragment is present.
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FIGURE 40
Cl-inhibitor gene RFLP in Family D generated by Xmn I and detected 
by using the exon 2-8 Cl-inhibitor cDNA as probe. Lane 1 represents 
DNA. from a normal family member and lane 2 represents DNA from the 
Type I HAE patient. There is an additional 14.3kb fragment in lane 2 
with a 50% reduction in the intensity of the 16.0kb fragment.
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FIGURE 41
Cl-inhibitor gene RFLP generated by Kpn I in Family D and detected 
by using the exon 2-8 Cl-inhibitor c D M  as probe. Lane 1 represents 
D M  from a normal family member. Lane 2 represents D M  from the 
Type I HAE patient. There is an additional 16.3kb fragment with a 
50% reduction in the intensity of the 13kb fragment in lane 2.
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FIGURE 42
Cl-inhibitor gene RFLPs generated by Sst I and Stu I in Family D and 
detected by using the exon 2-8 Cl-inhibitor cDNA as probe. Lanes 1 
and 2 represent Sst I digested DNA. from a normal family member and 
from the Type I HAE family member respectively. There is an 
additional 7.0kb fragment in lane 2 with a 50% reduction in the 
intensity of the 3.0kb fragment and approximately a 25% reduction in 
intensity of the 6kb doublet "fragment". Lanes 3 and 4 represent 
Sst I/Bgl II digested DNA from the same patient and normal family 
member respectively. There is an additional 6.4kb fragment in lane 3 
with a 50% reduction in the intensity of the 5.7kb and faint 1.9kb 
fragments. Lanes 5 and 10 represent Bgl II digested DNA from a
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FIGURE 42 (continued)
normal family member and from the Type I HAE patient respectively. 
In lane 5 a faint 1.9kb fragment is present, however, in lane 10 
this fragment is not visible. This represents a 50% reduction in the 
intensity of the 1.9kb fragment in lane 10 but at this auto­
radiograph exposure time no signal is apparent. In lane 10, although 
an additional 10.4kb fragment is created, this cannot be resolved 
from the normal 10.2kb fragment under these electrophoretic 
conditions. Lanes 6 and 7 represent Stu I digested DNA from a normal 
family member and the Type I HAE patient. An additional 9.4kb 
fragment is present with a 50% reduction in the intensity of the 
ll.lkb fragment. Lanes 8 and 9 represent Stu I/Bgl II digested DNA 
from the patient and a normal family member respectively. No 
difference in fragment pattern is present. Lanes 11 and 12 represent 
Sst I /Stu I digested DNA from a normal family member and the HAE 
patient. An additional 6.3kb fragment is present in lane 12 with a 
50% reduction in the intensity of the 5.9kb fragment.
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FIGURE 43
Cl-inhibitor gene RFLPs in Family D as detected by the middle
(exon 4-7) probe. Lanes 1 and 2 represent Sst I digested DNA. from a 
normal family member and the Type I HAE patient respectively. An 
additional 7.0kb fragment is present in lane 2 with a 50% reduction 
in the intensity of the singlet 5.7kb fragment. Lanes 3 and 4
represent Sst I/Bgl II digested DNA from the Type I HAE patient and 
a normal family member respectively. There is an additional 6.4kb 
fragment in lane 3 with a 50% reduction in the intensity 5.7kb
singlet fragment. Lane 5 represents Bgl II digested DNA from a
normal family member. There is a 10.2kb fragment which is 
appropriate for this region of the gene. Lanes 6 and 7 represent 
Stu I digested DNA from a normal family member and from the HAE 
patient respectively. An additional 9.4kb fragment is present in 
lane 7 with a 50% reduction in the intensity of the ll.lkb fragment.
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FIGURE 44
Cl-inhibitor gene RFLP generated by Sst I in Family D and detected 
by the 3’ (exon 8) probe. Lane 1 represents Sst I digested DNA from 
a normal family member. Lane 2 represents Sst I digested DNA from 
the Type I HAE patient. There is an additional 7.0kb fragment in 
lane 2 with a 50% reduction in the intensity of the 3.0kb fragment.
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FIGURE 45
Cl-inhibitor gene restriction fragment patterns in Family D as 
detected by the 51 (exon 2-4) probe. The order of DNA samples and 
the restriction enzymes used to digest each sample are identical to 
those described for Figure 42. No polymorphic fragments are 
detected, the fragment patterns being identical for the normal and 
patient DNA samples. In addition, the fragment sizes are appropriate 
for the 5* end of the gene (183).
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FIGURE 46
Restriction map of the 3’ half of the Cl-inhibitor gene for 
Family D. The middle (exon 4-7) probe detects the 5.7kb Sst I 
restriction fragment in normal family members* However, loss of the 
Sst I site just downstream of the 31 end of the seventh exon due to 
a 1.7kb deletion generates the additional 7.0kb fragment (5.7kb + 
3.0kb - 1.7kb) as shown in lane 2 of Figure 43. Using the 3* 
(exon 8) probe the 3.0kb Sst I fragment is detected in normal family 
members whereas an additional 7.0kb fragment is seen in the Type I 
HAE patient (Figure 44, lane 2). The size of the gene deletion is 
indicated by the reduction in size of the normal ll.lkb Stu I 
fragment to 9.4kb as shown in lane 7 of Figure 43. In addition, the 
deletion produces loss of the two Pst I sites and loss of the Bgl II 
site which are marked at opposite ends of the seventh exon.
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3.6 Kpn I and Hgi AI RFLPs in Type I and Type II HAE families
In each Type I and Type II HAE family the pattern of Kpn I and 
Hgi AI alleles present in both patients and normal family members 
was studied in order to establish whether it was possible to 
associate the mutated Cl-inhibitor gene with a particular Kpn I and 
Hgi AI allele. The results are shown in Table 10. It can be seen 
that for all the families an allele association with the mutant gene 
could be made with at least one of the polymorphic endonucleases. 
Furthermore, for nine of the Type I HAE families the abnormal 
Cl-inhibitor gene had an identifiable allele association with one 
allele generated by both polymorphic endonucleases. The commonest 
associations were with the 13kb Kpn I and 0.4kb Hgi AI alleles which 
reflects the overall commoner population frequency of each of these 
alleles as described in Section 3.4. In five of the families a 
definite allele association could not be established for one of the 
polymorphic endonucleases. The potential usefulness of these 
observations will be discussed.
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TABLE 10 Kpn I AND Hgi AI ALLELE ASSOCIATION WITH THE MUTANT 
CI-MUBITOR GENE IN HAE FAMILIES
ALLELE ASSOCIATION 
HAE FAMILY Kpn I Hgi AI
Type I Family A 13kb 0.4kb
Type I Family B 13kb 0.4kb
Type I Family C 13kb 0.4kb
Type I Family D 13kb 0.4kb
Type I Family E 30kb 0.4kb
Type I Family F 13kb not established
Type I Family G 13kb 0.4kb
Type I Family H 13kb not established
Type I Family I 13kb not established
Type I Family J 13kb 0.7kb
Type I Family K 13kb 0.4kb
Type I Family L 13kb 0.4kb
Type II Family A not established 0.4kb
Type II Family B 13kb not established
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3.7 Clinical survey of HAE in Scotland
(a) Disease incidence
This survey identified a total of 46 HAE patients derived from 
22 kindred. Type I HAE was present in 21 of these kindred whereas 
Type II disease affected in only one kindred. The disease incidence 
in Scotland is therefore approximately 1 in 110,000 since the
current population of Scotland is 5,090,700. Furthermore, a 
male:female patient ratio of 0.58:0.42 and a 43% incidence of HAE 
patients in the affected kindred was entirely compatible with an 
autosomal dominant mode of inheritance for the disease. A patient
age range of one year to 65 years of age existed.
(b) Diagnosis and symptoms
Detailed clinical histories have so far been obtained for 21 
HAE patients from 17 kindred. The following analysis is based on the 
findings in these patients. The diagnosis of HAE was made in 17 out 
of 21 patients before the age of 30 years with virtually equal 
numbers being diagnosed in each of the three decades. Only four
patients had the diagnosis made later than this, three being in 
their thirties and one patient being 50 years of age. This last 
individual had no symptoms prior to the episodes of angio-oedema 
which led to diagnosis. It was commonplace for a number of years to 
elapse between the onset of symptoms and diagnosis. Indeed, for one 
individual the delay was in excess of 20 years. This length of delay 
was exceptional in this study, however, for approximately 20% of 
patients the diagnostic delay exceeded four years. The delay in the 
remaining 80% of patients was often not significantly less than four
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years. Mild and infrequent initial symptoms appeared to have a 
significant role to play in causing this delay.
In the majority of patients, 16 out of 21, the symptoms 
experienced were a combination of angio-oedema of the skin and 
gastro-intestinal upset, although not necessarily simultaneously. 
For the remaining five patients gastro-intestinal symptoms were not 
a feature of their disease. The commonest cutaneous sites involved 
by angio-oedema were the hands, face and feet whereas gastro­
intestinal oedema usually manifested itself as colicky abdominal 
pain, nausea, vomiting and abdominal distension. In five individuals 
gastro-intestinal involvement was prominent but was never the only 
manifestation of the disease. A total of six patients experienced 
oedema of the upper respiratory tract with resultant respiratory 
difficulty of variable degree. This represented the most serious 
effect of HAE since laryngeal oedema with resultant asphyxia is the 
only recorded way in which the disease can be fatal.
Considerable variation between patients was seen in the length 
of acute disease attacks with the range being 36 hours up to four 
days. Likewise the frequency of attacks varied markedly between 
individual patients and in some cases varied at different times for 
the same individual. In those patients with frequent attacks, 
sometimes two or three attacks every month with each attack lasting 
approximately three days, the result could be up to nine days 
illness each month for that patient. When regarded in these terms it 
is easy to appreciate how disruptive HAE can be for the patients and 
for their families. Precipitating factors for acute disease attacks 
were identified for ten of the 21 patients. Trauma was the commonest
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trigger, being reported by eight of the ten patients, with dental 
procedures representing the single most potent event. Premenstrual 
accentuation of the disease and acute attacks following emotional 
stress were evident in the remaining two patients.
Disease remission during pregnancy was experienced by 
one patient in this study. Remission was complete in that no 
symptoms or signs of the disease were apparent during the second and 
third trimesters. This quiescent disease state also persisted for a 
number of months after delivery. The same degree of remission 
occurred in each of the patient' s three pregnancies with each 
"disease-free" period representing a very welcome relief from her 
usual frequent and severe symptoms.
(c) Treatment
Drug therapy was being prescribed for 19 of the 21 patients. 
The reasons for two patients not receiving treatment were that one 
patient was an asymptomatic six year old diagnosed biochemically 
during a family study and the second patient refused therapy. 
Treatment consisted of an attenuated androgen (danazol or in a 
single case stanazolol) for 13 patients, the anti-fibrinolytic agent 
tranexamic acid for three patients and a combination of androgen and 
tranexamic acid for the remaining three patients. Combination 
therapy for these three patients was an attempt to control their 
severe symptoms, however, in each case disease control remained 
incomplete, one patient in particular still experiencing frequent 
attacks of cutaneous angio-oedema and abdominal pain. The effective 
dose of danazol varied for each patient with therapy being regularly
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adjusted to achieve the minimum effective dosage for each 
individual. This helped to minimise the side-effects of these potent 
drugs. Despite this, drug-induced weight gain and, for women, a 
variable degree of menstrual irregularity were very commonly seen. 
Other more severe side-effects which included hepatic dysfunction 
and depression were confined to individual cases. When interpreting 
the apparent effectiveness of attenuated androgens in HAE it should 
be remembered that of the 13 individuals treated with them three had 
mild symptoms before treatment and five patients had periods of 
breakthrough symptomatic disease during treatment. For these five 
individuals drug compliance was not thought to be a problem. The use 
of tranexamic acid alone as a form of therapy in three patients was 
for a specific reason in each case. The prepubertal status of 
one patient precluded the use of androgens, one patient was 
unwilling to take androgens because of their potential side-effects 
and finally one patient developed hepatic side-effects due to 
danazol therapy thereby necessitating its withdrawal. All three of 
the patients receiving tranexamic acid alone had their symptoms only 
partly controlled by the drug, although in one patient drug 
compliance was poor.
The extent to which Cl-inhibitor concentrate had been used was 
ascertained in this study. It was found that concentrate had been 
administered to six patients from six kindred in two main 
situations. In five cases it was used to prevent an acute disease 
attack following elective dental surgery. In a sixth patient its use 
successfully interrupted a spell of severe disease activity that was 
not being controlled by increasing doses of danazol and tranexamic
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acid in combination.
Disease-related deaths do still occur in HAE despite modem 
drug therapy. Two kindred were identified in whom a definite 
asphyxial disease-related death had occurred in recent years and a 
further two kindred had each recorded a possible disease-related 
death.
(d) Clinical genetic considerations
A definite parental history of HAE was documented for eight 
patients and for a further two patients the disease affected at 
least one brother or sister so indicating parental origin. For the 
remaining 11 patients there was a complete lack of family history of 
the disease. This absence of a family history raises the possibility 
that the genetic abnormality in each of these patients represents a 
spontaneous gene mutation. Before this possibility can be accepted, 
however, the presence of asymptomatic parental disease must be 
excluded. This can be achieved by testing parental blood samples for 
Cl-inhibitor and C4 levels. Both parents of two patients were shown 
to be biochemically normal in this way so indicating the spontaneous 
nature of the Cl-inhibitor gene mutation in these two patients. In 
the remaining nine patients with no parental clinical history of HAE 
there was no documented evidence of parental complement system 
status. It was therefore possible that a spontaneous mutation 
accounted for the disease in these nine patients, however, the 
likelihood is that for a significant number of them the parent 
carrying the mutant Cl-inhibitor gene was asymptomatic or else the 
parental disease was mild and had never been diagnosed.
-169-
Excluding the four children, 16 of the remaining 17 patients 
had married with 14 of these married patients subsequently having 
children. One married patient decided against having a family 
because of the risk of the children inheriting the disease and 
one married patient had not yet started a family but was prepared to 
do so despite the risk. Potential interest was shown in the concept 
of prenatal diagnosis by nine patients with a definite decision to 
use it, should it become available, being made by two of these 
individuals. The four children were too young to be questioned about 
prenatal diagnosis.
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3.8 Genomic library construction
At the outset generating sufficient numbers of recombinant 
bacteriophage proved difficult. These problems resolved when the 
protocol for high molecular weight DNA preparation described in 
Section 2.2.15 was adopted. Prior to this, prolonged proteinase K 
digestion and phenol extraction steps had been employed in addition 
to multiple ethanol precipitations and RNase A treatment of the DNA 
preparation. Cumulatively all of these manoeuvres appeared to 
produce an unacceptable degree of damage to the DNA in the form of 
random breaks. This damage was not apparent when an aliquot of the 
final DNA preparation was visualised after agarose gel electro­
phoresis. However, following endonuclease digestion by Sau 3AI a 
significant proportion of the 15-20kb fragments purified by sucrose 
gradient ultracentrifugation would have an end which had been 
created by this random cleavage and not by the action of the 
endonuclease. Such fragments would be unable to ligate completely 
into the vector and so their presence would markedly reduce cloning 
efficiency (201). Once this problem had been overcome two genomic 
libraries were constructed, the first from a normal individual and 
the second from Type II HAE patient DNA. An input of approximately
1.2 jig of size-fractionated insert DNA and 3 ^ ig of EMBL3 DNA was 
sufficient to generate 47,000,000 genuine recombinant bacteriophage 
in the normal library and 27,000,000 genuine recombinants in the HAE 
library. Both libraries are to be used to isolate Cl-inhibitor 
genomic clones.
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4.1 Restriction fragment analysis of the normal Cl-inhibitor gene
The initial selection of the restriction endonucleases to be 
used in this RFLP study of the Cl-inhibitor gene was determined by a 
number of factors, the most important of which were as follows - 
published statistical likelihood of each endonuclease detecting an 
RFLP (202); enzyme availability; cost. The enzymes selected were the 
ones which combined a high likelihood of detecting an RFLP based on 
recognition sequence characteristics with a previous record of 
success, ready availability and reasonable cost since relatively 
large amounts of enzyme would be necessary. Since no Cl-inhibitor 
gene sequence data were available at the outset of the investigation 
the use of a wide range of restriction enzymes helped to ensure the 
generation of sets of DNA fragments which were both representative 
of the whole gene and its flanking sequences and which were of a 
size that could be accurately examined by standard 0.8% agarose gel 
electrophoresis and Southern blotting. A total of 38 restriction 
endonucleases were used with 20 of these enzymes generating multiple 
well spaced, easily resolved fragments as shown in Table 7, 
Section 3.3. Subsequently it was members of this group that were 
informative in RFLP analysis of the Cl-inhibitor gene. The other 18 
enzymes listed in Tables 5 and 6 of Section 3.3 were largely 
uninformative due to the nature of their fragment patterns. Analysis 
of the restriction map of the normal Cl-inhibitor gene indicated 
that many of these latter enzymes did generate polymorphic fragments 
in two of the RFLP positive Type I HAE families. However, due to the 
fact that these enzymes generated either very large fragments or 
else multiple small fragments, the polymorphic fragments generated
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could not be resolved from the normal fragments with the electro­
phoretic conditions employed. Major alterations in electrophoretic 
methodology would have been necessary to produce identifiable 
abnormalities in the fragment patterns generated by these enzymes.
4.2 Cl-inhibitor gene RFLPs in the normal population
The restriction enzymes Kpn I and Hgi AI both generated RFLPs 
for the Cl-inhibitor gene in the normal population as described in 
Section 3.4. The Kpn I polymorphism (203) was previously unreported 
since no other investigator had used this restriction enzyme. To 
obtain good resolution of the 30kb polymorphic fragment from the 
invariant 24kb fragment it was necessary to use a prolonged period 
of electrophoresis through 0.8% agarose gels. Routinely 64 hours at 
25 volts was employed to achieve good separation. Standard 
electrophoretic conditions of 16 hours at 40 volts produced only a 
single, wide 24kb fragment which meant that identification of a 
heterozygote was dependent upon recognition of a 50% reduction in 
the intensity of the 13kb fragment (Figure 19, Section 3.4). Only 
the homozygote for the 30kb allele would be immediately apparent due 
to the complete absence of the 13kb fragment. Recognition of a 50% 
reduction in the intensity of a fragment can be difficult 
particularly when an autoradiograph is overexposed or an adjacent 
control sample does not match exactly the test sample with regard to 
the quantity of DNA loaded into the gel. Detection of the Kpn I 
polymorphism emphasised the importance of adequate fragment 
resolution in RFLP analysis. In this study the use of 200mm long
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agarose gels and 16 hour electrophoresis runs helped to ensure 
reasonable fragment resolution.
Localisation of the mutation responsible for the Kpn I RFLP 
showed that it lay approximately lOkb downstream of the Cl-inhibitor 
gene. No attempt was made to further characterise the mutation 
responsible for the RFLP, however, since no alterations were seen in 
the sizes of restriction fragments which extended this distance 
downstream of the Cl-inhibitor gene, it could be inferred that the 
mutation was not a major deletion. Lying at this distance from the 
Cl-inhibitor gene the mutation was unlikely to be able to 
quantitatively affect the gene product. This was borne out by the 
fact that no relationship could be demonstrated between possession 
of a particular allelic combination and serum Cl-inhibitor protein 
level.
Demonstration of the Hgi AI RFLP in the normal population 
confirmed the observations of Bock et al (67) in the North American 
population. No relationship could be demonstrated between possession 
of a particular Hgi AI allelic combination and serum Cl-inhibitor 
protein level or Cl-inhibitor functional activity despite the fact 
that the gene mutation responsible for the RFLP produced an amino- 
acid substitution in the Cl-inhibitor polypeptide. This substitution 
was very close to the carboxy-terminus of the protein, distal to its 
reactive site in an area which has no known role to play in 
maintaining the stressed loop of the reactive site or in forming 
part of the ’’bait sequences” of the molecule. Thus a lack of 
biological effect for such a mutation was not entirely surprising.
In a study of HAE the relevance of Cl-inhibitor gene RFLPs in
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the normal population is their potential application as indirect 
genetic markers of the mutated Cl-inhibitor allele responsible for 
the disease (204). Such an application is dependent upon a low level 
of recombination between the disease locus and the RFLP locus and 
upon the presence of a reasonable degree of polymorphism. For both 
the Hgi AI and Kpn I polymorphisms the chances of recombination 
between the disease locus and the RFLP locus will be very low. This 
is particularly true for the Hgi AI RFLP since the imitation 
responsible for it resides within the Cl-inhibitor gene itself. For 
the Kpn I RFLP the risk of recombination is also very low since lOkb 
is a relatively short distance in terms of recombination when it is 
considered that there is only a 1% chance of recombination between 
two loci separated by l,000kb (204). Furthermore, since the distance 
between the two loci responsible for the RFLPs is only marginally 
greater than lOkb, the chance of recombination occurring between 
these two loci is also very small. Detection of more than one RFLP 
in the normal population makes it possible to combine the 
information from each independent RFLP to construct a simple 
haplotype for the Cl-inhibitor gene locus in each individual. The 
whole haplotype can then be used as an "allele” for that locus. The 
Kpn I and Hgi At RFLP system as detected by the exon 2-8 cDNA. probe 
allows the generation of four different haplotype "alleles” each of 
which comprises a different arrangement of cutting or non-cutting at 
each of the two restriction sites. Since the individual alleles for 
the Kpn I and Hgi At RFLPs are not excessively rare it is likely 
that each of the four haplotype "alleles” will be present in the 
general population and so will be potentially useful as indirect
-176-
genetic markers for the disease. Identification of additional 
Cl-inhibitor gene RFLPs in the normal population would be worthwhile 
since it would markedly increase the number of potentially 
informative haplotypes. One additional RFLP would increase the 
number of haplotypes from four to eight and if two additional RFLPs 
were identified 16 different haplotype "alleles" could theoretically 
be generated. In summary, it is apparent that the potential 
usefulness of multiple RFLPs is more than the simple addition of the 
usefulness of each individual RFLP.
The use of both the Kpn I and Hgi AI RFLPs as indirect genetic 
disease markers will be of particular importance to those Type I and 
Type II HAE families for whom no disease-specific RFLP can be 
identified. Indeed, in this and in other studies at least 70% of the 
Type I HAE families fall into this category. In Type II HAE current 
evidence suggests that the gene mutations responsible for the 
disease remain to be identified in only 30% of families (185). As 
shown in Table 10 of Section 3.6, allele allocation of the disease 
locus for at least one of the polymorphic endonucleases has been 
made in all the Type I and Type II HAE families. In addition, for 
five of the Type I families without a disease-specific RFLP, allele 
allocation for both endonucleases was possible. More detailed and 
extensive studies would need to be undertaken in each family, 
however, before the Kpn I and Hgi AI RFLPs could be used in a 
predictive capacity for disease presence in a particular member of 
these families.
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4.3 Disease-specific Cl-inhibitor gene RFLPs in HAE
In this study a total of four out of 12 Type I HAE kindred 
showed identifiable, unique Cl-inhibitor gene RFLPs which co­
segregated with the disease. In each case the RFLP affected one 
Cl-inhibitor allele as expected for an autosomal dominant, 
heterozygous disease. Neither of the Type II HAE kindred showed an 
abnormality with the endonucleases employed. This detection rate of 
33% in Type I HAE is higher than that reported in other published 
studies where approximately 16% was the previous maximum (188,189). 
The large number of restriction endonucleases employed in this study 
appeared to be the most important reason for this higher detection 
rate. For example, the enzyme Sty I was used by just one other 
investigator to examine DNA from a single Type I HAE family (67). A 
second potential source of variation in the RFLP detection rate 
between studies was the size of the cDNA probe employed to screen 
for abnormalities. Since some investigators used shorter cDNA probes 
which lacked 5! exonic sequence compared with the exon 2-8 cDNA, it 
was possible that these shorter probes may not have been able to 
detect all the gene mutations. This was not the case. For the two 
previously published disease-specific gene mutations (188,190) and 
the two new mutations reported herein the shorter probes would have 
detected them all had the appropriate restriction enzymes been 
employed. Finally, it should be remembered that in this study 12 
Type I HAE kindred were analysed. In percentage terms a single extra 
kindred with an identifiable RFLP produces a relatively large 
increase in the overall detection rate. With the analysis of greater 
numbers of HAE families the detection rate may fall.
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The diversity of disease-specific gene mutations identified by 
RFLP analysis in this study was greater than that described by other 
authors. Four distinct gene mutations were characterised, one lying 
in the 5' half of the gene and three mutations located in the 3' 
half of the gene. Two of these mutations were small, possibly point 
mutations and neither had been reported previously in HAE. The other 
two mutations, which were the same as those characterised recently 
by Stoppa-Lyonnet (188) and Ariga (190), comprised an exon 4 
deletion and an exon 7 deletion respectively. In both cases sizeable 
lengths of DNA had been deleted from the Cl-inhibitor gene. Stoppa- 
Lyonnet observed only 5f deletion/insertion events and Ariga 
detected only the exon 7 deletion. This contrasts with the findings 
in this study in which four widely separated gene abnormalities were 
identified within the one patient population. As described in
Section 1.4.8 the reasons for this lack of overlap between the 
findings of Stoppa-Lyonnet and Ariga were thought to be the 
different ethnic origins of the two populations they studied rather 
than methodological differences since both investigators studied 
reasonable numbers of kindred, used a very similar range of
restriction enzymes and probed with Cl-inhibitor cDNAs capable of 
detecting both forms of mutation. The diversity of genetic origins
present in our patient population may have had a role to play in
producing the heterogeneity of Cl-inhibitor gene mutations observed 
in this study particularly when combined with the large number of 
restriction enzymes used.
In Families A and B small mutations involving the 3’ end of 
the sixth exon and the eighth exon respectively were present. This
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represents the first report of abnormalities affecting these areas 
of the Cl-inhibitor gene in Type I HAE. The gene mutation in 
Family A lay at the boundary between the sixth exon and the sixth 
intron. Sty I, the restriction enzyme which generated the 
polymorphism, has the recognition sequence 51 CCAAGG 3'. The first 
five nucleotides of this recognition sequence represent the last 
five nucleotides of the sixth exon and the sixth nucleotide is the 
first nucleotide in the sequence GT which is the donor splice site 
for excision of the sixth intron during RNA processing (205). It is 
therefore possible that a mutation in this sequence could interfere 
with normal RNA splicing and gene expression from this allele so 
giving rise to Type I HAE. A similar mechanism is well recognised in 
other genetic diseases including p-thalassaemia (206), haemophilia A 
(207), haemophilia B (208) and Tay-Sachs disease (209). Nucleotide 
sequence analysis of the mutated area should confirm the likely 
mechanism and will define the extent of the mutation. In this 
kindred it may also be informative to examine patient RNA. 
Theoretically, unless the mutant RNA species is unstable and rapidly 
degraded intracellularly, a Cl-inhibitor RNA species of abnormal 
size should be present. In Family A it is highly likely that the 
Cl-inhibitor gene mutation detected by the Sty I RFLP is the cause 
of the disease since the RFLP co-segregated absolutely with the 
disease in the six main branches of the family shown in Figure 25. 
No recombination events were identified.
In Family B the Cl-inhibitor gene mutation pinpointed by the 
Bgl II RFLP was in the eighth exon approximately 50 base pairs from 
its 5' end. The effect of this mutation on the gene product remains
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uncertain, however, if this mutation is responsible for the disease 
the most likely effects would be 1) to alter the reading frame of 
the eighth exon; 2) to create a premature termination codon; 3) to 
adversely affect the stability of the Cl-inhibitor mRNA as has been 
reported for the oncogene c-fos (210). Nucleotide sequence analysis 
of the abnormal area should resolve this uncertainty. It should be 
remembered, however, that since only three family members were 
available for genetic linkage analysis the possibility exists that 
sequencing will indicate that the RFLP is detecting a mutation in 
the eighth exon which is not responsible for the disease. Should 
this be the case the RFLP could still be used in this family as an 
indirect disease marker along with the Kpn I and Hgi AI RFLPs. 
Furthermore, if the RFLP is not disease-specific it must represent a 
very infrequent Cl-inhibitor gene RFLP since it was not observed in 
any other individual in this study nor has it been seen by other 
investigators within their test populations.
In Families C and D the gene mutations identified had been 
characterised by other investigators (188,190). Each mutation 
involved the deletion of a sizeable length of DNA from the 
Cl-inhibitor gene, approximately lkb in Family C and 1.7kb in 
Family D. Contained within the deleted segment was the entire fourth 
exon for Family C and the entire seventh exon for Family D. Based on 
detailed normal Cl-inhibitor gene structure and the RFLP data, it 
appears that both deletions extend into the sets of ALU repeat 
sequences that are present in the introns which flank the fourth and 
seventh exons (191). This observation is entirely compatible with 
the pathogenesis of these deletions being a process of non-
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homologous crossing over at meiosis between the ALU repeat 
sequences. Recently Tosi (191) reported the genomic cloning and 
sequencing of the abnormal area of the Cl-inhibitor gene in two 
families with a complete exon 4 deletion. This paper convincingly 
demonstrated that the limits of each deletion lay within intronic 
ALU sequences and that in each case the 5f and 3' deletion 
boundaries, although different in each family, both lay within short 
runs of identical sequence in the 5' and 3' ALU elements. For both 
families the 5' deletion boundary was within the same ALU element 
however different 31 ALU elements contained the 31 boundary for each 
family. Recombination between ALU elements is a recognised cause of 
gene mutation in other genetic diseases such as familial hyper- 
cholesterolaemia in which there is duplication of the whole 5' end 
of the gene as a result of unequal crossing over between intronic 
ALU sequences (192). In some cases of Tay-Sachs disease there is 
partial deletion of the p-hexosaminidase gene as a result of the 
same pathogenetic mechanism (193). Demonstration of the extent and 
so likely mechanism of the exon 4 and exon 7 deletions in Family C 
and D respectively will require sequence analysis of the abnormal 
alleles. In Family C the Taq I RFLP data suggest that the 5' 
deletion boundary does not lie within the same ALU element as that 
reported by Tosi (191). The reasons for this are as follows. The 
Taq I recognition site at the 5f end of the 1.4kb polymorphic Taq I 
fragment shown in Figure 38 must be preserved or else an additional 
4.9kb Taq I fragment would be seen in Figure 35. Since this 5' Taq I 
site lies in the third intron within the ALU element that is 
immediately 3' to the ALU element which forms the 5f boundary of the
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deletion described by Tosi (191), this Taq I site would be deleted 
if the 5f deletion boundary for Family C was within the same ALU 
element as that of Tosi (Figure 47). The inference is that since 
this 5f Taq I site is preserved, the 5f deletion boundary for
Family C lies within either the 3' half of the ALU element
containing the Taq I site or else it lies within the ALU element 3' 
to this. Confirmation of this will have to await sequence analysis 
of the abnormal Cl-inhibitor allele.
Messenger RNA transcripts derived from exon 4 and exon 7 
deleted alleles have been reported by Ariga (190) and by Tosi (191).
In each case the mRNA species was shorter than the normal
Cl-inhibitor mRNA by the length of the deleted exon. The failure to 
detect mutant Cl-inhibitor protein in the sera of their patients 
indicated that either the shortened mRNAs were not translated or 
that if a protein was produced, it was unstable and was degraded 
intracellularly or could not be secreted from the cell of origin. 
Stability of the protein derived from a Cl-inhibitor allele with a 
deleted fourth exon would certainly be suspect since this exon codes 
for a cysteine residue that participates in one of the intra­
molecular disulphide bonds (67). Further work is required to 
establish the exact mechanism through which exon 4 or exon 7 
deletions cause Type I HAE. Recently an mRNA species shortened by 
approximately 200 base pairs has been identified in Family D 
(K. Whaley, personal communication).
In this study the gene mutations in Family C and Family D co­
segregated with the disease although in Family D there was only one 
HAE patient. Stoppa-Lyonnet and Ariga analysed extended families
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FIGURE 47
Limited restriction map of the Cl-inhibitor gene in the area of the 
third and fourth exons. The three ALU elements in the third intron 
are marked "a”, "b" and "c". The position of the 1.4kb Taq I
fragment is indicated. It can be seen that the Taq I site at the 5* 
end of this fragment lies within ALU element "b”. If the 5* boundary 
of the exon 4 gene deletion for Family C lay within ALU element "a" 
as described by Tosi (191) the Taq I site in ALU element "b" would 
be lost. This would create an additional 4.9kb Taq I fragment which 
would extend in the 5* direction beyond exon 3 so allowing it to 
hybridise to the cDNA probe. Since no such fragment is seen 
(Figure 35), the 5* exon 4 deletion boundary must be 31 to the ALU 
element "b" Taq I site. Since there are a total of three Taq I sites 
distributed along the 4kb length of the fourth intron the abnormal 
Taq I fragment created by the exon 4 deletion would now be purely 
intronic in origin and so would not hybridise to the cDNA probe. 
This is in keeping with Figure 35.
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with exon 4 and exon 7 deletions respectively and showed absolute 
co-segregation with the disease (188,190). No genetic recombination 
events were observed and lod score analysis carried out by Stoppa- 
Lyonnet for the exon 4 deletion was entirely compatible with a 
causative relationship between the deletion and Type I HAE.
RFLP analysis of the Cl-inhibitor gene in eight out of 12 
Type I HAE kindred and in both Type II HAE kindred failed to show an 
RFLP which co-segregated with the disease. In Type II HAE this was 
not a surprising result since all the reactive site Pi point 
mutations and the single P9 point mutation characterised at the 
nucleotide sequence level and which account for 70% of all Type II 
HAE cases produced no alteration in a restriction enzyme recognition 
site. Although the nature of the mutations in the remaining 30% of 
cases are currently unknown, the likelihood is that they will be 
small since no disease-specific RFLP was identified. It is probable 
that further RFLP analysis will be unhelpful in localising the 
remaining Type II HAE gene defects. For the eight Type I HAE kindred 
with no identifiable disease-specific RFLPs it is also highly likely 
that no major deletion or insertion event has occurred within the 
Cl-inhibitor gene. As in Type II HAE, the remaining gene mutations 
will most probably be small but critically placed. A good example of 
this type of abnormality is seen in Family A where a small mutation 
is centred around an exon/intron boundary. It was simply fortuitous 
that the mutation altered a restriction enzyme recognition site. In 
summary, it is felt that RFLP analysis is unlikely to make a major 
contribution to defining the remaining Cl-inhibitor gene mutations
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responsible for HAE. The investigative approaches necessary to 
achieve this will be discussed in Section 4.6.
4.4 Clinical survey of HAE in Scotland
A reported disease incidence for HAE of approximately 
one patient for every 110,000 of the population (Section 3.8a) 
represents the first documented attempt to calculate this figure for 
Scotland. It should be remembered, however, that this figure will 
almost certainly be an underestimate of the actual disease incidence 
for the following reasons -
1) A proportion of individuals with the disease will remain 
undiagnosed as a result of being asymptomatic or as a result of 
having mild symptoms for which they never seek medical advice. The 
discovery during family studies of completely asymptomatic 
individuals who have all the characteristic biochemical features of 
HAE is strongly supportive of this possibility.
2) Mild, infrequent symptoms will predispose to either no diagnosis 
or to an incorrect diagnosis being made despite medical advice being 
sought.
3) After diagnosis patients may be treated in a primary care setting 
without involving the hospital based specialists contacted in this 
survey. The number of HAE patients not detected for this reason is 
likely to be small.
4) Failure to disclose HAE patients to the survey. This was known to 
have occurred with two kindred whose existence only became apparent 
through their involvement with a second medical practitioner
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contacted in the survey. It is possible that further instances of 
this could exist.
The clinical data regarding age at onset, precipitating 
factors, symptoms and treatment, as described in Sections 3.8b and 
3.8c, were in general agreement with other published clinical 
surveys of HAE (126,128,130,168,211,212). Despite this a few of the 
observations deserve more detailed discussion. It was apparent that 
the 29% incidence of symptomatic respiratory tract oedema in this 
survey was markedly lower than the 70% incidence reported by Frank 
et al (126) and Cicardi et al (128). By comparison the 21% incidence 
reported in Finland more closely resembled this survey (211). 
Although the reasons for this variation are not entirely clear, the 
clinical threshold for diagnosing significant respiratory tract 
oedema and improvements in treatment appear to have an important 
role to play in this regard.
A definite precipitating factor for acute attacks of HAE could 
be identified in 48% of the patients in this survey, a figure which 
is very similar to other studies (126,128). Trauma represented the 
single commonest trigger with minor trauma not infrequently being 
capable of inducing an attack. Typing or standing upright for a 
significant period of time are examples of this minor trauma. It is 
therefore likely that a 48% incidence is an underestimate since a 
"'number of these precipitating events of a minor traumatic nature 
will remain unrecognised by the patient.
The clinical surveys of HAE which studied patients treated 
with androgens or Cl-inhibitor concentrate (128,130,168,211), 
including this survey, were in agreement with the following
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statements regarding treatment.
1) The most effective long term therapy is attenuated androgens, 
danazol being the most widely employed. Approximately one third of 
patients will continue to experience significant symptoms despite 
taking androgens. Their potentially severe side-effects make it 
important to establish the minimum effective dose of androgen for 
each patient.
2) The anti-fibrinolytic agent tranexamic acid is less effective in 
the treatment of HAE compared with attenuated androgens. The 
majority of patients treated with this drug show definite 
symptomatic improvement, however, only the minority of patients 
become symptom free. Side-effects due to tranexamic acid are 
uncommon. It is most commonly used when a definite contraindication 
or objection to the use of attenuated androgens exists or else as an 
addition to androgen therapy in patients experiencing severe disease 
activity that is only partly responsive to androgens.
3) Cl-inhibitor concentrate is a very valuable form of therapy 
because of its specificity and rapidity of action. Its main uses 
include the prevention of acute disease attacks when a patient has 
to undergo surgery, particularly dental surgery. Furthermore, it is 
very effective at relieving life threatening disease attacks or can 
be used to interrupt a spell of debilitating disease activity. 
Limited availability, cost and the potential risk of transmitting 
viral infections such as hepatitis and the human immunodeficiency 
virus, especially in non-heat-treated concentrate, are the main 
problems associated with its use. To date, no such side-effects have 
been reported following its administration.
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One of the most significant effects of improved treatment 
regimes has been the reduction in mortality statistics for the 
disease. Mortality rates of 56% and 33% were reported by Frank et al 
(126) and Landerman et al (212) respectively based largely on 
observations made before the advent of modem drug therapy. By 
comparison, this survey demonstrated that approximately 10% of 
deaths were directly attributable to the disease. Although this is a 
very significant reduction, 10% still represents a high mortality 
rate for the young adults most commonly affected.
In summary, the medical management of HAE has greatly improved 
in recent years with the use of attenuated androgens and 
Cl-inhibitor concentrate. Despite this there is still an un­
acceptable level of patient morbidity and mortality. The recent 
advances in the molecular genetics of the disease create a further 
potential therapeutic avenue for patients and their families to 
consider, namely prenatal diagnosis.
4.5 Prenatal diagnosis and HAE
The prenatal diagnosis of HAE represents a potential 
application for the RFLPs which co-segregate with the disease in 
Families A, B, C and D and for the Kpn I and Hgi AI RFLPs in the 
remaining families. It has been argued that the application of 
prenatal diagnostic techniques to HAE is inappropriate and 
unnecessary because of the much improved prognosis that exists for 
patients as a result of modem therapeutic regimes (213). This is
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true to an extent, however, as discussed in Section 4.4 a number of 
clinical problems do still exist for HAE patients - 1) The death of 
HAE patients in their early adult years due to the disease still 
occurs at an unacceptable rate. 2) Patients are faced with the 
prospect of long term androgenic steroid therapy which in 
approximately one third of cases will produce incomplete disease 
control. 3) Compliance with drug therapy can be variable. 4) For 
women, who constitute 42% of the patients in Scotland, androgens can 
have particularly unpleasant masculinising side-effects. 5) If a 
woman wishes to become pregnant therapy has to be interrupted to 
facilitate pregnancy as well as to obviate any teratogenic effects 
of the drugs on the embryo. Early pregnancy also represents a period 
of increased frequency of acute disease attacks independent of 
drug therapy. 6) There are the potentially distressing and 
psychologically damaging effects on patients of the knowledge that 
there is a 50% risk of a child inheriting the disease. For these 
reasons hereditary angio-oedema is not fully under medical control 
and the contribution that prenatal diagnosis can make to patients 
and their families is potentially very substantial. Since it is a 
disease which affects relatively few kindred, a high acceptance rate 
for prenatal diagnosis could reduce the disease incidence to very 
low levels with resultant greatly diminished disease associated 
morbidity and mortality in future generations. Such a marked impact 
is probably rather optimistic and currently with the molecular 
genetics of the disease still in its infancy, such an impact is 
unrealistic. A reasonable certainty, however, is that in the future 
with careful family studies and fuller elucidation of the gene
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mutations responsible for HAE, there will be no need for non­
curative, potentially harmful medical treatment in those families 
who wish to avail themselves of prenatal diagnosis.
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4.6 Suggestions for future study
The first priority will be to establish the nature and extent 
of the Cl-inhibitor gene mutations in the four RFLP positive 
Families A, B, C and D. For Families A and B where the mutation is 
small, the most effective way to do this will be by using the 
polymerase chain reaction (PCR) followed by nucleotide sequencing of 
the amplified product either directly or after cloning it into 
bacteriophage Ml 3 (214). The entire normal Cl-inhibitor gene
sequence is now known so selection of suitable PCR oligonucleotide 
primers which flank the mutated areas is straightforward. Following 
amplification, restriction enzyme digestion of the PCR product using 
Sty I or Bgl II for Family A and B respectively will establish 
whether the appropriate area of the gene has been amplified. Since 
patients are heterozygous, Sty I or Bgl II digestion will cleave the 
PCR product from the normal allele into two fragments whereas the
PCR product from the mutated allele will not be cut. The mutated
fragment can then be purified for cloning or direct sequencing as 
required. For both Family A and B nucleotide sequencing will 
establish the likely effect of the gene mutation on allele 
expression. PCR results have already confirmed the sites of the 
Cl-inhibitor gene mutations in Families A and B and preliminary 
nucleotide sequencing of the mutated area in Family A indicates a G 
to T point mutation affecting the first nucleotide of the GT donor 
splice site at the beginning of the sixth intron (K. Whaley,
personal communication).
Defining the limits of the exon 4 and exon 7 deletions in 
Families C and D respectively will require genomic library
-192-
construction and isolation of clones containing the mutated area of 
the gene. The technique of genomic library construction has already 
been established as described in Section 2.2.15 and Section 3.8. 
Clones containing Cl-inhibitor gene sequence will be identified by 
probing the library with the exon 2-8 Cl-inhibitor cDNA followed by 
restriction analysis of the positive clones to identify their site 
of origin within the gene and to identify which of the clones is 
carrying gene sequence from the mutated allele. Subsequent 
subcloning and nucleotide sequence analysis will be carried out. Use 
of the polymerase chain reaction to define exon 4 and exon 7 
deletions from the Cl-inhibitor gene poses problems because choosing 
primers is difficult when the exact limits of the deletion are not 
defined. Furthermore, the primers chosen would almost certainly lie 
within intronic ALU repeat elements which could markedly interfere 
with amplification specificity.
The main challenge in HAE is the identification and 
characterisation of the Cl-inhibitor gene mutations which lie 
outwith the categories described in the preceding pages but which 
are responsible for the majority of Type I disease and approximately 
30% of Type II disease. As stated earlier the remaining mutations 
are likely to be small, critically placed abnormalities which RFLP 
analysis is unlikely to detect. Other techniques will have to be 
employed. Sequencing the entire Cl-inhibitor gene to detect a small 
abnormality would be tedious, time-consuming and expensive. What is 
required is a selection procedure which can be carried out initially 
to detect and localise a mutation. To date a number of methods have 
been developed to pinpoint base changes in genes. These include the
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analysis of RNase A cleavage products of RNA.:DNA. heteroduplexes or 
RNA:RNA heteroduplexes between wild type and mutant molecules 
(215,216) or else the detection of base pair mismatches between 
DNA:DNA heteroduplexes detected by their reaction with carbodiimide 
(217). These methods have limitations in that they do not detect all 
mutations. Recently a relatively straightforward chemical cleavage 
reaction has been described using osmium tetroxide and hydroxylamine 
to chemically modify the mismatched bases between the strands of a 
defined DNA: DNA heteroduplex followed by piperidine cleavage at the 
modified bases (218). This method potentially detects all possible 
base pair mismatches depending on the conditions used and allows the 
position of the mismatch and so mutation to be identified following 
polyacrylamide gel electrophoresis and autoradiography of the 
radiolabelled cleavage products. Application of this detection 
system to HAE in order to identify Cl-inhibitor gene mutations seems 
a potentially very informative investigative step to take. Exonic 
and exon/intron boundary mutations will be sought at the outset. The 
source of exonic material to form the defined heteroduplexes will be 
the PCR product of the appropriate exon being examined. Since HAE is 
a heterozygous disease the PCR product from patient genomic DNA will 
contain an equal parts mixture of amplified normal exon and mutant 
exon which is ideal for the formation of normal:mutant hetero­
duplexes during the initial stages of the chemical cleavage 
reaction. Having identified a potential mutation, nucleotide 
sequence analysis of the appropriate PCR product can be carried out.
In one of the Type I HAE families for whom no disease-specific 
RFLP could be demonstrated, a shortened Cl-inhibitor mRNA species
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has recently been identified (K. Whaley, personal communication). An 
exon deletion from the Cl-inhibitor gene cannot be responsible for 
this shortening which is approximately 200-300 bases since an RFLP 
would have been identified. The most likely alternative explanations 
are either a small mutation causing premature termination of 
transcription or else a mutation creating an alternative splice 
site. Confirmation of the first possibility can be achieved by 
sequence analysis of the seventh and eighth exons following 
amplification of each exon by PCR. Establishing the existence of an 
alternative splice site would be more difficult but PCR 
amplification of each exon using patient Cl-inhibitor mRNA as the 
PCR template may identify the missing exonic material and so direct 
further investigation to the appropriate area of the gene where the 
mutation could be exonic or intronic.
It can be argued that a justifiable alternative approach for 
identifying some of the remaining Cl-inhibitor gene mutations 
responsible for HAE would be to "blindly" sequence only the exonic 
component of the Cl-inhibitor gene from a patient in each HAE 
kindred, each exon having been prepared by PCR. In this way a number 
of abnormalities would be found which would represent a proportion 
of the mutations responsible for Type I HAE and all of the mutations 
that cause Type II HAE. Since the exonic component of the gene is 
only 12% of its total length the sequencing task would not be too 
daunting. Unfortunately with this investigative protocol it is 
likely that a number of the Cl-inhibitor gene mutations that cause 
Type I HAE would remain undetected. In these cases the chemical 
cleavage reaction would have to be applied to patient DNA.
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In conclusion, it is probable that a multiplicity of 
Cl-inhibitor gene mutations responsible for Type I and Type II HAE 
will be characterised in the near future. From a molecular genetic 
standpoint HAE will then more closely resemble other better 
characterised genetic diseases such as haemophilia A (207), 
haemophilia B (208) and p-thalassaemia (219), all of which are 
caused by a wide range of gene mutations.
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